The most current laboratory reference ranges are included in the laboratory report from the LIS. Laboratory testing information is also available on the Laboratory Guide to Services Website, https://clinicallabs.osumc.edu This descence applied at themost protein of More Proc. The International Proc. Pro

					UHE): 181 Taylor Avenue, Columbus OF ratory (JWC): 2121 Kenny Rd, Columbus				
Analyte	Synonym	Methodology / Reaction Type	Instrument or Kit Manufacturer	Units	Reference Ranges	Critical Values	Source of Reference Range	Technical Range / AMR	Reportable Range / CRR
Base Excess	Base Excess, Base Deficit	Calculation of the expression that approximates the amount of acid or base required to titrate one liter of blood back to a normal pH of 7.40.	Radiometer	mmol/L	-3.0 to + 3.0	N/A	Contemporary Practice in Clinical Chemistry 3rd Edition 2016. Chapter 32. Table 32-1 p450	-30.0 - 30.0	-30.0 - 30.0
		HCO ₃ - 24.8 + 16.2 x (pH - 7.4)	GEM Premier 5000	mmol/L	-3.0 to + 3.0	N/A	Contemporary Practice in Clinical Chemistry 3rd Ed 2016. Chapter 32. Table 32-1 p450	N/A	-30.0-30.0
					Arterial:		Arterial: Blood Gases and Critical Care Testing		
		0.1.1.5		107	>30 Days: 22-28	277	Physiology, Clinical Interpretations, and Laboratory Applications. 3rd Edition, 2021 (p.3).	0.114	01.14
нсоз	Bicarbonate,	Calculation	Radiometer	mmol/L	Venous:	N/A	Venous: Clinical Guide to Laboratory Tests 3rd	Calculation	Calculation
	CO2 Whole Blood				22-29		Edition, Tietz, 1995.		
		$Log(HCO_1(c)) = pH + log(pCO_2) -$	GEM Premier 5000	mmol/L	>30 Days <u>Arterial:</u> 22-28	N/A	Clinical Guide to Laboratory Tests Third Edition,	N/A	N/A
		7.608 mmol/L			Venous: 22-29	>1 year:	Tietz, 1995		
		Amperometric	Radiometer	mg/dL	1+ years: 70-99	<50 and >400 <1 year:	Clinical Guide to Laboratory Tests, 3rd Edition Tietz, 1995; Pediatric Reference Ranges, Soldin,	1-1030	1-1030
Glucose, Whole Blood	Whole Blood Glucose					<40 and >200	1999		
		Amperometry	GEM Premier 5000	mg/dL	Fasting, 1+ years: 70-99	>1 year: < 50 and > 400 <1 year: < 40 and > 200	Clinical Guide to Laboratory Tests, Tietz, 1995; Pediatric Reference Ranges, Soldin, 1999	16-685	16-685
					>18 years				
		Calculation	Radiometer	%	Male: 40.2-50.4	N/A	Derived from total hemoglobin reference interval. ABL 800 FLEX Reference Manual, 2008.	Calculation	Calculation
Hematocrit (Calculated)	N/A				Female: 34.2-45.6				
		3.0 x tHb	GEM Premier 5000	%	>18 years Male: 40.2-50.4	N/A	Derived from total hemoglobin reference interval based on GEM calculation of HCT.	15-60	15-60
					Female: 34.2-45.6		based on GEM calculation of HC1.		
Total Hemoglobin, Whole Blood	N/A	Cooximetry	Radiometer	g'dL	>18 years Male: 13.4-16.8 Female: 11.4-15.2	>12y: <7.0 and >22.0 8d-12y; <8.0 and >22.0 0d-7d: <11.0 and >22.0	OSU Internal Normal Range Study, October 2018	4.8-23.5	4.8-23.5
		Co-oximetry: THb = O2Hb + COb + MetHb +	GEM Premier 5000	g/dL	>18 years Male: 13.4-16.8	>12v: < 7.0 and > 22.0 8d+12v: < 8.0 and > 22.0	OSU Internal Normal Range Study, October 2018;	5-20	5-20
		ННЬ		-	Female: 11.4-15.2	0d-7d: < 11.0 and > 22.0	Verified with GEM Validation Study, 2021.		. ==
		Potentiometric	Radiometer	mg/dL	4.60-5.30	<3.40 and >6.20	Blood Gases and Critical Care Testing Physiology, Clinical Interpretations, and Laboratory	1.00-13.00	1.00-13.00
Ionized Calcium, Whole Blood	ICA	rotemometric	rausofficter	ing/dL	4.00-3.30	<3.40 and ≥0.20	Applications. 3rd Edition, 2021 (p.102)	1.00-13.00	1.00-13.00
		Potentiometry	GEM Premier 5000	mg/dL	4.60-5.30	<3.40 and >6.20	Tietz Textbook of Clinical Chemistry and	1-13.0	1-13.0
					***************************************		Molecular Diagnostics Sixth Edition, 2018	4-10-0	1-100
Ionized Calcium, Serum	LAB54	Potentiometric	Radiometer	mg/dL	4.60-5.30	<3.40 and >6.20	 Blood Gases and Critical Care Testing Physiology, Clinical Interpretations, and Laboratory Applications. 3rd Edition, 2021 (p.102) 	1.00-13.00	1.00-13.00
Tables Calcium, Scradi				gus			Applications. 3rd Edition, 2021 (p.102)	10.00	13.000
Ionized Calcium (CRRT)	ICACRT	Potentiometric	Radiometer	mg/dL	1.00-2.00	N/A	Email_ICA CRRT RR Physician Established 11-19-2020	1.00-13.00	1.00-13.00
	ICACRT	Amperometric	Radiometer	mmol/L	Adult:	≥5.0	ABL 800 Flex Reference Manual, 2008	0.0-30.0	0.0-30.0
Lactate, Whole Blood	Lactic Acid	Amperometry	GEM Premier 5000	mmol/L	0.5 - 1.6 Adult:	≥5.0	ABL 800 Flex Reference Manual, verified by GEM	0.3-17	0.3-17
Lactate, Blood			Radiometer	mmol/L	0.5-1.6 Adult:	25.0	Validation Study, 2021. ABL 800 Flex Reference Manual, 2008	0.0-30.0	0.0-30.0
Lactate, Blood		Amperometric	Radiometer	mmol/L	0.5 - 1.6 Arterial	25.0		0.0-30.0	0.0-30.0
					0-365 days: 40-90		Arterial: Clinical Guide to Laboratory Tests, 3rd Edition,		
		Visible absorption spectroscopy	Radiometer	%	>1 year: 94-98	N/A	Tietz, 1995	5-100	5-100
sO2	sO2						Venous: Blood Gas O2Sat: Radiometer Bulletin No: 44		
					Venous: 70-80		Compendium of reference intervals		
		Co-oximetry:	GEM Premier 5000	%	Arterial: 0-365 days: 40-90		Arterial: Clinical Guide to Laboratory Tests third Edition, Tietz, 1995; Venous: Blood Gas O2Sat:	0-100	0-100
		sO2 = 100 x O2Hb%/(O2Hb% + HHb%)	GEM Premier 5000	76	>1 year: 94-98 Venous: 70-80	N/A	Radiometer Bulletin No: 44 Compendium of reference intervals	0-100	0-100
					>31 days Arterial:	Arterial:	Arterial: Clinical Guide to Laboratory Tests, Tietz,		
		Potentiometric	Radiometer	mmHg	32-48 Venous:	<20 and >65 Venous:	1995 & Fundamentals of Clinical Chem, 1987 / Venous: Respirology. 2014 Feb;19(2):168-75,	5-115	5-115
pCO2	N/A				36-52	<24 and >64	doi:10.11111/resp.122225. Pub 2014 Jan 3.		
		Potentiometry	GEM Premier 5000	mmHg	>31 days Arterial: 32-48	Arterial: <20 and >65 Venous: <24 and >64	Arterial: Clinical Guide to Laboratory Tests Third Edition, Tietz, 1995; Venous: Respirology. 2014	18-125	18-125
					Venous: 36-52 >31 days	Arterial:	Feb;19(2):168-75.		
		Potentiometric	Radiometer	pH	Arterial: 7.35-7.45	<7.20 and >7.55	Clinical Guide to Laboratory Tests Tietz 3rd Edition, 1995.	6.80-8.00	6.80-8.00
pH	N/A				Venous: 7.32-7.43	Venous: <7.17 and >7.52	Edmon, 1995.		
		Potentiometry	GEM Premier 5000	pH	>31 days Arterial: 7.35-7.45	Arterial: <7.20 and >7.55	Clinical Guide to Laboratory Tests Third Edition,	7-7.92	7-7.92
		Tokimanay	CLIN FICHICI 5000	p	Venous: 7.32-7.43	Venous: <7.17 and >7.52	Tietz, 1995	1-1.92	1-1.92
					Arterial		Arterial: Clinical Guide to Laboratory Tests, Tietz 3rd Edition, 1995 & Fundamentals of Clinical		
					<u>Arterial</u> : 83-108		Chem, 1987		
		Amperometric	Radiometer	mmHg	Venous:	Arterial: ≤44 Venous: N/A	Venous: Respirology. 2014 Feb;19(2):168-75,	0-700	0-700
pO2	N/A				Venous pO2 is not recommended for the evaluation of oxygen status, clinical correlation is recommended		doi:10.11111/resp.122225. Pub 2014 Jan 3. © 2012 Radiometer Medical ApS. All rights		
					cunical correlation is recommended		© 2012 Radiometer Medical ApS. All rights reserved. 995-950. 201206B.		
					Arterial: 83-108				
		Amperometry	GEM Premier 5000	mmHg	Venous: Venous pO2 is not recommended for the evaluation of	Arterial: ≤44 Venous: N/A	Clinical Guide to Laboratory Tests Third Edition, Tietz, 1995	35-529	35-529
					oxygen status, clinical correlation is recommended		,		
		Potentiometric	Radiometer	mmol/L	18+ years:	1 - 18+ years: <3.0 and >6.0	Clinical Guide to Laboratory Tests, Tietz 3rd	1.0-14.0	1.0-14.0
Potassium, Whole Blood	Whole Blood Potassium	rotentiometric	Kadiometer	mmol/L	3.5-5.0	<1 year: <3.0 and >7.0	Edition, 1995	1.0-14.0	1.0-14.0
		Potentiometry	GEM Premier 5000	mmol/L	18+ years: 3.5-5.0	1-18+ years: <3.0 and >6.0	Clinical Guide to Laboratory Tests, Tietz, 1995. Upper limit adjusted and verified with GEM	1-10	1-10
		7		-	,	<1 year: <3.0 and >7.0	Validation Study, 2021.		
		Potentiometric	Radiometer	mmol/L	1+ years: 135-145	<125 and >160	Blood Gases and Critical Care Testing Physiology, Clinical Interpretations, and Laboratory	80-175	80-175
Sodium, Whole Blood	Whole Blood Sodium				133-143		Applications. 3rd Edition, 2021 (p.165).		
		Potentiometry	GEM Premier 5000	mmol/L	1+ years: 135-145	<125 and >160	Clinical Guide to Laboratory Tests Third Edition, Tietz, 1995. Lower limit adjusted and verified with	100-180	100-180
	<u> </u>	Cooximetry	Radiometer	%	≤1.5	N/A	GEM Validation Study, 2021. ABL 800 Flex Reference Manual 2008	0.0-50.0	0.0-50.0
Carboxyhemoglobin	Carboxyhemoglobin	Co-oximetry: COHb% = 100 x (COHb/THb) %	GEM Premier 5000	%	≤1.5	N/A	Clinical Guide to Laboratory Tests Third Edition, Tietz, 1995	0-75	0-75
Methemoglobin	Methemoglobin	Cooximetry Co-oximetry:	Radiometer GEM Premier 5000	%	≤1.5 ≤1.5	N/A N/A	ABL 800 Flex Reference Manual 2008 Tietz Textbook of Clinical Chemistry and	0.0-30.0 0-30	0.0-30.0
		MetHb% = 100 x (MetHb/THb) % Cooximetry	Radiometer	%	51.5 Adult: 94-98	N/A N/A	Molecular Diagnostics Sixth Edition, 2018 ABL 800 Flex Reference Manual 2008	0-30 0-100	0-30
Oxyhemoglobin	Oxyhemoglobin	Co-oximetry: O2Hb% = 100 x (O2Hb/THb) %	GEM Premier 5000	%	Adult: 94-98	N/A	ABL 800 Flex Reference Manual, verified by GEM Validation Study, 2021.	0-100	0-100
pH, Pleural Fluid	Fluid pH (by blood gas analyzer)	Potentiometric	Radiometer	pH	N/A	N/A	N/A	6.80-8.00	6.80-8.00
					Cord Blood Arterial:				
pCO2 Cord Blood Gas	pCO2, Cord Blood Arterial pCO2, Cord Blood Venous	Potentiometric	Radiometer	mmHg	41-58 Cord Blood Venous:	N/A	Clinical Guide to Laboratory Tests, Tietz 3rd Edition, 1995	5-115	5-115
					33-44 Cord Blood Arterial:				
pH Cord Blood Gas	pH, Cord Blood Arterial pH, Cord Blood Venous	Potentiometric	Radiometer	pH	7.23-7.33 Cord Blood Venous:	N/A	Clinical Guide to Laboratory Tests, Tietz 3rd Edition, 1995	6.80-8.00	6.80-8.00
					7.30-7.40 Cord Blood Arterial:		9		
pO2 Cord Blood Gas	pO2, Cord Blood Arterial pO2, Cord Blood Venous	Amperometric	Radiometer	mmHg	12-24	N/A	Clinical Guide to Laboratory Tests, Tietz 3rd Edition, 1995	0-700	0-700
Cora Blood Gas	pt/2, Cord Blood Venous				Cord Blood Venous: 23-35		,		
sO2 Cord Blood Gas	sO2, Cord Blood Arterial	Visible absorption spectroscopy	Radiometer	%	Cord Blood Arterial: 3-69	N/A	Brit Journ Obst Gyn 8-2000 Vol 107 pp 987-994 Cord Bld O2 SAT in vigorous infants at birth: What	5-100	5-100
502 Cord Blood Gas	sO2, Cord Blood Venous	same annurpuon spectroscopy	rausofficter	76	Cord Blood Venous: 16-83	IN/A	Cord Bid O2 SAT in vigorous infants at birth: What is normal?	3-100	3-100
Bicarbonate (HCO ₂ ')	Bicarbonate, Cord Blood Arterial				Cord Blood Arterial: 20-25		Clinical Guide to Laboratory Tests, Tietz 3rd		
Cord Blood Gas	Bicarbonate, Cord Blood Venous	Calculation	Radiometer	mmol/L	Cord Blood Venous: 16-25	N/A	Edition, 1995	Calculation	Calculation
	1				10-25				l

Base Excess Cord Blood Gas	Base Excess/Deficit, Cord Blood Arterial Base Excess/Deficit, Cord Blood Venous	Calculation of the expression that approximates the amount of acid or base required to titrate one liter of blood back to a normal pH of 7.40.	Radiometer	mmol/L	Cord Blood <u>Arterial</u> : -3.0-3.0 Cord Blood <u>Venous</u> -2.0-2.0	N/A	Email_Cord blood Gas RR Physician Established Base Excess_11-2020	-30.0 - 30.0	-30.0 - 30.0
Acetaminophen Level	Tylenol, Datril, Tempra, Liquiprin, Tenlap	Enzyme Immunoassay	Beckman	mcg/mL	Therapeutic: 10.0 - 32.0	>150.0 after 4 hours of ingestion	Applied Pharmacokinetics: Principles of Therapeutic Drug Montoring, 2nd Edition 2002 Applied Therapeutics, Inc. and Micromedex On OSU Intranet.	10.0-200.0	10.0-600.0
ALT	SGPT, Alanine Aminotransferase	Transfer of the amino group from almine to α-cooglutarate to form pyrvoste and glutamate. The pyrvoste enters a lactate dehydrogenase (LD) catalyzed reaction with MADH to produce lactate and NAD+. The decrease in absorbance due to the consumption of NADH is measured at 340mn and is proportional to the ALT activity in the sample.	Beckman	UL	18+ years: Femals: 9-48 Male: 10-52	N/A	OSUWMC Reference Range Study effective 12.11.2013; verified by OSUWMC Reference latered Study 2021. Pedatric Reference Range, Soldin, 1999 (Lover end of reference Range, modified to agree with the linear limits.)	3-500	3-25,000
Albumin	N/A	This Albumin method is a modification of the Doumas and Rodkey procedures utilizing a different buffering system. At pH 42, bromsercost green reacts with albumin to form an intense green complex. The absorbance of the albumin -BCG complex is measured birthornatically (600 800 mm) and is proportional to the albumin concentration in the sample.	Beckman	gˈdL	19+ years: 3.5-5.0	N/A	Tetz 2nd Edition referenced by Beckman Coulter B'U for recumbant adult and verified by OSUWAIC Reference Interval Study 2021.	1.5-6.0	1.5-18.0
Albumia, Body Fluid	N/A	See ALB	Beckman	gdL	Pleant Serum-pleural fluid albumin gradients of \$1.2 gidL are consistent with transdates. Parknaud Serum-sockes albumin- gradient (Mode) of 11 gidl. e- greater suggests portal hypertension. Persenald: The reference range has not been established for this fluid specimen. The fluid results also albumin- ted to the concentration in compared with the concentration in clinical context for interpretation.	N/A	Pleumit Roth, B.J., et al. Chees, Vol 98, 546-549, 1900. Peritoneal: Runyon, B.A. Am Intern Med. 1992;117:215-220.	0.5-6.0	0.5-6.0
Albumin, CSF	Microalbumin, CSF	Turbidimetry Based on an enzymatic reaction.4 Reagent 1 contains the buffering	Beckman	mg/dL	10.0-30.0	N/A	CCLM Vol 54 issue 2 p285-292 Feb 2016	1.0-45.0	1.0-450.0
Alcohol (Ethanol), Blood	Scrum Alcohol	system. Reager Leontina school dehydrogenase (ADH), the coerny me incircinamile adenie affectoriate (ANA), buffer, preservatives, and stabilizers. The ADH cash/zes the oxidation of ethyl ackool to acealidelyde. During this reaction, NAD is reduced to NADH. The increase in absorbance at 340 m in is proportional to the concentration of ackobol in the specimen.	Beckman	mgidL	<10	2300	N/A	10-600	10-600
Alk Phosphatase	ALP	This ALP procedure is based on the method developed by Bowers and McComb2 and has been formulated as recommended by the AACC and BFCC3. Alkaline phosphatase activity is determined by measuring the rate of conversion of p-ndro-phenylphosphate (pNPP) in the presence of 2-mino2-methyl-1-propanol (AMP) at pH 10.4.	Beckman	U/L	19+ years: 32-126	N/A	OSLWMC Reference Range Study effective 12.11.2013. Verified by OSLWMC Reference Interval Study 2017. Podatire Reference Ranges, Soldin, 1999. Synchron Performance Verification Manual AZ2219	5-1,500	5-15,000
Alpha 1 Antitrypsin	N/A	Turbidimetry	Beckman	mg/dL	84-218	N/A	Package Insert. Verified by OSUWMC Reference Interval Study 2021.	30-500	30-5,000
Ammonia	Ammonia, Venous	Direct enzymatic procedure based on the following reaction sequence: Gattamate dehydrogenase (GLDH) NH4+ o-ketoghtumate + NADH — Gattamate + NAD + H2O. The reagest contains LDH in excess, so rapidly reduce endogenous provises to that it does not interfere with the assay system: reagent also incorporates a patented stabilization process which readers the reagest assay system readers the reagest assay system readers the reagent assay in the reagent assay system reagent also process which readers the reagent stable in the liquid phase.	Beckman	umol/L	6-47	N/A	Package Insert	10-600	10-3,000
Ammonia, Arterial	N/A	Direct enzymatic procedure based on the following reaction sequence: Chammate delydrogenuse (CLDI) Chammate delydrogenuse (CLDI) Chammate ADA + IRO. The reagent contains LDH in excess, to rapidly reduce endogenous pyrunutes to that it does not interfere with the assay system reagent also incorporates a patented stabilization process which renders the reagent grocess which renders the reagent stable in the liquid phase.	Beckman	umol L	6-47	N/A	Package Insert	10-660	10-3,000
Amylase	N/A	The release of 2-chloro-4-nitrophenol (CNP) from the substrate and the resulting absorbance increase per minute is directly related to the α-Amylase activity in the sample. The resulting increase in absorbance can be measured spectrophotometrically at 410/480mm.	Beckman	UA.	19+ years: 20-103	0-18 years: ≥400 19+ years: ≥500	Prior study verified by OSLWMC Reference Interval Study 2021.	10-2,000	10-10,000
Amylase, 24 Hour Urine	N/A	See Amylase	Beckman	U/24 hrs	24 hour sample: 0-400	N/A	OSU validated 48 outpatients from Family Practice. See Method Validation binders.	N/A (calculation)	N/A (calculation)
Amylase, Body Fluid	N/A	Calculation: AMY*VOL/1000	Beckman	UL	Pleural Pleural fluid rich is amplies (fluid amplies to serum)pleura mythe erits (-1) is associated with surpline ritins (-1) is associated with respect to the proposal leakage, midgiancy, cirrhois, or percumonia. Placeratic part Very low patternets of the proposal leakage, midgiancy, or this simple processoriation (-2 20 UL), exclude a psoudocyst in the majority of cash of the processoriation of the proposal proposal proposal proposal processoriation in serum plasma or integrated into the clinical content for temperation in serum plasma or integrated into the clinical content for temperation.	N/A	Pleural: State of the art. The pleurs Salas SA Am Rev Respir Dis. 1988;138(1):1584. Pancreatic cyst: Elia GH, et al. Am J Gauroenterol. 308;113:464-479.	10-2,000	10-160,000
Amylase, Urine Random	N/A	See Amylase	Beckman	U/L	None established	N/A	N/A	10-1,500	10-75,000
Anion Gap	Gap	Calculation: ANION GAP=(NA+K)- (CL+CO2)	N/A	mmol/L	7-17	N/A	OSUWMC Study 2015 Package Insert. Verified by OSUWMC Reference	N/A	N/A
Anti Streptolysin O	N/A	Turbidimetry Catalyzes the transamination of	Beckman	IU/mL	<250	N/A	Interval Study 2021.	100-1,000	100-10,000
AST	SGOT, Aspartate Aminotransferase	Catalyzes the transamination of saparates and a-cooglutarus, forming Leglutamate and oxalacetate. The oxalacetate is then reduced to L-mainte by malate delydrogenase, while NADH is simultaneously converted to NAD+. The decrease in absorbance due to the consumption of NADH is measured at 340 mm and is proportional to the AST activity in the sample.	Beckman	UL	19+ years: 10-39	N/A	Verified by OSLWMC Reference Interval Study 2021.	3-1,000	3-50,000
	1	1		1	1	1	<u>I</u>		<u> </u>

									1
Beta HCG Quant, Blood	Quantitative Serum Pregnancy Test	Two-site Sandwich Immunoassay Chemilaminescent	Siemens	mUmL	Num.terapmatt = (10.0 Postmerospounds =	NIA	Advia Centur BICG Package Insert 10634917, IN Rev. F. 2011-04	26-1,000.0	2.6-128,000,000.0
B-hCG Qualitative, Blood	Serum Pregnancy Test	Lateral-flow test using a monoclonal antibody specific to the beta subunit of hCG.	Alere	Qualitative	Negative	N/A	Package Insert	Positive Negative	Positive Negative
Beta-Hydroxybutyrate	Beta Hydroxybutyrate	D-3 Hydroxybutyrate in the presence of NAD gets converted to acetoacetate and NADH. NADH produced reacts with INT in the presence of diaphorase to produce color at 505am. Absorbance is proportional to B- hydroxybutyrate in sample.	Beckman	mmol/L	<0.27	≥1.20	Stanbio Package Insert and verified by OSLWMC Reference Interval Study 2021.	0.10-8.00	0.10-24.00
Bicarbonate, Fluid	FCO2, CO2 Fluid	See CO2	Beckman	mmoVL	Stool: The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.	N/A	N/A	5-45	5-90
	Bilirubin, Total (Neonatal)	A stabilized diazonium salt, 3,5- dichlorophenyldiazonium tetrafluoroborate (DPD), reacts with bilirubin to form azobilirubin which absorbs at 570/660 nm.			0 Days: 1.4-8.7 1 Day: 3.4-11.5 3 Days: 1.5-12.0 5 Days: 0.3-1.2 1 Year: <1.5	<1 year: ≥14.0	Clinical Guide to Laboratory Tests, Kaplin, 2003	0.1-30.0	0.1-90.0
Bilirubín - Baby	Bilirubin, Direct (Neonatal)	Direct (conjugated) bilirubin couples directly with a diszonism salt of 3,5- dichloroaniline (DPD) in an acid medium to form azobilirubin. The direct bilirubin in serum is directly proportional to the color development of azobilirubin which is measured bichromatically at 570/660 nm.	Beckman	mg/dL	All: < 0.3	N/A	Clinical Guide to Laboratory Tests, Tietz, 1995	0.1-10.0	0.1-20.0
Bilirubin Direct	BILD	Direct (conjugated) bilirubin couples directly with a diazonism salt of 3,5- dichloroaniline (DPD) in an acid medium to form azobilirubin. The direct bilirubin in serum is directly proportional to the color development of azobilirubin which is measured bichromatically at 570/660 nm.	Beckman	mg/dL	All: < 0.3	N/A	Clinical Guide to Laboratory Tests, Tietz 1995, verified by OSUWMC Reference Interval Study 2021.	0.1-10.0	0.1-20.0
Bilirubin Total	BILT	A stabilized diazonium salt, 3,5- dichlorophenyldiazonium tetrafluoroborate (DPD), reacts with bilirubin to form azobilirubin which absorbs at 570/660 nm.	Beckman	mg/dL	Adult: <1.5	N/A	Clinical Guide to Laboratory Tests, Tietz 1995, verified by OSUWMC Reference Interval Study 2021.	0.1-30.0	0.1-90.0
Bilirubin, Total, Fluid	FBILT	A stabilized diazonium salt, 3,5- dichlorophenyldiazonium tetrafluoroborate (DPD), reacts with bilirubin to form azobilirubin which absorbs at 570/660 nm.	Beckman	mg/dL	Peritoneal: Peritoneal bilirubin concentrations greater than that of serum/plasma may suggest bile within the abdomen. Drainage: Drain fluid bilirubin concentration-to-serum/plasma bilirubin concentration ratios exceeding 5 indicates bile leakage.	N/A	Peritoneal: Runyon BA J Clin Gastroenterol. 1987;9(5):543. Drain: Darwin. Gastrointest Endosc. 2010 Jan;71(1):99-104.	0.1-30.0	0.1-90.0
B-Type Natriuretic Peptide	BNP	Two site sandwich immunoassay using direct chemiluminescent technology which uses constant amounts of two monoclonal antibodies.	Siemens	pg/mL	All: 0-100	N/A	Atellica IM BNP Package Insert 11202199_EN Rev. 05-2020-11	2-4,500	2-4,500
BUN	N/A	Urea is hydrolyzed enzymatically by turease to yield ammonia and carbon detoxel. The ammonia and or detoxed the ammonia and superior of the control of the c	Beckman	mg/df.	Alt: 7-25	≥101	Beckman Coulter B'U for serum verified by OSUWMC Reference Interval Study 2021.	2-130	2-650
BUN/Creatinine Ratio	N/A	Calculation: BUN/Creatinine	Beckman	N/A	N/A	N/A	N/A	N/A (calculation)	N/A (calculation)
C Reactive Protein	N/A	in light intensity transmitted (increase			All: <10.00		Clinical Guide to Laboratory Tests, Tietz, 2005; Verified by OSUWMC Reference Interval Study	(Case damaces)	(Calculations)
C Reactive Protein For Cardiac Risk	CRPR, CRP High Sensitivity	in absorbance) through particles suspended in solution is the result of complexes formed during the immunological reaction between the CRP of the patient serum and rabbit anti-CRP antibodies coated on later	Beckman	mg/L	All: Non-specific: >10.00 High Risk: >2.00 Low Risk: <2.00	N/A	2021. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019 Sep 10;140(11):e596-e646.	0.20-80.00	0.20-480.00
C3 Complement	C3	Turbidimetry	Beckman	mg/dL	87-200	N/A	Package Insert. Verified by OSUWMC Reference Interval Study 2021. Historic Reference Range. Verified by OSUWMC	15-500	15-1,500
C4 Complement	C4	Turbidimetry Two cits conducts immunouscess	Beckman	mg/dL	18-52	N/A	Reference Interval Study 2021.	8-150	8-450
CA 125	CA125N	using direct chemiluminometric technology	Siemens	U/mL	All: ≤30	N/A	Advia Centaur CA 125II Package Insert 128516 Rev. H, 2009-02	3-600	3-360,000
CA 15-3N	CAI53N	Two-site Sandwich Immunoussay Chemiluminescent	Siemens	U/mL	0.0-32.4 for both female and male	N/A	Atellica IM CA 15-3 Package Insert 11206285_EN Rev. 04, 2020-03	3.0-200.0	3.0-200,000.0
CA 19-9	N/A	Two-site sandwich immunoussay using direct chemiluminometric technology	Siemens	U/mL	All: ≤37.00	N/A	Clinical Guide to Laboratory Tests, Tietz, 1995; see Source link for additional Reference Range information	15.00-700.00	15.00-33,600,000.00
Calcium	CA	Calcium ions (Ca2+) reacting with Arsenazo III (2,2'-{1,8-Dihydroxy- 3,6-disulphonaphthylene-2,7-bisazo)- bisbenzenear-sonic acid to form an intense purple colored complex. Absorbance of the Ca-Arsenazo III complex is measured bishromatically at 660/700 nm.	Beckman	mg/dL	>1 year: 8.6-10.5	<6.0 and >12.0	Established by OSUWMC Reference Interval Study 2013, verified by OSUWMC Reference Interval study 2021.	4.0-18.0	4.0-18.0
Calcium, Urine 24HR	N/A	Calculation: CA*VOL/100	Beckman	mg/24 hours	100.0-300.0	N/A	N/A	N/A (Calculation)	N/A (Calculation)
Calcium/Creat Ratio, Random Urine	CALCR LDL,	Calculation: Urine Calcium/ Urine Creatinine	Beckman	Ca mg/Creat mg	0-6 months: <0.86 7-18 months: <0.60 19 months-2 years: <0.42 >3 years: <0.22	N/A	Clinical Guide to Laboratory Tests, Tietz, 1995 National Cholesterol Education Project (NCEP)	N/A (Calculation)	N/A (Calculation)
Calculated LDL Cholesterol	Low-Density Lipoprotein Cholesterol	Calculation: CHOL - [(TRIG/5)+HDL]	N/A	mg/dL	Adult optimal : <100	N/A	Adult Treatment Protocol (ATP- III) (Circulation, 2002;106:3143-3421)	N/A	N/A
Carbamazepine Total Level	CARB	Competition between drug in the sample and drug labeled with the enzyme glacous-6-phosphate dehydrogenuse (CoPDII) for anibody building sites. Enzyme activity decreases upon binding to enibody, so the drug concentration in the sample can be measured in terms of enzyme activity, Active enzyme converts oxidized nicottamiaba adented disubciotich (PADI) to NADII, resulting in an absorbance change and the properties of the NADII, resulting in an absorbance change of the properties of the NADII, resulting in an absorbance change of the contract of the NADII, resulting in an absorbance change of the contract contract change of the contract co	Beckman	mcg/mL	All: 4.0-12.0 (Therapeutic Range)	>15.0	Applied Clinical Pharmacokinetics, 2001 Micromedes, OSU Intranet	2.0-20.0	2.0-100.0
CEA	N/A	Two-site Sandwich Immunoussay Chemiluminescent	Siemens	ng/mL	All: ≤5.0	N/A	Clinical Guide to Laboratory Tests, Tietz, 1995. See source link for additional Reference Range	2.0-100.0	2.0-8,000,000.0
CEA, Fluid	FCEA	Two-site Sandwich Immunoassay Chemiluminescent	Siemens	ng/mL	The reference range and other method performance specifications have not been established for this fluid	N/A	information. Clinical Guide to Laboratory Tests, Tietz, 1995; see Source link for additional Reference Range information	2.0-100.0	2.0-10,000.0
Ceruloplasmin	CERP	Turbidimetry	Beckman	mg/dL	specimen. 20-60	N/A	Verified by OSUWMC Reference Interval Study	6-200	6-4,000
upaamin		,		3			2021.	**	. 5000

Chloride	a	The ISE module for Na+, K+, and G1- employs crown other membrane electrodes for sodium and potassium and a molecular coriented PVC specific for each in of interest in the sample. An electrical potential is developed according to the Norsat Equation for a specific ion. When compared to the internal Reference Solution, this educivity alorestial is the internal contraction of the sample.	Beckman	mmol L	18+ yean: 98-108	<75 and >130	Established by OSUWMC Reference Interval Study 2013, verified by OSUWMC Reference Interval study 2021	50-200	59-200
Chloride, 24 Hr Urine	UCL, 24	Calculation: CL*VOL/1000	Beckman	mmol/24hrs	110-250	N/A	Clinical Guide to Laboratory Tests, Tietz, 1995	N/A (Calculation)	N/A (Calculation)
Chloride, Fluid	FCL	See Chloride	Beckman	mmol/L	The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.	N/A	N/A	50-200	50-200
Chloride. Random Urine	UCLR	See Chloride	Beckman	mmol/L	Random: None established	N/A	N/A	15-400	15-400
Cholesterol Total	CHOL	Cholestrol esters is serum are hydrolyzed by cholestrol esterase (CHE). The five cholestrol estraction produced is oxidated by cholestrol oxidate (CHO) to cholest-4-en-3-ene with the simulationary production of hydrolyn peroxide (GEO), which amountainly me and plean in the presence of peroxidate to yield a chromophore. The red quinomenting dye formed can be measured spectrophothemetrically at 5400600 mm as an increase in absorbance.	Beckman	mgidL	Desirable: <200 Borderline: 200.239 High: >240	N/A	National Choketernt Education Project (NCEP) Adult Treatment Protocol (ATP- III) (Circulation, 2002;166:3143-3421)	25-700	25-2,100
Cholesterol Total/HDL Ratio	N/A	Calculation: Chol/HDL	Beckman	N/A	<4.5	N/A	National Cholesterol Education Project (NCEP) Adult Treatment Protocol (ATP- III) (Circulation, 2002;106:3143-3421)	N/A (calculation)	N/A (calculation)
Cholesterol, Body Fluid	FCHOL	See Cholesterol	Beckman	mg/dL	Pleural: Pleural fluid cholesterol concentrations > 200 mg/dL are associated with pseudochylous efficients. Perionneal: Perionneal: fluid cholesterol concentrations greater than 32-70 mg/dL may suggest malignant asciles.	N/A	Pleural: Hooper C, et al. Thorax. 2010 AugóS-Suppl:284-17. McGrath, et al. lar J Clin Fract. 2009 NoviSel 1) EliSS-99. Perinonel: Block et al. Crit Rev Clin Lab Sci. 2013;50:107-124.	25-700	25-700
ск	Creatine Kinase, CKB	CK reversiby castly year the transfer characteristic for the control of the contr	Beckman	UI.	199-ymans. Frankir 30-184 Male: 30-220	2500	Established by CHUNAC Reference Interval Study 2013, verified by CHUNAC Reference Interval analy 2021	19-2,009	10-200,000
Clozapine Level	N/A	Turbidimetric immunoassay	Beckman	ng/mL	Therapeutic Range: 350-1000	>1500	N/A	68-1500	68-1500
CO2 Total	CO2	Bicarbonate (HCOT) and phosphoenohymoute (PEP) are converted to exaborate and phosphate in the rection cutalyzed by phosphoenohymvate carbox just (PEP). Abdates dehydrogenome (PEP) and phase dehydrogenome (PEP) and phase dehydrogenome (PEP) and phase dehydrogenome (PEP). Addates dehydrogenome (PEP) and phase dehydrogenome (PEP) and phase dehydrogenome (PEP) are conceniumlate valaction of rection (NADI). This could make the phase dehydrogenome (PEP) are conceniumlated and phase dehydrogenome (PEP) are continued to the Bicarbonate content of the sample.	Beekman	mmoliL	3+ years: 21-31	<10 and >40	Beckman Couler IFU verified by OSLWMC Reference Interval Study 2021.	S-45	5-45
Cortisol	ACTH Stimulation, CORT	Competitive immunoussay using direct chemiluminescent	Siemens	mcg/dL	All: 3.09-22.40	N/A	Atellica IM Cortisol Package Insert 11200393_EN Rev. 03-2020-03	0.50-75.00	0.50-2,400.00
Creatinine	CREA	technology This Creatinine procedure is a kinetic modification of the Jaffe procedure, in which creatinine reacts with picric acid at alkaline plf to form a yellow crange complex. The rate of change in absorbance at \$20.800mm is proportional to the creatinine concentration in the sample.	Beckman	mg/dL	19+ years: Female: 0.50 - 1.20 Male: 0.70-1.30	>10.00	OSUWMC Reference Range Study effective 12.11.2013; verified by OSUWMC Reference Interval Study 2021. Pediatric Reference Ranges, Soldin, 1999	0.20-25.00	0.20-25.00
Creatinine, 24 HR Urine	UCRE, 24	Calculation: (CRE/100)*(VOL/1000)	Beckman	g/24 hrs	18+ years male: 0.80-2.00 18+ years female:	N/A	NKDEP traceable :Clinical Guide to Laboratory Tests, Tietz, 1995; Pediatric Reference Ranges,	N/A (Calculation)	N/A (Cakulation)
Creatinine, 8 Hour Urine		See Creatinine		mg/dL	0.60-1.80		Soldin, 1999	1.00-300.00	1.00-900.00
Creatinine Clearance, 8 Hour Urine	SUCR	Calculation Urine Creatinine (mg/dL) X Urine Volume (mL) Serum/Plasma Creatinine (mg/dL) x Time (min) *serum/Plasma creatinine (CREA) must be collected within +/24 hours from the time of the time collection for the calculation to work is LLS	Beckman	mL/Min	N/A	N/A	N/A	N/A	N/A
Creatinine, Body Fluid	FLCREA	See Creatinine	Beckman	mg/dL	Perioneal and drainage: Fluid creatinine concentrations that are greater than serum/plasma creatinine concentrations may imply intraperioneal leakage of urine outside of the urinary truct. Pleural: Pleural fluid creatinine to serum/plasma creatinine concentration ratio > 1 suggests uniontherax.	N/A	Manahan KJ, et al. Obstet Gynecol. 1999 May;93(5 Pt 1):780-2. Pleural: Toubes, et al. J Thorac Dis. 2017;9(5):1209-1218.	0.20-25.00	0.20-25.00
Creatinine, Random Urine Cystatin C and Creatinine with estimated GFR	UCRER CYSC	See Creatinine Turbidimetric immunoassay	Beckman Beckman	mg/dL mg/L	N/A 0.51-1.05	N/A N/A	N/A Package Insert	1.00-300.00 0.40-8.00	1.00-900.00 0.40-32.00
Digoxin Level	Lanoxin, DIG	Enzyme Immunoassay	Beckman	ng/mL	0.5-1.0 (Therapeutic Range)	≥2.1	Applied Clinical Pharmacokinetics, Bauer, 2001	0.3-5.0	0.3-10.0
eGFR _{ee}	Estimated gloonerular filtration rate	CKD.EPI 2021 Calculation. eGFRer = 142 x min(Serke, 1) ax max(Serke, 1) ax max(Serke, 1) + 200 x 0.00 M/Seg ax 1012 Eg (make) where x = 0.7 (relandes) or 0.9 (makes) a -0.241 (female) or 0.90 (makes) serum creationie in mgild; dishide by 88.4 for creationie in mgild; minimum of Serik or 1.0 and "max(Serke, 1)" milcates the minimum of Serik or 1.0.	N/A	mL/mia/1.73 m²	$\geq 60~\mathrm{mL/mis}/1.73\mathrm{m}^2$	N/A	KDIGO 2012 Clinical Practice Guidelines	N/A	$\leq 90~\mathrm{mL/min/1.73}\mathrm{m}^2$

$eGFR_{rest}$	Estimated glomerular filtration rate	CXD.EP? 2021 Calculation. cGFRe- cys = 138 x min(Seric, II)*x max(Seric, I)*s*4 x min(Seric, II)*x max(Seric, II)*x max(Seric, II)*x max(Seric, II)*x max(Seric, II)*x max(Seric, II) max(Seric, II) max(Seric, II) max(Seric, II) max(Seric, III) max(Seric, I	N/A Stemens	md./mis/1.72m² pg/ml.	≥ 60 mL/min/1.73m ² Made 19 ⁴ years: <11.8-39.8 Adult Temals Folloader Place Makeyie Phase: 61.8-33.8-7	N/A N/A	KDIGO 2012 Clinical Practice Guidelines Abria Centure, Enhanced Estradiel (#E2) Package lanet 1004 160 Rev. C, 2010-009; Pedianie Beferone Bangus, Saldin, 190	N/A 11.8-3,000.0	≤ 90 mL/min 1.73m ²
		compete with estradiol for the binding of the acridinium-labeled antibody. After washing, acid and base are dispensed to initiate the chemiluminescent reaction.			Luteal Phase: 55.8-214.2 Post Menopausal: <11.8-32.2 Female 19+ years: 7.3-270.7		Siemens Atellica IM Reference Interval Verification Study 2023 Siemens Atellica IM		
Ferritin	FERIB	Chemiluminescent	Siemens	ng/mL	Male 19+ years: 10.5-307.3	N/A	Reference Interval Verification Study Summary (Amendment)	0.9-1,650.0	0.9-1,650,000.0
Folate, Serum	FOLSB	Competitive immunoassay using direct chemiluminescent technology	Siemens	ng/mL	19+ years: >5.38	N/A	Atellica IM Folate Package Insert 11200602_EN Rev. 04-2020-11; Pediatric Reference Ranges, Soldin, 1999	0.56-24.00	0.56-960.00
FSII	Follicle stimulating hormone	Two-site sandwich immunoassay using direct chemilumisometric technology	Siemens	mlUmL	Male: <18.1 Female, follicular: 2.5-10.2 Female, midervele: 3.4-33.4 Female, Luteal: 1.5-9.1 Female, program: <0.3 Female, program: <0.3 Female, program: <0.3	N/A	Atellica BM FSH Package Insert 11200384_EN Rev. 06-2020-09	0.3-200.0	0.3-6,400.0
GGT	Gamma Glutamyl Transferase	A modification of the Szazz procedure 2,3 GGT catalyzes the transfer of the gamma-glutamyl group from the substrate, gamma-glutamyl-3-carboxy-4-nitrosmilide, to glycylglycine, yielding 5-amino-2-nitrobenzoate. The change in absorbance at 10 (140 80) mr is due to the formation of 5-amino-2-nitrobenzoate and is directly proportional to the GGT activity in the sample.	Beckman	UL	19+ years: 8-64	N/A	Beckman Couher IFU verified by OSU/M/C Reference Interval Study 2021 (lower end modified). Peditire Reference Ranges, Soldin. 1999 (Lower end of reference range modified to agree with the linear limits).	3-1,200	3-6,000
Glucose	anc	Glecow is phophery futed by heardships (IK) in the presence of the presence of admonistration (IK), in the presence of admonistration (IK) and the presence of admonistration into no produce gleocody phospher (GeVP) and admonistration for the produce (GeVP, Glecow-Groupher (GeVP, Glecow-Groupher (GeVP, Glecow-Groupher (GeVP, Glecow-Groupher)	Beckman	mgstL	1+ years: 70-99 (flasting)	>1year: <50 and >400 <1 year: <40 and 2000	ADA Standards October 2012, Clinical Gaide to Laboratory Tests, Textz, 1992; Podiuric Reference Ranges, Soldin, 1999	10-800	10-2,400
Glucose, Rody Fluid	FGLIC	See Glacose	Beckman	ng/dL	Administration of the constraints of the constraints of the gold are constraints or 10 mg/d are constraints or 10 mg/d are constraints or 10 mg/d are constraints with prelabor requires of mentionase. Particused Provincian gloose concentrations >50 mg/d. (28 mg/d) are constraint with one concentrations >50 mg/d. (28 mg/d) are constant with necessite with which constitute with necessite with the presentation of mg/d). The presentation of mg/d).	N/A	Armiois: Gonzalez-Booque, et al. J Mattern Feul Med. Jul-Aug 1999;34(s):15-8. Pancreatic syst: Cart, et al. Sugary. 2018 Mart 1831/3648-606. Fertinous: Hospitaly Editorials: Elepatology. 1985-52(2):275. Pericardial: Berlinous S. et al. Am J Med. 2005;118:636-60. Pericardial: Berlinous S. et al. Am J Med. 2005;118:636-60. Pericardial: Berlinous S. et al. Am Med. 2007;24(3):140-140. Pericardial: Berlinous S. et al. Martinous S. et al. Sugary. 2007;24(3):140-140. 2007;24(3):14178-1488.	10-809	10-800
Glucose, CSF	CFG HAP	See Glucose	Beckman Beckman	mg/dL	All: 40-70 44-215	<30 and >300	Clinical Guide to Laboratory Tests, Tietz, 1995 Package Insert. Verified by OSUWMC Reference	10-800 30-400	10-800 30-1-200
Haptoglobin	HAP Urine Pregnancy Test	Turbidimetry Lateral-flow test using a monoclonal		mg/dL		N/A	Interval Study 2021.	Positive	Positive
hCG Qualitative, Urine	Urine Pregnancy Test HCGTM	antibody specific to the beta subunit of hCG. Two-site Sandwich Immunoassay	Alere	Qualitative mIU/mL	Negative	N/A N/A	Package Insert Advia Centaur tHCG Package Insert 10634917_EN	Negative 2.6-1.000.0	Negative 2.6-128.000.000.0
(Tumer Marker) HDL Chalesterol	HDL.	Chemhamisescent In plase one, free cholesterol in non- IDL-lipoportion is obsilized and commod by cholesterol contage. The control of the control of the control a unique detergent selectively a budge detergent selectively a budge detergent selectively to blookhilers IDLL-lipoportion. The IDL cholesterol is relaxed for reaction with cholesterol extrasac, system to yidd a blue color complex which can be measured belevomatically at 600 700m. The creating nervens in absorbance is directly reportional to the IDLL- concentration in the ample.	Stemens Beckman	macons.	<-100 20+ year: 340	N/A	Rev. F, 2011-04 Rev. F, 2011-04 National Cholesterol Education Project (NCEP) Adult Treatment Proscool (ATP-III) (Circulation, 2002:106-3143-3421)	3-200	3-200
High-Sensitivity Troponin-I (Single Order) High-Sensitivity Troponin I (Scrial Order)	HSTI1, Troponin I, Trop I HSTI2, Troponin I, Trop I	Three-site sandwich immunoassay using direct chemiluminometric technology	Siemens	ng/L	Female: <34 Male: <53	≥3000 first time in 24 hours AND Abnormal ED ≥300	Atellica IM TnIH Package Insert 11200498_EN Rev. 06, 2019-06	3-25,000	3-2,000,000
Homocysteine	HOMCYS, HCY	Competitive immunoassay using direct chemiluminescent	Siemens	umol/L	All: 3.7-13.9	N/A	Atellica IM Homocysteine Package Insert 10995362 EN Rev. 04-2021-03	0.5-65.0	0.5-130.0
IgA	Immunoglobulin A	technology Turbidimetry	Beckman	mg/dL	Adult 19-60Y: 66-433	N/A	Package Insert. Verified by OSUWMC Reference Interval Study 2021.	10-700	10-14,000
IgG	Immunoglobulin G	Turbidimetry	Beckman	mg/dL	Adult 19-60Y: 600-1,714	N/A	OSUWMC Immunoglobulin Reference Range Study; Verified by OSUWMC Reference Interval Study 2021.	75-3,000	75-60,000
IgM	Immunoglobulin M	Turbidimetry	Beckman	mg/dL	Adult 19-60Y: 45-281	N/A	Package Insert. Verified by OSUWMC Reference Interval Study 2021.	20-500	20-50,000

Iron Saturation Lactate Debydrogenane	N/A N/A	TFTZ [2.4.5.Tit. Opprish]ty-tristicity as the charactery as the contention in the charactery as the contention and the charactery as the contention and the contention and the contention and the charactery as the contention and the contention	Beckman Beckman	megdil. % UL	19+ years: 40-174 20-55 19+ years: 100-190	N/A N/A	Established by OSI/WMC Reference Interval Study 2013, worfied by OSI/WMC Reference Interval Study 2021. saidy 2021. Clinical Guide to Laboratory Tests, Tietz, 1995; verified by OSI/WMC Reference Interval Study 2021. Pediatra Reference Brangs, Saids, 1999	10-1,000 N/A (Calculation) 25-1,200	10-2,000 N/A (Calculation) 25-60,000
Lactate Dehydrogenase Body Phild	FLID	proportional to the LD activity in the sample. See Lactate Dehydrogenase (LD)	Beckman	UL	CSC Contamination with red Nord- com Balely necross LDII measurements. Elevated DDI in CSC performs may infacture a non-specific sequences and the CSC sequences sequences and the CSC sequences sequences and the CSC sequences sequences are sequences sequences and the CSC sequences sequences are sequences power and the CSC sequences power sequences power and the CSC sequences power sequences power power power sequences power pow	N/A	CSF: Clinical Utility of Bischemical Analysis of Corebrospinal Fluid Clinical Chemistry 1995 witten MA. witten MA. property Clinical Chemistry 1995 witten MA. Petural Light, RW. N. Engal Med. 2002 Jun 20;346(25):1971-1977.	25-1,200	25-30,000
Lactate, Blood	Lactate, Plasma	L-lactate is oxidized to pyrusute and hydrogen peroxide by lactate oxidiae (LOD). A colored product is produced by the reaction of peroxidase (POD), hydrogen peroxide, 4 ammontipyrine and a hydrogen donor (TOOS). The oxided product is measured photometrically. The color intensity is proportional to the concentration of lactate in the sample under examination.	Beekman	mmol [‡] L	Alt 0.5-2.2	2 5.0	Beckman Couler Literature (IFU) which cites, Text, N. W., Clinical Coules to Laboratory Tests, Jed Edition, W. B. Standers, Philadelphia, P.A. (1995).	02:10.0	0.2-30.0
	Lactic Acid	Amperometric	Radiometer	mmol/L	0.5 - 1.6		ABL 800 Flex Reference Manual, 2008 Beckman Coulter literature which cites Clinical	0.0-30.0	0.0-30.0
Lactate, CSF Lactate, Fluid	CSLACT FLACT	See Lactate See Lactate	Beckman Beckman	mmol/L	Adult: <2.8 The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.	N/A N/A	Guide to Laboratory Tests, Tietz, 1995 N/A	0.2-10.0 0.2-10.0	0.2-30.0
LDL, Direct Measure	LDLB. Low-Density Lipoprotein Cholesterol	Cholesterol is consumed by cholesterol extrane, cholesterol voltage, pervolution and 4. molesterol control of the cholesterol control of the cholesterol extrane cholesterol from the LDL — lapoproteins. This holesterol reacts with cholesterol reacts with cholesterol reacts with cholesterol reacts with cholesterol exterase, cholesterol voidsase and a chromogen system to yield a blue color complex which can be measured beliverousited by at \$40000m. The resulting increase in absorbance is deeply proportional to the LDL-C concentration in the sample.	Beckman	mg tiL	Aduk optimal : <100	N/A	National Cholestered Education Project (NCEP) Adult Treatment Protocol (ATP-18) (Circulation, 2002;10:514:5-81)	7-400	7-400
ы	Lateinizing Hormone	Two-de Sanbwich Immunoassay Chemiluminescent	Siemens	miUmL	Make 20.70 years: 1.5-0.3 Make >70 years: 3.1-4.6 Châlten: -0.1-1.6 plause: 1.0-1.2.5 Female, mid cycle: 8.7-76.3 Female, hetel: 0.5-16.9 Female, preguant: Female, post-menopassal: 15-5-4.0 Female on Contraceptives: 0.7-5.6	N/A	Atelica IM LH Package Insert 11200385_EN Rev. 04-3020-06: Pedants Reference Ranges, Soldin. 1999	0.07-200.00	0.07-6,400.00
Lipase	LIPA	Colorimetric method of Imamura, et al. Pancreatic Ispase hydrolyzes exters of long chain flaty acids, from their trighverides. The enzyma activity requires the presence of collipase. I. 2-Dighyerides in hydrolyzed to 2-monoglyceride and fatty acid. The 2-monoglyceride is then measured by coupled enzyme reactions catalyzed by monoglycerid gase (MAZ). Bycored linase (GAZ), glycerol phosphate oxidase (GPO) and percotation (FOD).	Beckman	UL	19+ years: 11-82	N/A	Beckman Coulter Chemistry Information Sheet. 9/2020; verified by USE/WAK Electrone interval Study 2021. Pediatric Reference Ranges, 1999	6-600	6-6,000
Lipase, Fluid	PFUNZ, PFUN15, PFUN30, PFUN45, PFUN60	See Lipase	Beckman	U/L	The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.	N/A	N/A	6-600	6-600
Lipid Panel With Reflex To Measured LDL	Lipid Screen, LIPDR	See individual testing methodology	See individual testing methodology	Varies	Varies	N/A	N/A	N/A	N/A
Lithium Level	ц	A spectrophotometric method which can be readily adapted to automated clinical chemistry analyzers. Lithiam present in the sample reacts with a substituted perphyrin compound at ar alkaline pH, resulting in a change in absorbance which is directly proportional to the concentration of Lithium in the sample.	Beckman	mmol/L	<60 years: 0.60-1.20 260 years: 0.40-0.80 (Therapeutic Range)	>1.50	Applied Clinical Pharmacokinetics, Baser, 2001; Clinical Pharmacokinetics, Elérs, 1995;29:442-50 Bipolar Disord. 2019 Mar;21(2):117-123. Bipolar Disord. 2019 May;21(3):190-191.	0.10-5.00	0.10-5.00
Magnesium	MG	Utilizes a direct method in which magnesium forms a cohered complex with xylidyl blue in a strongly basic solution, where cuckium interference is eliminated by glycother-diamine-N.N.N.N. tetranectic acid (GEDTA).4,6-The coke produced is measured bichromatically at 20:0800 m and is proportional to the magnesium concentration.	Beckman	mg/dL	19+ years: 1.6-2.6	<1.0 and >4.4	Clinical Gaisle to Laboratory Tests, Tietz, 1995; verified by OSJWMC Reference Interval Study 2021. Pediatric Reference Ranges, Saddin, 1999	0.5-8.0	0.5-24.0
Magnesium, 24Hr Urine	UMG, 24	Calculation: MG*VOL/100	Beckman	mg/24hrs	72.9-121.5	N/A	Clinical Guide to Laboratory Tests, Tietz, 1995	N/A (Calculation)	N/A (Calculation)
Magnesium, Urine, Random Microalbumin, Random Urine	N/A MALBR	See Magnesium Turbidimetry	Beckman Beckman	mg/dL mg/L	N/A N/A	N/A N/A	N/A Package Insert	0.5-10.0 7.0-450.0	0.5-100.0 7.0-4,500.0
Microalbumin, Random Urine Microalbumin, 24HR Urine	MALBR N/A	Turbidimetry	Beckman Beckman	mg/L mg/24 hours	N/A <30.0	N/A	Package Insert Package Insert	N/A	N/A
Microalbumin/Creatinine Ratio		Calculation:						(Calculation) N/A	(Calculation) N/A
(ACR) Mononucleosis Screen	N/A Mononucleosis Testing, Rapid	Urine Albumin(mg/L)/Urine Creatinine(mg/dL)*100=mg/g Immunochromatographic dipstick technology utilizing bovine erythrocyte extract	Beckman Fisher Healthcare Sure-Vue Signature	mg/g Qualitative	≤30.0 All: Negative	N/A N/A	Package Insert Sure Vue Signature Mono Package Insert	(Calculation) Positive / Negative	(Calculation) Positive / Negative
-	-	-				-	-		

Osmolality	Osmolality, Serum	Freezing point depression.	Advanced Instrument Osmometer	mOsm/kg	278 - 305	<250 and >325	OSU, In House Reference Range Validation, 2017	50-2.000	50-2,000
Osmolality, Stool	FOSMO	Freezing point depression.	Advanced Instrument Osmometer	mOsm/kg	275-300	N/A	Advanced Instruments Model A2O. June 2014.	50-2,000	50-2,000
Osmolality, Serum	Osmolality	Calculation	Beckman	0.4	278-305	N/A	OSU, In House Reference Range Validation, 2015	N/A	N/A
(Calculated)	Osmolainy	(1.86 (Na +K) + 1.15 (Glucose/18) + (Urea/2.8) + 14	Beckman	mOsm/kg	2/8-303	N/A		N/A	N/A
Osmolality, Urine	UOSMR	Freezing point depression.	Advanced Instrument Osmometer	mOsm/kg	All: 300-900	N/A	Clinical Guidelines for Laboratory Tests, Tietz, 1995	50-2,000	50-2,000
Phenobarbital Level, Random	PHNOR	The assay is based on competition between drug in the sample and drug labeled with the currying gloscoe ⁴ , plouphate delydrogenase (CRPIDI) section of the control of the	Beckman	mcgmL	All: 15.0-40.0 (Therapeutic Range)	>45.0	Applied Clinical Pharmacokinetics, 2001	5.0-80.0	5.0-240.0
Phenobarbital Level, Trough	PHNO	The away is based on competition between drug in the sample and drug labeled with the enzyme glosco-6-phosphate dehydrogensus (G8D1H) for antibody hunging site. Enzyme activity decreases upon binding to the design of the cample can be measured in terms of enzyme activity. Active enzyme converts nicolomamical admine dimucleotiste (NAD) so NADH, resulting in an abovebance change that is measured that is measured appet topolometrically.	Beckman	mcg/mL	All: 15.0-40.0 (Therapeutic Range)	>45.0	Applied Clinical Pharmacokinetics, 2001	5.0-80.0	5.0-240.0
Phenytoin Total Level	PTN	The away is based on competition between drug in the sample and drug labeled with the enzyme glucose-6- phosphate debydrogensus (GePD11) for antibody binding sites. Enzyme authorly, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidired incintamatic admine dinucleotide (NAD) to NADBI, resulting in an absorbance of the converts oxiding in an absorbance of the converts oxiding in an absorbance of the converts oxiding the converts oxiding spectrophotometrically.	Beckman	meg/mL	All: 10.0-20.0 (Therapeutic Range)	222.0	Applied Clinical Pharmacokinetics, 2001	2.5-40.0	2.5-200.0
Phosphate, Inorganic	IP	Inorganic phosphate reacts with molybdate to form a heteropolyacid complex. The use of a surfactunt climinates the need to prepare a protein fine filtrate. The absorbance at 340/380 mm is directly proportional to the larorganic Phosphorus level in the sample.	Beckman	mg/dL	19+ years: 2.2-4.6	<1.0 and >10.0	OSLWMC Reference Range Study effective 12.11.2013; verified by OSLWMC Reference Interval Study 2021. Pediatric Reference Ranges, Soldin, 1999	1.0-20.0	1.0-60.0
Phosphorus, 24Hr Phosphorus, Random Urine	UIP, 24 UIPR	Calculation: (IP/1000)*(VOL/1000) See Phosphorus	Beckman Beckman	g/24hrs mg/dL	0.4-1.3 N/A	N/A N/A	Clinical Guide to Laboratory Tests, Tietz, 1995 N/A	N/A (Calculation) 10.0-200.0	N/A (Calculation) 10.0-1.000.0
Potassium	К	The ISE module for Na+, K+, and CI employs crown ether membrane electrodes for sodium and potassium and an molecular oriented PVC membrane for behirds that are specific for each ion of interest in the sample. An electrical potential is developed according to the Nernat Equation for a specific into. When Equation for a specific into. When Sodiation, this electrical potential is a translated into wodage and then into the ion concentration of the sample.	Beckman	mmol/L	18+ yean: 3.5-5.0	>18Y: <3.0 and >6.0 1-18Y: <3.0 and >6.0 <1Y: <3.0 and >7.0	OSJWMC Reference Range Study officialty 12.11.2015; verified by OSJWMC Reference Interval Study 2021. Pediatric Reference Ranges, Saldin, 1999	1.0-10.0	1.0-10.0
Potassium Body Fluid	FK	See Potassium	Beckman	mmol/L	The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.	N/A	N/A	2.0-200.0	2.0-200.0
Potassium, 24 Hr Urine	UK, 24 UKR	See Potassium See Potassium	Beckman Beckman	mmol/24hrs mmol/L	25-125 N/A	N/A N/A	Clinical Guide to Laboratory Tests, Tietz, 1995 Clinical Guide to Laboratory Tests, Tietz, 1995	N/A (Calculation) 2.0-200.0	N/A (Calculation) 2.0-200.0
Potassium, Random Urine Prealbumin	PALB	Turbidimetry	Beckman	mg/dL	17-34	N/A	Package Insert. Verified by OSUWMC Reference Interval Study 2021.	3-80	3-1,600
Procalcitonin	PROCAL	Two-site Sandwich Immunoassay Chemiluminescent	Siemens	ng/mL	<0.50		Atellica IM Procalcitonin 11200767_EN Rev. 03,		
		Circinnaniacoccia				N/A	Atelica IM Procacitonin 11200/6/_EN Rev. 03, 2010.06	0.04-50.00	0.04-2,000.00
Progesterone	PROG	Competitive immunoussay using direct chemilaminescent technology	Siemens	ng'mL	Male: 0.28-1.22 Fermak, follicular: Not detected-1.40 Fermale, lutenal: 3.34-25-56 Fermale, mid-lutenal: 4.4-28.03 Fermale, post-menopausal: Not detected-0.73	N/A	Atellica IM Processedani II 20016 - En Rev. Us. 2019-06 Atellica IM Progesterone Package Imert 11200386, EN Rev. 04-2020-06	0.04-50.00	
Progesterone Productin	PROG	direct chemiluminescent	Siemens Siemens		Male: 0.28-1.22 Female, follicular: Not detected-1.40 Female, luteal: 3.34-25.56 Female, mid-luteal: 4.44-28.03 Female, post-monopausal:		2019-06 Atellica IM Progesterone Package Insert		0.04-2,000.00
		direct chemilaminescent technology Two-site Sandwich Immunoassay		nginil.	Male: 0.28-1.22 Female, folfiscular: Not detected-1.40 Female, folfiscular: 3.34-1.25 Americal 4.44-2.80 Female, post-monopusul: Not detected-0.73 Males: 2.1-1.77 Female, post-monopusul: 1.5-20.2 Female, post-monopusul: 1.5-20.3 Female, post-monopusul: 1.5-20.3 Female, post-monopusul: 1.5-20.3 General, post-mon	N/A	2019-06 Atelica IM Progesterone Package Insert 11/200386_EN Rev. 04-2020-06 Atelica Consur Productin Package Insert 1117 Advis Consur Productin Package Insert 111746. Rev. N. 2008-09_Polisints Reference Inservals, 06	0.21-60.00	0.04-2,000.00 0.21-3,000.00
Productin	PROL	direct chemilaminescent technology Two-site Sundwich Immunoussay Chemilaminescent Cupric ions in an alkaline solution react with proteins and polyopetides containing at least two peptide bonds produce a video-forced complex. Studeoffic or protein in the concentration of protein in the concentration of protein in the concentration of protein in the	Skenens	nginiL	Male: 0.28-1.22 Female, folfischer: Nor desected, J. da Female, folfischer: Nor desected, J. da Female, folfischer: Female, folfischer: 4.44-2.803 Moles: Female, protection, mid-traited, 4.42-2.803 Moles: 1.41-77 Female, nonoprognati. Female, prognatie. 9.7-2.805 Female, popularie. 9.7-2.805 Female, popularie. 1.43-2.03 -2.3 years. 3.3.4.17 2.4 years. 3.3.4.13 2.4 years. 3.4.4.4.3	N/A	2019-06 Atelica IM Progesterone Package Insert 11200386, EN Rev. 04-2020-06 11200386, EN Rev. 04-2020-06 Advis Centuar Probactin Package Insert 111746. Rev. N. 2006-09; Pecliatric Reference Inservals, 5th ed Soldin, 2005 Clinical Guide to Laboratory Teas, Tetz, 1995; verified by OSEWMC Reference Interval Study	0.21-40.00 0.3-290.0 3.0-12.0	0.04-2,000.00 0.21-3,000.00 0.3-800,000.0
Protein Protein Total	PROL TP	direct chemilaminescent technology Two-site Sandwich Immunoussay Chemilaminescent Cupric ions in an alkaline technica recent with proteins and polyoprides containing at least two peptide bonds preduce a wide conduction and produce a wide conduction of the containing at least two peptide bonds in the produce as wide confidence of the containing of the properties and the concentration of protein in the concentration of protein in the sample. Calculation:	Siemens Beckman	ng'mL ng'mL	Male: 0.28-1.22 Female, follicular: Not detected-1.40 Female, bined: Female, mid- female, post- female, post- post- post- female, post- post- female, po	N/A N/A	2019-06 Artika IM Progesterone Package Insert 11200186_IN Rev. 04-2020-06 11200186_IN Rev. 04-2020-06 Advis Centsur Probactin Package Insert 111746 Rev. N. 2006-09. Pediatric Reference Intervals, 5th ed Soldin, 2005 Clinical Guide to Luboratory Tests, Tietz, 1995; verified by OSUWAK Reference Interval Stuly. 2011. Pediatric Reference Ranges, Soldin, 1999	0.21-60.00 0.3-200.0 3.0-12.0	0.04-2,000.00 0.21-3,000.00 0.3-890,000.0
Protein Total Protein, 24 Hr Urine	PROL TP UPRO	Greet chemisminescent technology Two-side Sandwich Immunosassy Chemismines and polypopida. The contrast of th	Siemens Beckman Beckman	ng/mL ng/mL g/dL mg/24brx	Male: 0.28-1.22 Femile, folfiscular: Not detected.1-40 Femile, brind: 3.44-2.54 A-2.54 A-2.54 A-2.54 A-2.54 A-2.54 A-3.54	N/A N/A N/A	2019-06 Atelica IM Progesterone Package Insert 11200316, EN Rev. 04-2020-06 II Rev. 04-2020-06 Advia Centuur Probactin Package Insert 111746 Rev. N. 2006-09; Prelatura Reference Inservals, 5th ed Soldin, 2005 Clinical Guide to Labocatory Tests, Tietz, 1995; Clinical Guide to Labocatory Tests, Tietz, 1995	0.21-46.00 0.3-200.0 3.0-12.0 NA (Calculation)	0.04-2,000.00 0.21-3,000.00 0.3-900,000.0 3.0-24.0 N.A. (Calcularison)
Protein Total Protein, 24 Hr Urine Protein, CSF Protein, Fluid Protein, Fluid	PROL TP UPRO CFP FLP UPROR	first chembaninescent technology Two-site Sandwich Immunosasay Chembaninescent Sendwich Immunosasay Chembaninescent Sendwich Immunosasay Chembaninescent Sendwich Se	Siemens Beckman Beckman Beckman	ng/mL g/dL mg/dL g/dL g/dL	Male: 0.28-1.22 Female, folfiscular: Nor descried-1.40 Female, formale, for	N/A N/A N/A N/A N/A	Artika IM Progesterone Package Insert 11200186 EN Rev. 04-2020-06 Arbia Centus Probactin Package Insert 111746 Rev. N. 2008-09. Podatine Reference Intervals, 5th of Soldin, 2005 Clinical Gaide to Laboratory Tests, Tietz, 1995; verified by OSUWAK Reference Interval Stuly 2011. Pediatric Reference Ranges, Soldin, 1999 Clinical Gaide to Laboratory Tests, Tietz, 1995; Podiatric Reference Ranges, Soldin, 1999 Clinical Gaide to Laboratory Tests, Tietz, 1995; Podiatric Reference Ranges, Soldin, 1999 4th Edition of Tietz	0.21-40.00 0.3-200.0 3.0-12.0 NA (Calculation) 4-200	0.04-2,000.00 0.21-3,000.00 0.3400,000.0 3.0-24.0 N/A (Calculation) 4.5,000
Protein Total Protein, 24 Hr Urine Protein, CSF	PROL TP UPRO CFP	first chembanimescent technology Two-side Sandwich Immunoanasy Chembanimescent with problem and polyprofiles containing at least two popular body and polyprofiles are vide received by the proteins and polyprofiles to produce a vide colored complex. Claylines: (PROTVCVI) 100 (mseu UCSF Protein read) the produce a vide colored complex. The Charley CSF Protein read) the Complex of the Complex o	Siemens Beckman Beckman	ng/mL ng/mL g/dL mg/24brs mg/dL	Male: 0.28-1.22 Female, folfischer: Nort descried-1.40 Female, bind: Female, bind: 4.42-2.63 Female, mid-tensel: 4.42-2.63 Female, mid-tensel: 4.42-2.63 Female, point-compound: Nort-description: 1.25-2.72 1.21-7 1.21-7 1.25-2.72 1.25-2.	N/A N/A N/A N/A	Artifica IM Progesterone Package Insert 11200330, EN Rev. 04-2020-06 Arbita Connaur Productin Package Insert 111766 Rev. N. 2006-09; Podante Reference Inservals, 5th of Swidth, 2005 Clinical Gailes to Laboratory Tests, Tierz, 1995; verified by OSI WMC Reference Intervals Swidth, 2002 Clinical Gailes to Laboratory Tests, Tierz, 1995 Pediatric Reference Ranges, Soldin, 1999 4th Edition of Tietz	0.21-40.00 0.3-200.0 3.0-12.0 N/A (Calculation) 4-200	0.04-2,000.00 0.21-3,000.00 0.3400,000.0 3.0-24.0 N/A (Calculation)

PSA - Tumor Marker	PSATM	Two-site Sandwich Immunoussay Chemiluminescent	Siemens	ng/mL	All: <4.00	N/A	Atellica IM PSA Package Insert 10997799_EN	0.04-100.00	0.04-6.400.000.00
Rheumatoid Factor	RF	Chemiluminescent Turbidimetry	Beckman	IU/mL	≤14	N/A	Rev. 03-2019-09 Package Insert. Verified by OSUWMC Reference Interval Study 2021.	10-120	10-3,000
Salitylate Level	Aspirin	Serum is mixed with Reagent I, which contains antibodies to salely, for a contain and the contain and the contain and the contain and the sale and the contain salely for all the sale and the sale with the course gloscoe de-phosphate contains salely for all the day with the compregations of phosphate with the compact for antibody being associated with the compact for antibody to the salely for a compact active and contains a contained to the salely for a contained to the salely for a contained to the salely for a contained to the compact activity. A contained to the salely for a contained to the contained to the salely for a c	Beckman	mg/dL	Therapentic: 20.0-30.0	>30.0	Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring 200 Edition 2002 Applied Therapeutics, lie. and Micromodes: On OSU Intranet.	50-80.0	5.0-240.0
Sodium	Na+	The ISE module for Na+, K+, and G- employs crown ether membrane electrodes for sodium and potassium and an molecular oriented PVC membrane for chelarle that are specific for each into of interest in the developed accounting to the Nerma Equation for a specific into When compared to the internal Reference Solution, this electrical potential is translated into Voltage and then into the sin concentration of the sample.	Beckman	mmol ^s L	1+ years: 135-145	<125 and >160	Verified by OSLWMC Reference interval Study 2021.	59-200	50-200
Sodium Body Fluid	FNA	See Sodium	Beckman	mmol/L	The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.	N/A	N/A	50-200	50-200
Sodium, 24 Hr Urine	UNA, 24	Calculation: NA*VOL/1000	Beckman	mmol/24hrs	40-220	N/A	Clinical Guide to Laboratory Tests, Tietz, 1995	N/A (Calculation)	N/A (Calculation)
Sodium, Random Urine T3 Free	UNAR FT3	See Sodium Competitive immunoassay using direct chemiluminescent technology	Beckman Siemens	mmol/L pg/mL	N/A 19+ years: 2.3-4.2	N/A N/A	N/A Atellica IM Free T3 Package Insert 10995347_EN Rev. 03-2020-06	10-400 0.2-20.0	10-400 0.2-20.0
T3 Total (Triiodothyronine)	T3, T3RIA	Competitive immunoassay using direct chemiluminescent	Siemens	ng/mL	19+ years: 0.60-1.81	N/A	Atellica IM Total T3 Package Insert 10995424_EN Rev. 03-2020-06	0.10-8.00	0.10-80.00
T4	Thyroxine, Total	technology Competitive immunoassay using direct chemiluminescent	Siemens	meg/dL	19+ years: 4,5-10.9	N/A	Atellica IM Total T4 Package Insert 10995425_EN Rev. 03-2020-069; Pediatric Reference Ranges,	0.4-30.0	0.4-300.0
T4 Free	Thyroxine, Free	technology Competitive immunoassay using direct chemiluminescent	Siemens	ng/dL	4.5-10.9 19+ years: 0.89-1.76	≥4.50 (ED Only)	Soldin, 1999 Atellica IM Free T4 Package Insert 10995348_EN Rev. 06-2020-11; Pediatric Reference Ranges,	0.10-12.00	0.10-12.00
Testosterone	TESTOS	technology Competitive immunoassay using direct chemiluminescent	Siemens	ng/dL	Male: 240-950	(ED Only) N/A	Soldin, 1999 Siemens Atellica IM Reference Interval	7-1,500	7-3,000
resource		technology Based on competition between drug			Female: 8-60		Verification Study 2023		
Theophylline Level	ТНЕО	in the sample and drug labeled with the enzyme glosso-of-phosphate the enzyme glosso-of-phosphate although control of the property of satishody binding sites. Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxilized nicotinamide adenine dimutectide (NAD) to NADII, resulting in an aborbance change that is measured spectrophotometrically.	Beckman	meg/mL	Adult: 5.0-20.0 (Therapeutic Range)	≥20.0	Applied Clinical Pharmacokinetics, 2001	2.5-40.0	2.5-200.0
Tobramyvin Level, Random	TOBR	This assay is based on competition for antibody binding sizes between drug in the sample and drug labeled with the enzyme glacose of phosphate activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidard nicotianness, and the converts oxidard nicotianness and entire distriction of the converts oxidard nicotianness and entire districtions of the converts oxidard incictainness of the converts oxidard incictainness of the converts oxidary in measured change that in measured spectrophotometrically.	Beekman	mcg/mL	Displays in Comment Field: Peak 10.0-15.0 Trough < 1.0	≥20.0 Peak	Antimicrobial Stewardship Program, 2013	0.5-10.0	0.6-50.0
Tobramycin Level, Extended Interval	TOBREI	This assay is based on competition for antibody binding sizes between drug in the sample and drug labeled with the enzyme glucose-6-phosphate declydulegense (1967B1). Euryme declydulegense (1967B1). Euryme the sample can be measured in terms of enzyme activity, Active enzyme converse oxidized nicotiannished admine disucleotide (NAI) to the converse oxidized nicotiannished admine disucleotide (NAI) to exclude the converse oxidized incinciannished admine disucleotide (NAI) to exclude the converse oxidized in measured change that is measured spectrophotometrically.	Beckman	mcg/mL	Displays in Comment Field: Peak 10.0-15.0 Trough < 1.0	≥20.0 Peak	Antimicrobial Stewardship Program, 2013	0.6-10.0	0.6-50.0
Tobramycin Level, Peak (Post Drug Level)	TOBRPK	This assay is based on competition for antibody binding sizes between drug in the sample and drug labeled with the enzyme glucose-6-phosphate declyslogeness (1967 IDI). Enzyme declyslogeness (1967 IDI). Enzyme the sample can be measured in terms of enzyme activity, Active enzyme converts oxided nicotiannishe adenine dissuelectuide (NAI) to NAIM; resulting in an absorbance of the converts oxide in an absorbance of the converts oxide in an absorbance of the converts oxide (NAIM; resulting in an absorbance of the converts oxide).	Beckman	neginl.	All: 10.0-15.0 (Therapeutic Range)	≥20.0 Peak	Antimicrobial Stewardship Program, 2013	0.6-10.0	0.6-50.0
Tobramycin Level, Trough (Pre Drug Level)	TOBRTR	This many is based on competition for antibody binding sines between drug in the sample and drug labeled with the enzyme glucose-6-phosphate deleyslong-men (SGPID). Enzyme activity decreases upon binding to the deleyslong-men (SGPID). Enzyme activity decreases upon binding to the sample can be measured in terms of enzyme activity. Active enzyme converts oxidard nicotiannishe administ disactive discontinuity of the converts oxidard incistamnishe administ disactive disactiv	Beckman	meginiL	Al-<1.0 (Therapeutic Range)	≥1.0 Trough	Antimicrobial Stewardship Program, 2013	0.6-10.0	0.6-50.0
Total Iron Binding Capacity	Transferrin/Iron Binding	Calculation: Transferrin*1.49	Beckman	meg/dL	19+ years: 250-425	N/A	Clinical Guide to Laboratory Tests, Tietz, 1995; Pediatric Reference Ranges, Soldin, 1999	112-1,118	112-1,118
Transferrin	TRANB	In the procedure, the measurement of the decrease in light transmitted (increase in absorbance) through particles suspended in solution as a result of complexes formed during the antigen-antibody reaction, is the basis of this assay.	Beckman	mg/dL	200-400	N/A	Fundamentals of Clinical Chemistry, Tietz 4th ed; Verified by OSUWMC Reference Interval Study 2021.	75-750	75-2,250

Triglycerides	TRIG	The glycerd is phosphorylated by adenoise triplosphate (ATP) in the specime of physical families (GX) to produce glycerds in phosphate. They produce glycerds in the greater of GPO (glycerd) phosphate exists power of GPO (glycerd) phosphate exists produce bydrough except the greater of GPO (glycerd) phosphate exists produce bydrough personate (HOO) and dilydrough except phosphate exists (HOO) and dilydrough except phosphate exists (HOO) and dilydrough except phosphate exists (HOO) and dilydrough except (HOO) and dilydrough except (HOO) and dilydrough except (HOO) and the greater of provides a chromopher, which is read as follows:	Beckman	mg/dL	Desirable: <150 Bookerine: 130-199 High: 200-099 Very High: ±500	N/A	National Cholesierol Education Project (NCEP) Adult Treatment Protocol (ATP-III) (Circulation, 2002;166:3143-3421)	10-1,000	10-10,060
Trigbeerides, Budy Fluid	FTRIG	See TG	Beskman	mg tiL	Derinoued Portusent fluid triplycerids values grater than 110 mg/dt. have chylose accies. Measurement may also be useful in designabing cirrhoic versus muligant origina also be useful in designabing cirrhoic versus muligant origina. Plancal Portus ripleyardes > 10 mg/dt. excludes a diyelorizer. Plendi spectrus diagnosi of a chylodorar. Denia planca in the contract of the fluid projection. The fluid results should be compared with the concentration in currentlysians or integrated into the clinical contract for interpretation.	N/A	Pleurah State BA, et al. Mayo Clin Proc. 1980:55(11):00. Peritonesh Jinger D, et al. Hepatology. 1980:66(2):238.	10-1,000	10-10,000
TSH	Thyroid Stimulating Hormone, TSH High Sensitivity	The Atellica IM TSH3-UL assay is a third-generation assay that employs anti-FITC monoclemal antibody covalently bound to paramagnetic particles, as FITC-babed anti-TSH capture mouse monocloral antibody, and a tuncer consisting of a proprietary acrification setter and an anti-TSH mouse monocloral antibody and information of the property of the prope	Siemens	uïUmL	19+ years: 0.550-4.780	Call aboormal ED only ≥150.000	Aselica IM TSHI-LIL Package Insert 11202198_EN Rev. 04-2021-03	0.008-150.000	0.008-150.000
TSH w FT4 Reflex	TSHQR	The Atellica IM TSH3-UL assay is a third-generation assay that employs anti-FITC monoclemal antibody covalently bound to paramagnetic particles, as FITC-babed anti-TSH capture mouse monocloral antibody, and a tuncer consisting of a proprietary acrification setter and an anti-TSH mouse monocloral antibody and information of the property of the prope	Siemens	ulUmL	19+ years: 0.550-4.780	Call aboormal ED only ≥150.000	Aselico IM TSHI-LIL Package Insert 11202198_EN Rev. 04-2021-03	0.008-150.000	0.008-150.000
Urea Nitrogen, 24 Hr Urine	UUREA	Calculation: (UREA/1000)*(VOL/100)	Beckman	g/24hrs	10.0-20.0	N/A	Clinical Guide to Laboratory Tests, Tietz, 2012	N/A (Calculation)	N/A (Calculation)
Uric Acid	URICB, UA	Uria acid is converted by uricase to alluntoin and hydrogen peroxide. Hydrogen peroxide reacts with 4-aminoantipyrine (4-A/P) in the presence of NA-bisid-audifobaryly-3-5-dimethylaniline, disodium salt (MADB) to produce a chromophore which is read bichromatically at 660/800 mm. The amount of dye formed is proportional to the uric acid concentration in the sample.	Beckman	mgʻdL	19+ years: Female: 2.8-6.0 Male: 3.5-7.0	N/A	OSLIWMC Reference Range Study effective 12.11.2013; verified by OSLIWMC Reference Interval Study 2021. Pediatric Reference Ranges, Soldin, 1999	1.5-30.0	1.5-60.0
Uric Acid (Spec Handling)	N/A	Lric acid is converted by uricase to allumin and hydrogen percoxie. Hydrogen percoxie reacts with 4- aminoantpyrine (4-AAP) in the presence of N. holid 4-sulfoburtyl-3-5- dimethylamiline, disodium salt (MADB) to produce a chromosphore which is read bichromatically at 660:900 mm. The amount of dye formed is proportional to the uric acid concentration in the samelor.	Beckman	mg/dL	19+ years: Female: 2.8-6.0 Male: 3.5-7.0	N/A	OSL/WMC Reference Range Study effective 12.11.2013; Pediatric Reference Ranges, Soldin, 1999	1.5-30.0	1.5-60.0
		•							
Uric Acid, 24Hr	UURIC, 24	Calculation:	Beckman	g/24hrs	0.3-0.8	N/A	Clinical Guide to Laboratory Tests, Tietz, 1995	N/A (Calculation)	N/A (Calculation)
Uric Acid, Random, Urine	UURICR	Calculation: (URIC/100) * (VOL/1000) See Uric Acid	Beckman	mg/dL	N/A	N/A	N/A	(Calculation) 1.0-100.0	(Calculation) 1.0-300.0
		Calculation: (URIC/100) * (VOL/1000)						(Calculation)	(Calculation)
Uric Acid, Random, Urine Urine Calcium	UURICR Calcium, Random Urine	Calculation: (URIC/100) * (VOL/1000) See Uric Acid See Calcium	Beckman Beckman	mg/dL mg/dL	N/A N/A	N/A N/A	N/A N/A	(Calculation) 1.0-100.0 0.1-40.0	(Calculation) 1.0-300.0 0.1-120.0
Uric Acid, Random, Urine Urine Calcium Urine Urea Nitrogen - Random	UURICR Calcium, Random Urine UREAR	Calcularion: (URC1001 * VOL/1000) See Uke Acid See Calcum See Uke Acid See Calcum See BUN See BUN See BUN See BUN See BUN See	Beckman Beckman Beckman	may'dL may'dL mg'dL	N/A N/A N/A N/A	N/A N/A N/A	N/A N/A N/A Clinical Guide to Laboratory Tests, Tietz, 1995 Guide Test of Laboratory Tests, Tietz, 1995 Applied Clinical Pharmacohiseries, 2001 Clinical Pharmacohiseries, 2001 Assimicrobial Pharmacohiseries, 2001, Assimicrobial	(Calculation) 1.0-100.0 0.1-40.0 20-1,300	(Calculation) 1.0-300.0 0.1-120.0 20-13,000
Urin And Random Urin Urin Cledium Urin Cledium Urin Uren Nitrogen - Random Vancomycin Level, Random Vancomycin Level, Random	UJECK Culcium, Random Urac UREAR VANCTR	Calculationes Calculationes CRECUISTO 1/2007/10090 See Use Acad See One See One See One	Beckman Beckman Beckman	mg/dL mg/dL mg/dL mg/mL	NA. NA. NA. NA. NA. NA. NA. A. NA. NA. A. A. NA. A. A. NA. A. A. NA. A. A. NA. A. A	N/A N/A N/A N/A 225.1 Trough	N/A N/A N/A Clinical Golde to Laboratory Tests, Tietz, 1995 Clinical Golde to Laboratory Tests, Tietz, 1995 Applied Clinical Pharmacokinetics, 2001 Clinical Pharmacokinety, 1995; 153-54, Astrimicrobial Societablish Program, 2013 Societablish Program, 2013 Applied Clinical Pharmacokinetics, 2001 Clinical Pharma	(Calculation) 1.0-1000 0.1-400 20-1-300	(Calculation) 1.0.3909 0.1.1289 20-13.000 20-13.000
Urie And, Random, Urine Urine Cheine Cheine Cheine Cheine Urine Cheine Urine U	UJERCE Colsium Random Urne UREAR VANCTR	Calculatione: Calculatione: Calculatione: Calculatione: See Use Acid Acid	Beckman Beckman Beckman Beckman	mg/dL mg/dL mg/dL mg/mL mg/mL	NA. N/A N/A N/A N/A N/A N/A N/A Peak 20.40.0 Trough 10.0-20.0 Trough 10.0-20.0 (Therapeutic Range) AR 10.0-20.0	N/A N/A N/A N/A 225.1 Trough	NA. NA. Clinical Guide to Laboratory Tests, Test, 1995 Clinical Guide to Laboratory Tests, Test, 1995 Applied Clinical Pharmacodoirede, 2001 Clinical Pharmacodorrapy, 1995; 1535-91, Antimicrobial Stewardship Program, 2013 Applied Clinical Pharmacodoiredes, 2001 Clinical Pharmacodorrapy, 1995; 153-691, Antimicrobial Stewardship Program, 2013 Applied Clinical Pharmacodoiredes, 2001 Clinical Pharmacodorrapy, 1995; 153-691 Applied Clinical Pharmacodoiredes, 2001 Clinical Pharmacodorrapy, 1995; 154-691	(Calculation) 1.0-1000 0.1-800 20-1.300 20-1.300	(Cabadriso) 1.0.3009 0.1.7039 20.13000 20.13000 20.250.0
Uris Acid, Random, Urine Urea Villen Urine Urea Nitrogen - Random Urine Urea Nitrogen - Random Vancomycin Level, Random Vancomycin Level, Random Vancomycin Level, Trough (Pee Drug Level) Vancomycin Level, Trough (Pee Drug Level)	ULBECK Cokisms, Enadom Urice UREAR VANCTR VANCTR VANCTR	celebratese Celebr	Beckman Beckman Beckman Beckman Beckman	mgidi. mgidi. mgidi. mgidi. mgidi. mgidi. mgini.	NA. NA. NA. NA. NA. NA. NA. NA. All 200-200 Trough 100-200 Trough 100-200 (Theraposite Range) All 200-400 (Theraposite Range)	N/A N/A N/A N/A 223.1 Trough	N/A N/A N/A Clinical Guide to Laboratory Tests, Tietz, 1995 Applied Clinical Pharmacodineries, 2001 Clinical Pharmacodineries, 2001 Clinical Pharmacodineries, 2013 Applied Clinical Pharmacodineries, 2001 Clinical Pharmacodineries, 2011 Applied Clinical Pharmacodineries, 2001 Clinical Pharmacodineries, 2011 Applied Clinical Pharmacodineries, 2001 Clinical Pharmacodineries, 1995; 15:85-91 Applied Clinical Pharmacodineries, 2001 Clinical Pharmacodineries, 1995; 15:85-91	(Calculation) 1.0.1009 0.1.40.0 20-1.100 20-1.000 20-500	(Cabadoso) (Cabadoso) (A 1-200) (A 1

Antibodies		-	IgG Antibodies: VersaMax plate	IgG Antibodies: U/mL	IgG Antibodies; ≤12.0 U/mL	****	• • • • • • • • • • • • • • • • • • • •	IgG Antibodies: 6.0-104.0 U/mL	IgG Antibodies: 6.0-104.0 U/mL
Alternative Activation Pathway	Bb Complement	ELISA	reader, Technozym kit VersaMax Plate Reader, Quidel kit	ng/mL	695-1,974	N/A	Biomarker Reference Lab	See Quidel kit values (lot number specific)	See Quidel kit values (lot number specific)
EM Platelet (Electron Microscopy)	Tissue Exam	Whole mount	N/A	dg/plt	3.68-6.24	N/A	Old journal articles; lab derived	N/A	N/A
SC5b-9 Complement	Terminal Activation Pathway	ELISA Chemiluminescent two-step	VersaMax Plate Reader, Quidel kit	ng/mL	6-598	N/A	Biomarker Reference Lab	See Quidel kit values (lot number specific)	See Quidel kit values (lot number specific)
Anti-Cardiolipin Ab, IgG	ACA; ACL; APA; Anti- Phospholipid Antibody IgG	immunoassay with paramagnetic microparticles as the solid phase, and a derivative of isoluminol as the chemiluminescent molecule.	lnova	cu	0.0-20.0	N/A	Inova Quanta-Flash Package Insert Verified in house	10.0-500.0	10.0-10,000.0
Anti-Cardiolipin Ab, IgM	ACA; APA; ACL; Anti- Phospholipid Antibody IgM	Chemiluminescent two-step immunoassay with paramagnetic microparticles as the solid phase, and a derivative of isoluminol as the chemiluminescent molecule.	lnova	cu	0.0-20.0	N/A	Inova Quanta-Flash Package Insert Verified in house	10.0-200.0	10.0-4,000.0
Antithrombin	AT	Chromogenic measurement system consisting of a beam of monochromatic light at 405nm. This is a two step thrombin neutralization process.	Stago	%	17+ years: 85-118	N/A	OSU Inhouse Study 02/2004; Blood, Vol 80, 1998- 2005, Andrew, 1992; Amer. Jour. Ped. Hematol. Oncol, Vol 12, 95-104, Andrew, 1990	See Stago Unicalibrator assayed values (lot number specific)	9-200
Anti Xa DOAC (Apixaban)	Apicaban, DOAC, Eliquis	Chronogenic measurement system consisting of a beam of most-chromate light at 405 am.	Stago	nginiL	Diplayed Comment: Routine mentoring of and IAA activity Agricultus. Thereposite reference Agricultus. Thereposite reference ranges have not been established. At stately state: medium (5th-95th stately state: medium (5th-95th have been observed in clinical trials.	N/A	1. Package insert: Apicaban: Diagnostica Stago. Revised January 2015 2. Hurst KV, OʻLaliqhan M, Handa A, Quick-reference guide to giptaban. Vasc Health Rick Activation of the property of the	23-500	23-500
Anti Xa DOAC (Rivaresaban)	Rivarosabun, DOAC, Xarelto	Chromogenic measurement system consisting of a beam of mounce/termate light at 405 am.	Stago	ngʻmL	Displayed Comment: Routine membering of and XA, activity Routine technology of and XA, activity Routenshabe. The reposite reference regards have not been established. At study state: mediant (50-596) proventile) peak and trough levels have been observed in classed trials.	N/A	I. Package insert. Resureashure Diagnostica Stago. Revision December 2014 2. Museck W. Sampfins J. Kehker D. Beech and V. Christical pharmacologumic and pharmacodynamic christian pharmacologumic production of the production and pharmacolynamic production of the production of the pharmacologumic product pharmacologumic products (Datasette Characteristics, 2013. 2014; 53(1):1-16 doc. 10.1007/s0026-011-010007 2014; 53(1):1-16 doc. 10.1007/s0026-011-010007 2014; 53(1):1-16 doc. 10.1007/s0026-011-010007 2015; 63(1):1-10007 2015; 63(1):1-10007 2015; 63(1):1-10007 2015; 63(1):1-10007 2015; 63(1):1-10007 2015; 63(1):1-10007 2015; 63(1):1-10007 2015; 63(1):1-10007 2015; 63(1):1-10007 2015; 63(1):1-1007 2015; 64(1):1-10007 201	25-500	25-500
Anti Xa LMWH (Enoxaparin) 4 Hr Post	Anti-Xa for LMWH, Peak Dose, AXMLPK	Chromogenic measurement system consisting of a beam of monochromatic light at 405nm.	Stago	Anti-Xa IU/mL	0.60-1.00 (Therapeutic Range: applies to 4 hour post dose collections)	N/A	Chest, vol. 119, issue 1, January 2001, pgs. 64S- 75S.	0.10-1.60	0.10-1.60
Anti Xa LMWH (Enoxaparin) Random	Anti-Xa for low molecular weight heparin	Chromogenic measurement system consisting of a beam of	Stago	Anti-Xa IU/mL	0.60-1.00 (Therapeutic Range: applies to 4 hour	N/A	Chest, vol. 119, issue 1, January 2001, pgs. 64S-75S.	0.10-1.60	0.10-1.60
Beta-2 Glycoprotein 1 Ab, IgG	Beta 2 Glycoprotein 1 IgG Antibody	monochromatic light at 405nm. Chemiluminescent two-step immunoassay with paramagnetic microparticles as the solid phase, and a derivative of isoluminol as the chemiluminescent molecule.	lnova	CU	post dose collections) 0.0-20.0	N/A	Inova Quanta-Flash Package Insert Verified in house	10.0-500.0	10.0-10,000.0
Beta-2 Glycoprotein 1 Ab, IgM	B2GP1, IgM; Beta 2 Glycoprotein 1 IgM Antibody	Chemiluminescent two-step immunoassay with paramagnetic microparticles as the solid phase, and a derivative of isoluminol as the chemiluminescent molecule.	lnova	cu	0.0-20.0	N/A	Inova Quanta-Flash Package Insert Verified in house	10.0-200.0	10.0-4,000.0
Beta-2 Glycoprotein 1, Domain 1	Beta2 GP1 Domain 1, B2GP1 Dm1, β2GP1 Domain 1, β2GP1 Dm1	Chemiluminescent two-step immunoassay with paramagnetic microparticles as the solid phase, and a derivative of isoluminol as the chemiluminescent molecule.	lnova	CU	0.0-19.9	N/A	Inova Quanta-Flash Package Insert Verified in house	10.0-200.0	10.0-2,000.0
D-Dimer, Quantitative	HSDDI	Immunoturbidimetric - photometric measurement system consisting of a beam of monochromatic light at 540nm passing through a solution of antibody coated microlatex particles.	Stago	mcg/mL FEU	<0.50	N/A	OSU Lab Normal Range Study (08/2007)	0.27-4.00	0.27-20.00
DIC Workup	DIC Panel Includes: Platelet Count, PT, PTT, Fib, TT, D-Dimer, PTT/TT Mixing Studies (as appropriate) and Pathologist Interpretation	See individual tests	See individual tests	See individual tests	See individual tests	See individual tests	See individual tests	See individual tests	See individual tests
Dilute Russell Venom Time	DRVVT	Mechanical Clot Detection	Stago	Ratio	Screen ratio: ≤1.10 Normalized ratio: ≤1.21	N/A	OSUWMC, in-house reference range study performed yearly Clinical Guide to Laboratory Tests, Tietz, 1995;	N/A	N/A
Factor II Activity	Prothrombin Activity, FA2	Mechanical Clot Detection	Stago	% Activity	17+ years: 60-150	<5	Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987	See Stago Unicalibrator assayed values (lot number specific)	3-500
Factor IX Activity	Christmas Factor, FA9	Mechanical Clot Detection	Stago	% Activity	17+ years: 77-147	<5	OSU Inhouse Study 02/2004; Blood, Vol 80, 1998- 2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987	See Stago Unicalibrator assayed values (lot number specific)	1-500
Factor IX Inhibitor	Factor IX Antibody, FAC9AB	Mechanical Clot Detection Bethesda Assay	Stago	Bethesda units	Negative (0.0 Bethesda units)	N/A	N/A	N/A	0.0 - dilute to endpoint
Factor V Activity	Labile Factor, FA5	Mechanical Clot Detection	Stago	% Activity	17+ years: 50-150	<5	Clinical Guide to Laboratory Tests, Tietz, 1995; Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987	See Stago Unicalibrator assayed values (lot number specific)	3-500
Factor VII Activity	FA7	Mechanical Clot Detection	Stago	% Activity	17+ years: 65-135	<5	Clinical Guide to Laboratory Tests, Tietz, 1995; Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987	See Stago Unicalibrator assayed values (lot number specific)	3-1000
Factor VIII Activity	Anti Hemophilic Factor, FA8	Mechanical Clot Detection	Stago	% Activity	17+ years: 75-220	<5	OSU Inhouse Study 02/2004; Blood, Vol 80, 1998- 2005, Andrew, 1992; Blood, Vol 70, 165-172,	See Stago Unicalibrator assayed values (lot number specific)	1-500
Factor VIII Inhibitor Assay	Factor VIII Antibody	Mechanical Clot Detection Bethesda Assay	Stago	Bethesda units	Negative (0.0 Bethesda units)	N/A	Andrew, 1987 N/A	values (lot number specific) N/A	0.0 - dilute to endpoint
Factor X Activity	Stuart Prower Factor, FA10	Bethesda Assay Mechanical Clot Detection	Stago	% Activity	(0.0 Bethesda units) 17+ years: 60-130	<5	Clinical Guide to Laboratory Tests, Tietz, 1995; Blood, Vol 80, 1998-2005, Andrew, 1992; Blood,	See Stago Unicalibrator assayed values (lot number specific)	3-500
Factor XI Activity	Hemophilia C, FA11	Mechanical Clot Detection	Stago	% Activity	17+ years: 65-135	<5	Vol 70, 165-172, Andrew, 1987 Clinical Guide to Laboratory Tests, Tietz, 1995; Blood. Vol 80, 1998-2005. Andrew, 1992: Blood.	See Stago Unicalibrator assayed	1 - 500
Factor XI Activity Factor XIII Activity	Hemophila C, FA11 Fibrin Stabilization Factor, FA13	Mechanical Clot Detection Solubility	Stago N/A	% Activity N/A	17+ years: 65-135 Present	<5 N/A	Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987	values (lot number specific)	1 - 500 Present Absent
Factor XIII Activity Fibrinogen, Clottable	Fibrin Stabilization Factor, FA13	Sommery	N/A	N/A	Present 220-410	N/A <75	N/A OSU Lab Normal Range Study (05/2003)	N/A	Absent Absent
Fibrinogen, Obstetrical	FIB, OB	Mechanical Clot Detection	Stago	mg/dL	First Trimester: 244-516 mg/dt. Second Trimester: 291-538 mg/dt. Third Trimester: 373-619 mg/dt. OB Patient Comment: Fibrinogan levels may be altered by the normal physiologic changes of pregnancy and should be interpreted considering reference ranges specific to gentational age.	200	(05.2003) OB Patient Comment: Reference Abbassi-Ghansun M. Geer LG. Clanninghan FG. Forgun; and abovesary indices a reference sub-long-state of the state of th	66-900	60-900
Heparin Anti-Xa Unfractionated	HEPAS	Chromogenic measurement system consisting of a beam of	Stago	IU/mL	0.30-0.70 (Therapeutic Range: applies to 4 hour	N/A	Chest, vol. 119, issue 1, January 2001, pgs. 64S-	0.10-0.80	0.10-1.60
Heparin Platelet Factor 4 (HIT	PF4IGP	monochromatic light at 405nm.			post dose collections) O.D. <0.400		75S. Immucor LIFECODES® PF4 IgG Assay Package	0.10-0.80	0.10-1.60
Screen) With Reflex To SRA	PF4IGP	ELISA, IgG	Immucor	O.D., % Heparin Inhibition	Heparin Inhibition- <50%	N/A	Insert	0.000-3.000	0.000-3.000

Hexagonal PL Neutralization	Hexagonal PL Neutralization; STACLOT-LA	Mechanical Clot Detection	Stago	sec	±9.7	N/A	OSUWMC, in-house reference range study performed yearly	N/A	≥0.0
					0.9-1.1				
					Oral Anticoagulant Therapy Target Ranges:				
INR	N/A	Calculated from PT value, the ISI and the geometric mean value of the PT	Stago	(ratio)	Standard Therapy	INR >4.9	OSUWMC in-house reference range, verified yearly	0.5 - 15.1	0.5 - 15.1
		normal reference range.			2.0-3.0		yemiy		
					High Dose				
					2.5-3.5				
	Lupus Workup Package includes PT, INR, TT,								
Lupus Anticoagulant	DRVVT Screen, PTT-LA, Mixing Studies, DRVVT Confirm and or	See individual	See individual	See individual	See individual	See individual	See individual	See individual	See individual
	Hexagonal Phase Phospholipid Neutralization	tests	tests	tests	tests	tests	tests	tests	tests
	(as appropriate)								
					ADP 5 umol/L 67 - 92				
					ADP 10 umol/L 73 - 91				
					Arachidonic Acid 05 mmol/L				
					72 - 91 Collagen 2 ug/mL				
					80 - 96 Collagen 5 ug/mL				
				% Aggregation	71 - 92 Epinephrine 5 umol/L				
					64 - 105 Ristocetin 0.5 ma/mL				
					0 - 6				
					Ristocetin 1.25 mg/mL 70 - 105				
		Born method of Turbidimetric			Thromboxane 20 umol/L 73 - 112				
Platelet Aggregation	N/A	Aggregation with simultaneous measurement of ATP release by	Chrono-Log		Pathologist Interpretation: Normal	N/A	OSUWMC In-house Reference Range Study	N/A	N/A
		Platelet Lumi-Aggregometry	_		Aggregation.		(02-2023)		
					ADP 5 umol/L 0.28 - 0.93				
					ADP 10 umol/L				
					0.44 - 1.19 Arachidonic Acid 05 mmol/L				
					0.37 - 0.90 Collagen 2 ug/mL				
				nmole	0.26 - 1.07 Collagen 5 ug/mL				
					0.49 - 1.32				
					Epinephrine 5 umol/L 0.35 - 0.96				
					Thrombin 1 Unit 0.36 - 0.99				
					Pathologist Interpretation: Normal				
					Aggregation.				
					Collagen/Epinephrine: 73-172				
Platelet Function Test	Platelet Function Assay, PFA	Instrument PFA-100 Closure Time: The time measured from the start of	Siemens	sec	Collagen/ADP:	N/A	OSU Normal Range Study (07/2004)	31-300	31-300
Finitelet Function Test	e muces runction Assay, PFA	the test until a platelet to close aperture after exposure to agonist	Siemens	sec	53-111	N/A	OSO (vorma) Kange Study (07/2004)	31-300	31-300
					Platelet function interpretation: Normal Function				
Platelet P2Y12 Inhibition Test	P2Y12 Inhibition Test; Verify Now PRU Test	Platelet Aggregation is a self- contained test device	Verify Now	PRU	194 - 418	N/A	Accumetries, verified at OSU	1-999	1-999
							OSU Inhouse Study; Blood, Vol 80, 1998-2005,	See Stago Unicalibrator assayed	
Protein C Activity	PROTC	Mechanical Clot Detection	Stago	% Activity	17+ years: 72-220	N/A	Andrew, 1992; Amer. Jour. Ped. Hematol. Oncol, Vol 12, 95-104, Andrew, 1990	values (lot number specific)	10-300
							OSU Inhouse Study; Blood, Vol 80, 1998-2005,		
Protein S Activity	PROTS	Mechanical Clot Detection	Stago	% Activity	17+ years: 50-168	N/A	Andrew, 1992; Amer. Jour. Ped. Hematol. Oncol, Vol 12, 95-104, Andrew, 1990	See Stago Unicalibrator assayed values (lot number specific)	10 - 300
PT	Protime-INR	Mechanical Clot Detection	Stago	sec	11.9 - 14.2	N/A	OSUWMC in-house reference range, verified	7.0 - 109.0	7.0 - 109.0
	Prothrombin Time Mixing Study						yearly		
PT and PT Mixing Study	Protime Mixing Study	Mechanical Clot Detection	Stago	sec	N/A	N/A	N/A	See PT Test	See PT Test
PT Mix w/ Normal Plasma	N/A	Mechanical Clot Detection	Stago	sec	N/A	N/A	N/A	See PT Test	See PT Test
PTT	APTT	Mechanical Clot Detection	Stago	sec	24.0-34.3	Inpatient: >150.0	OSUWMC, in-house reference range study	20.0 - 180.0	20.0 - 180.0
	Partial Thromboplastin Time				Heparin Therapeutic Range (HTR): 77.0 - 91.0	Outpatient: >60.0	performed yearly		
PTT Mix w/ Normal Plasma PTT with Mixing Study	Partial Thromboplastin Time N/A N/A	Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection	Stago Stago Stago	sec sec sec	Heparin Therapeutic Range (HTR):		performed yearly N/A N/A	20.0 - 180.0 See PTT Test See PTT Test	20.0 - 180.0 See PTT Test See PTT Test
PTT Mix w/ Normal Plasma	Partial Thromboplastin Time N/A	Mechanical Clot Detection	Stago	sec	Heparin Therapeutic Range (HTR): 77.0 - 91.0 N/A	Outpatient: >60.0 N/A	performed yearly N/A	See PTT Test	See PTT Test
PTT Mix w/ Normal Plasma PTT with Mixing Study PTT-LA	Partial Thromboplastin Time N/A N/A N/A LA-PTT; PTT- Lupus Sensitive, Includes PTT-LA Mixing Study	Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Platelet Agglutination	Stago Stago Stago	sec sec sec	Heparin Therapeutic Range (HTR): 77.0 - 91.0 N/A N/A N/A ≤43.2	Outpatient: >60.0 N/A N/A N/A	N/A N/A OSUWMC, in-house reference range study performed yearly	See PTT Test See PTT Test	See PTT Test See PTT Test 20.0-180.0
PTT Mix w Normal Plasma PTT with Mixing Study PTT-LA Ristocetin CoFactor	Partial Thromboplastin Time N/A N/A N/A LA-PTT; PTT- Lupus Sensitive, Includes PTT-LA Mixing Study Von Willebrand Factor Activity	Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Platelet Agglutination Light Transmittance Aggregometry	Stago Stago Stago Helena	sec sec sec	Heparin Therapeutic Range (HTR): 77.0 - 91.0 N/A N/A S/43.2 40-200	Outpatient: >60.0 N/A N/A N/A N/A N/A	performed yearly N/A N/A OSUWMC, in-house reference range study performed yearly OSU Normal Range Study	See PTT Test See PTT Test 20.0-180.0 See Helena SARP calibrator assayed value (lot number specific)	See PTT Test See PTT Test 20.0-180.0
PTT Mix w/Normal Plasma PTT with Mixing Study PTT-LA Ristocetin CoFactor Thrombin Time	Partial Thromboplastin Time N/A N/A N/A LA-PTT; PTT- Lupus Sensitive, Includes PTT-LA Mixing Study	Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Platelet Agglutination	Stago Stago Stago	sec sec sec	Heparin Therapeutic Range (HTR): 77.0 - 91.0 N/A N/A N/A ≤43.2	Outpatient: >60.0 N/A N/A N/A	N/A N/A OSUWMC, in-house reference range study performed yearly	See PTT Test See PTT Test 20.0-180.0 See Helena SARP calibrator assayed	See PTT Test See PTT Test 20.0-180.0
PTT Mix w Normal Plasma PTT with Mixing Study PTT-LA Ristocctin CoFactor Thrombin Time TT Mix w Normal Plasma	Partial Thromboplastin Time N/A N/A N/A LA-PTT; PTT- Lupus Sensitive, Includes PTT-LA Mixing Study Von Willebrand Factor Activity	Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Platelet Agglutination Light Transmittance Aggregometry	Stago Stago Stago Helena	sec sec sec	Heparin Therapeutic Range (HTR): 77.0 - 91.0 N/A N/A S/43.2 40-200	Outpatient: >60.0 N/A N/A N/A N/A N/A	performed yearly N/A N/A OSUWMC, in-house reference range study performed yearly OSU Normal Range Study	See PTT Test See PTT Test 20.0-180.0 See Helena SARP calibrator assayed value (lot number specific)	See PTT Test See PTT Test 20.0-180.0
PTT Mix w/Normal Plasma PTT with Mixing Study PTT-LA Ristocetin CoFactor Thrombin Time	Partial Thromboplastin Time N/A N/A N/A LA-PTT; PTT. Lapus Sensirive, Includes PTT-LA Mixing Study Von Willebrand Factor Activity Thrombin Clotting Time	Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Light Transmittance Aggregatetry Mechanical Clot Detection	Stago Stago Stago Helena Stago	sec sec sec % Activity	Heparin Therapeutic Range (HTR): 77.0 - 91.0 N/A N/A S/A \$43.2 40.200 13.0-20.0	Outpatient: -60.0 N/A N/A N/A N/A N/A N/A N/A	performed yearly N/A N/A N/A OSUWMC, is-bouse reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study	See PTT Test See PTT Test 20.0-180.0 See Helena SARP calibrator assayed value (lot number specific) 10.0-120.0	See PTT Test See PTT Test 20.0-180.0 13-400 10.0-120.0
PTI Mix w/Normal Plasma PTI with Mixing Study PTI-LA Ristocctin CoFactor Thrombin Time TI Mix w/Normal Plasma (Not individually orderable, Order Lupus Anticogulant Workup)	Partial Thromboplastin Time NIA NIA LA-PIT; PIT. Lapus Sensitive, Includes PIT-LA Mixing Study Von Willebrand Factor Acting Thrombin Clotting Time Thrombin Clotting Time	Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Light Transmittance Aggregatetry Mechanical Clot Detection	Stago Stago Stago Helena Stago	sec sec sec % Activity	Heparin Therapeutic Range (HTR): 77.0 - 91.0 N/A N/A S/A \$43.2 40.200 13.0-20.0	Outpatient: -60.0 N/A N/A N/A N/A N/A N/A N/A	performed yearly N/A N/A N/A OSUWMC, is-bouse reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study	See PTT Test See PTT Test 20.0-180.0 See Helena SARP calibrator assayed value (lot number specific) 10.0-120.0	See PTT Test See PTT Test 20.0-180.0 13-400 10.0-120.0
PIT Mix w/ Normal Hamm. PTI with Mixing Study. PTI-LA Ristocctin CoFactor Thrombin Time TT Mix w/ Normal Plasma (Not individual) predeable, Order Lapas Anticoagulart Workup) TT Mix w/ Protamine Sulfate	Partial Thromboplastin Time NIA NIA LAPTE, PIT. Lagus Sensire, lackete, PIT.LA Mring Shady Von Wildehand Factor Activity Thrombin Closting Time Thrombin Clotting Time Thrombin Time with Heparin	Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Mechanical Clot Detection Light Transmittance Aggregatetry Mechanical Clot Detection	Stago Stago Stago Helena Stago	sec sec sec % Activity	Heparin Therapeutic Range (HTR): 77.0 - 91.0 N/A N/A S/A \$43.2 40.200 13.0-20.0	Outpatient: -60.0 N/A N/A N/A N/A N/A N/A N/A	performed yearly N/A N/A N/A OSUWMC, is-bouse reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study	See PTT Test See PTT Test 20.0-180.0 See Helena SARP calibrator assayed value (lot number specific) 10.0-120.0	See PTT Test See PTT Test 20.0-180.0 13-400
PTI Mix w/Normal Plasma PTI with Mixing Study PTI-LA Ristocctin CoFactor Thrombin Time TI Mix w/Normal Plasma (Not individually orderable, Order Lupus Anticogulant Workup)	Partial Thromboplastin Time NIA NIA LA-PIT; PIT. Lapus Sensitive, Includes PIT-LA Mixing Study Von Willebrand Factor Acting Thrombin Clotting Time Thrombin Clotting Time	Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Platelet Agglustination Light Transmissions Aggregamenty Mechanical Cist Detection Mechanical Cist Detection	Stago Stago Stago Stago Stago Helena Stago Stago	sec sec sec % Activity sec	Hepwin Therapeuris Range (HTR): 770 - 91.0 NA. NA. S43.2 40-220 13.0-20.0	Outpatient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A N/A OSUNG: shower reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study OSU Lab Normal Range Study	See PTT Test See PTT Test 20.4180.0 See Helena SARP callerator assayed where (se member specific) 10.0-120.0	See PTT Test See PTT Test 20.0-180.0 13-400 10.0-120.0
PTT-Mix w/ Normal Planns PTT stifs Mixing Study PTT-LiA Ristocctia CaPactor Throught Time TTMix w/ Normal Planns (Not individually orderable, Order Lapas Anticognalm Workup) TT Mix w/ Protamine Sulfate (Not individually orderable, Order Lapas Anticognalm Workup)	Partial Thromboplastin Time NAA NAC NAC LA-PTF PT Lupa Semitive, Include PTF1-LA Mining Study Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization	Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Plateket Agglorization Light Transmittance Aggregateity Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection	Stage Stage Stage Stage Stage Hickena Stage Stage	sec	Hepwin Therapeuris Range (HTR): 770 - 91,0 NA NA S43 40-200 13.0-20.0	Outpatient: ~60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A N/A OSUWAC, abouts reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study OSU Lab Normal Range Study OSU Lab Normal Range Study	See PIT Feet See PIT Teet See PIT Teet 20-180.0 See Helman SARP calibrator assuped value (for number specific) 10-0-120.0 10-0-120.0	See PTT Test See PTT Test 20.0-180.0 13-400 10.0-120.0 10.0-120.0
PIT Mix w Normal Plasma PIT stift Miking Study PIT-LA Ristocetia CoFactor Throuble Time TI Mix w Normal Plasma (Not individually orderable, Order Lupus Anticoggulant Workup) TI Mix w Protamine Sulfate (Not individual you individually orderable, Order Lupus Anticoggulant Workup) Van Willebrand Buttery Agn + Van Willebrand Buttery Agn +	Partial Thromboplastin Time NAA NIA NIA LA-FIF PIT. Lapus Sensirie, Includes FIFT-At Mang Shady Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Von Willebrand Workup Includes. Von Willebrand Workup Includes. Fig. 88 Sensirie Clotting Vity Von Willebrand Workup Includes. Fig. 88 Sensirie Clotters and 4 Von Fig. 88 Sensirie Clotters and 4 Von	Mechanical Cist Detection Platect Agglerianton Light Transmittance Light Transmittance Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection See indokhal	Stago Stago Stago Stago Helena Stago Stago Stago Stago	sec	Heparin Therapeuric Range (HTR): 77.0 - 91.0 NA NA NA 40-200 13.0-20.0 13.0-20.0 See individual	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A OSUWMC, in shouse reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study OSU Lab Normal Range Study OSU Lab Normal Range Study SU Lab Normal Range Study	See PTT Yet See PTT Test See PTT Test 20-180.0 See Helena SARP calibrator assayed whic (ist number specific) 10-0-120.0 10-0-120.0 See Helena Sarpator Sarpa	See PTT Test See PTT Test 20.6-180.0 13-400 10.0-120.0 10.0-120.0 See individual
PTI Mix of Normal Planns PTI with Mixing Study PTI Act Ristocctian CoFactor Throught Time TT Mix w Normal Plasma (Not Individually ordensite, Order Lappes Anticognalent Workup) TT Mix w Protuntine Suffate (Not Individually ordensite, Order Lappes Anticognalent Workup)	Partial Thromboplastin Time NIA NIA NIA LA-TIP, TIT. Lapus Seminie, Inchée PTT-LA Ming Shady Von Willehrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Von Willehrand Workup Inchées Von Willehrand Workup Inchées	Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Plateket Agglorization Light Transmittance Aggregateity Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection	Stage Stage Stage Stage Stage Hickena Stage Stage	sec	Hepwin Therapeuris Range (HTR): 770 - 91,0 NA NA S43 40-200 13.0-20.0	Outpatient: ~60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A N/A OSUWAC, abouts reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study OSU Lab Normal Range Study OSU Lab Normal Range Study	See PIT Feet See PIT Teet See PIT Teet 20-180.0 See Helman SARP calibrator assuped value (for number specific) 10-0-120.0 10-0-120.0	See PTT Test See PTT Test 20.0-180.0 13-400 10.0-120.0 10.0-120.0
PTI Mix w Normal Planna PTI with Mixing Study PTI-LA Ristocetin CoFactor Thrombin Time TI Mix w Normal Planna (Not individually orderable, Order Lapse Anticoagulant Workup) TI Mix w Prostamine Sulfate (Not individual proferable, Order Lapse Anticoagulant Workup) Van Willebrand Buttery Agn +	Partial Thromboplastin Time NIA NIA LAPTE, PIT. Lagus Sensire, Includes PTT-LA Mining Study Von Willehrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Von Willehrand Workup Includes. PTT. Factor VIII. VWF Autigen. Willehrand Workup Includes. Willehrand Workup Includes. Willehrand Workup Includes. Willehrand Miningric Will. Willehrand Miningric Will.	Mechanical Cist Detection Platect Agglerianton Light Transmittance Light Transmittance Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection See indokhal	Stago Stago Stago Stago Helena Stago Stago Stago Stago	sec	Heparin Therapeuric Range (HTR): 77.0 - 91.0 NA NA NA 40-200 13.0-20.0 13.0-20.0 See individual	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A OSUWMC, in shouse reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study OSU Lab Normal Range Study OSU Lab Normal Range Study SU Lab Normal Range Study	See PTT Yet See PTT Test See PTT Test 20-180.0 See Helena SARP calibrator assayed whic (ist number specific) 10-0-120.0 10-0-120.0 See Helena Sarpator Sarpa	See PTT Test See PTT Test 20.6-180.0 13-400 10.0-120.0 10.0-120.0 See individual
PTI Mix w Normal Finana. PTI with Mixing Study PTI-LA Ristocctin CaPactor Thrombin Time TT Mix w Normal Finana (Not individually orderable. Order Lupus Auticougulant Workspi) TT Mix w Protamina Sulfate (Not individually orderable. Order Lupus Auticougulant Workspi) Von Willebrand Battery Agn + Factor VIII	Partial Thromboplastin Time NA NA NA LA-FIT PIT. Lupu Semirie, Incheke FIT-1A Mising Shady Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Neutralization Von Willebrand Wurkup Incheke. First Fischer VIII, WWF Ausgan. Selected Codecter, and a Von Willebrand Madimerrie (as applicable)	Mechanical Cist Detection Light Transmitance Light Transmitance Light Transmitance Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection See individual tota Immuniturificative ophotometric necessarrement waven consisting of a	Stago Stago Stago Stago Helena Stago Stago Stago Stago	sec	Heparin Therapeuris Range (HTK): 776-918 NA NA NA 100 110-200 110-200 130-200 130-200 5cc infrobball tests	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A OSUWMC, in-bosue reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study	See PTT Yest See PTT Test See PTT Test 20.0-180.0 See Helman SARP calibrator ansayed what (10 minubes specific) 10.0-120.0 10.0-120.0 See individual tests tests See individual tests	See PTT Test See PTT Test 20.0-180.0 13-400 10.0-120.0 10.0-120.0 10.0-120.0 See individual tests
PIT Mix w Normal Plasma PIT stift Miking Study PIT-LA Ristocetia CoFactor Throuble Time TI Mix w Normal Plasma (Not individually orderable, Order Lupus Anticoggulant Workup) TI Mix w Protamine Sulfate (Not individual you individually orderable, Order Lupus Anticoggulant Workup) Van Willebrand Buttery Agn + Van Willebrand Buttery Agn +	Partial Thromboplastin Time NIA NIA LAPTE, PIT. Lagus Sensire, Includes PTT-LA Mining Study Von Willehrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Von Willehrand Workup Includes. PTT. Factor VIII. VWF Autigen. Willehrand Workup Includes. Willehrand Workup Includes. Willehrand Workup Includes. Willehrand Miningric Will. Willehrand Miningric Will.	Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Planted Agglorization Light Transmissioner Aggregateity Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection See Individual Cite Detection Immunolub Mineries photometric measurement system consisting of a	Stago Stago Stago Stago Helena Stago Stago Stago Stago	sec	Heparin Therapeuric Range (HTR): 77.0 - 91.0 NA NA NA 40-200 13.0-20.0 13.0-20.0 See individual	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly NA NA OSUWAC, in-house reference rungs study performed yearly OSU Normal Range Study OSU Lab Normal Range Study OSU Lab Normal Range Study OSU Lab Normal Range Study See individual tests	See PTT Test See PTT Test 20-180.0 See Helens SARP calibrator assayed white (in number specific) 10-120.0 10-120.0 See individual tests see individual tests	See PTT Test See PTT Test 20.0-180.0 13-460 10.0-120.0 10.0-120.0 500 500 500 500 500 500 500
PTT-Mix w/Normal Pisson PTT-Mix Mixing Study PTT-Lin Ristoccian CaFactor Throughin Time TTMix w/Normal Pisson TMix w/Normal Pisson TMix w/Normal Pisson TMix w/Normal Pisson TMix w/Protamine Sulfate Not individually ordenshic. Order Lupes Anticongulant Workup) Van Willebrand Battery Agn + Factor VIII Von Willebrand Factor Ag Von Willebrand Factor Ag	Partial Thromboplastin Time NA NA NA LA-FIT PIT. Lupu Semirie, Incheke FIT-1A Mising Shady Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Neutralization Von Willebrand Wurkup Incheke. First Fischer VIII, WWF Ausgan. Selected Codecter, and a Von Willebrand Madimerrie (as applicable)	Mechanical Cist Detection Light Transmitance Light Transmitance Light Transmitance Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection See individual tota Immuniturificative ophotometric necessarrement waven consisting of a	Stago Stago Stago Stago Helena Stago Stago Stago Stago	sec	Heparin Therapeuris Range (HTK): 776-918 NA NA NA 100 110-200 110-200 130-200 130-200 5cc infrobball tests	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A N/A N/A OSUNG: habour reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study	See PTT Yest See PTT Test See PTT Test 20.0-180.0 See Helman SARP calibrator ansayed what (10 minubes specific) 10.0-120.0 10.0-120.0 See individual tests tests See individual tests	See PTT Test See PTT Test 20.0-180.0 13-400 10.0-120.0 10.0-120.0 10.0-120.0 See individual tests
PTI Mix w/ Normal Pianna. PTI stift Mixing Study FTI-LA Ristocctin CaFactor Thrombin Time TT Mix w/ Normal Pianna (Not individually orderable. Order Lupus Auticogglant Workup) TT Mix w/ Protamine Sulfate (Not individually orderable. Order Lupus Auticogglant Workup) Von Willebrand Battery Agn + Factor VIII	Partial Thromboplastin Time NIA NIA NIA LA-TIF, PIT. Lapus Sensirie, Inchée PTT-LA Miring Study Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Von Willebrand Workup Inchées Van Willebrand Workup Inchées (as applicable) VWFAG	Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Platefar Agglorination Light Transmatures Light Transmatures Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection See androkala tests Immunituristicative photometric measurement system consisting of a beam of mosochromatic light at beam of mosochromatic light at author) and microbian sprintless Manual Differential Manual Differential	Stage Stage Stage Hickens Stage	sec	Hepwin Therapeutic Range (HTK): 770 - 940 NA NA S43.2 40-200 113.0-20.0 113.0-20.0 See individual tests 17° years: \$0-180	Outpatient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yardy N/A N/A N/A N/A N/A OSUNG: shows reference range study performed yeardy OSU Normal Range Study OSU Lab Normal Range Study See individual texts ISSUE Individual (1992) OSU Individual (1992) OSU Individual (1993) OSU Individual (19	See PTT Yest See PTT Yest 20-1150.0 See Helmas AADP calibrator assayed what (st mished specific) 10-0-120.0 10-0-120.0 See individual tests to see individual tests See Stago VWF-Ag Calibrator manyed white (st mimber specific)	See PTT Test See PTT Test See PTT Test 20.0-180.0 13-400 10.0-120.0 10.0-120.0 5cc indowheal tests
PTI Mix w/ Normal Finana. PTI with Mixing Study PTI-LiA Ristocccia CaFactur Throubin Time TTMix w/ Normal Finana (Not individually orderside, Order Lapsa Anticoagulant Workay) TMix w/ Portsumine Sulfate (Not individually orderside, Order Lapsa Anticoagulant Workay) Von Willebrand Buttery Agn + Factor VIII Von Willebrand Factor Ag Band Nestrophili. Band Band + Neg Ratio Bassobili Relative (Field)	Partial Thromboplastin Time N/A N/A N/A N/A LA-PTF, PTI. Lups Sensitive, Includes PTI-LA Mining Study Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Noutralization Von Willebrand Wurkup Includes, PTIF, Factor VIII, WWF Anigne, PTIF, Factor VIII, WWF Anigne, Stalescenic Cofficier, and a Von Willebrand Multimerrie (an applicable) VWFAG N/A	Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Platefar Agglinitation Light Transmittance Light Transmittance Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection See individual tests Immunitation of the Cist Detection of the Cist Detection Immunitation of the Cist Detection of	Stago Stago Stago Stago Hickena Stago Stago Stago Stago Stago Stago Stago Stago N/A	sec	Hepwin Therapeutic Range (HTK): 770 - 94 0 NA NA S43 2 40 209 13.0-20.0 13.0-20.0 13.0-20.0 13.0-20.0 17+ years: 50-180 NA NA NA	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A N/A OSUWAC, as bosses reference runge study performed yearly OSU Normal Range Study OSU Lab Normal Range Study NORMA N	See PIT Feet See PIT Teet See PIT Teet 20.0-180.0 See Helman SARP calibrator assuped whate (16 minubes specific) 10.0-120.0 10.0-120.0 See individual teets See individual teets See Stago VWF- Ag Calibrator assuped value (16 minubes specific) 0.0-100.0 0.0-100.0 0.0-100.0	See PTT Test
PTT Mix w Normal Planns PTT with Mixing Study PTT-Lin Ribstoccia CoPactor Thrombin Time TT Mix w Normal Planns Not individually orderable. Order Lapas Anticognatu Weekup) TT Mix w Prestamine Sulfate (Not individually orderable. Order Lapas Anticognatu Weekup) Von Willebrand Battery Agn + Factor VIII Von Willebrand Factor Ag Von Willebrand Factor Ag Von Willebrand Factor Ag Band Nortrophils Band Stand - Seg Ratio	Partial Thromboplastin Time NIA NIA LA-FIF, FIT. Lapus Senizire, Includes FIT-LA Minig Study Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Nontralization Von Willebrand Workup Includes Thrombin Clotting Time Thrombin Time with Heparin Nontralization Von Willebrand Workup Includes (as applicable) VWFAG NVA BANDR	Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Platest Agglorization Light Transmission Aggregatory Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection See individual total Immunosite/Minierite-photometric measurement system consisting of a Soliton promising for a Soliton promising through a solution of Soliton promising through the solution of the soluti	Stago Stago Stago Helena Stago Stago Stago Stago Stago Stago Stago Stago Stago NA NA	sec	Heparin Therapeuris Range (HTK): 776 - 91.0 NA. NA. S40.2 40.200 11.0-20.0 13.0-20.0 13.0-20.0 13.0-20.0 17. years: 50-180 NA. NA. NA.	Outpatient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A OSUWC, in shouse reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study See individual texts See individual texts Vol. 160-172, Audrew. 1997. OSU Inhouse Study: Blood, Vol. 30, 1998-2005. Andrew. 1992. Blood, Vol. 70, 165-172, Audrew. 1997. N/A N/A	See PTT Yest See PTT Yest See PTT Yest 20.0-180.0 See Helcon SARP cultirator assayed tube (at month's epocific) 10.0-120.0 10.0-120.0 See individual texts See Stags VWF- Ag Cultirator assayed value (let number specific) 0.0-10.0 0.00-10.0	See PTT Test See PTT Test See PTT Test 20.0-180.0 13-400 10.0-120.0 10.0-120.0 See pidoxidual tests 3-400 0.0-100.0 0.0-100.0
PTI Mix w Normal Finana PTI with Mixing Study PTI LA Ristoccian CaFactor Throughin Time TTMix w Normal Finana (Not individually orderside, Order Lapse Anticoagulant Workspy) TY Mix w Protunine Sulfate (Not individually orderside, Order Lapse Anticoagulant Workspy) Von Willebrand Buttery Agn + Factor VIII Von Willebrand Factor Ag Band Neutrophilis Band Neutrophilis Band Meximphilis	Partial Thromboplastin Time NAA NAC NATE NA LA-PIT PIT Lapu Sensitive, Include PIT-IA Mining Study Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Notartalization Von Willebrand Workup Includes PIT, Factor VIII, WPF Antigon, Stancelor Coffect, and a Von Wildebrand Molitary (as applicable) VWFAG NAA BANDR	Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Planted Agglorization Light Transmissioner Aggregateity Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection See adoubted total Immunorun/bidmetric-photometric measurement system consisting of a 5-50m passing through a solution o	Stago Stago Stago Hickena Stago Stago Stago Stago Stago Stago Stago Stago NA NA NA	sec	Hepsein Therapeutic Range (HTK): This - 94,0 NA	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A N/A OSUWAC, as bosses reference runge study performed yearly OSU Normal Range Study OSU Lab Normal Range Study NORMA N	See PIT Feet See PIT Feet See PIT Teet See PIT Teet 20-180.0 See Helma SARP calibrator assayed white (int number specific) 10.0-120.0 10.0-120.0 See individual tests See individual tests See Saaga VWF- Ag Calibrator assayed value (lot number specific) 0.0-100.0 0.00-100.0	See PTT Test See PTT Test See PTT Test 20.0-180.0 13-400 10.0-120.0 10.0-120.0 5cc individual tests 3-400 0.0100.0 0.000.1.00 0.0100.0 Distrings:
PTI Mix w Normal Finana PTI with Mixing Study PTI LA Ristoccian CaFactor Throughin Time TTMix w Normal Finana (Not individually orderside, Order Lapse Anticoagulant Workspy) TY Mix w Protunine Sulfate (Not individually orderside, Order Lapse Anticoagulant Workspy) Von Willebrand Buttery Agn + Factor VIII Von Willebrand Factor Ag Band Neutrophilis Band Neutrophilis Band Meximphilis	Partial Thromboplastin Time NAA NAC NATE NA LA-PIT PIT Lapu Sensitive, Include PIT-IA Mining Study Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Notartalization Von Willebrand Workup Includes PIT, Factor VIII, WPF Antigon, Stancelor Coffect, and a Von Wildebrand Molitary (as applicable) VWFAG NAA BANDR	Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Planted Agglorization Light Transmissioner Aggregateity Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection See adoubted total Immunorun/bidmetric-photometric measurement system consisting of a 5-50m passing through a solution o	Stago Stago Stago Hickena Stago Stago Stago Stago Stago Stago Stago Stago NA NA NA	sec	Heparin Therapeuris Range (HTK): 776 - 91 0 NA	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A N/A N/A OSUWACC, aboute reference range study performed yearly OSU Lab Normal Range Study See individual tests See individual tests NA NA NA NA NA NA OSU Inhouse Study: Blood, Vol 80, 1998-2005, Andrew, 1992. Blood, Vol 70, 165-172, Andrew, 1992. Blood, Vol 70, 165-172, Andrew, NA NA NA NA NA NA Solitateral Normal Range Study, October 2018 Soldin, Seeven J. Peduris Reference Interval.	See PTT Yest See PTT Test See PTT Test See PTT Test 20.0-180.0 See Helman SARP calibrator ansayed what (16 minubes specific) 10.0-120.0 10.0-120.0 See individual tests See individual tests See Stapp VWF- Ag Calibrator ansayed value (16 minubes specific) 0.0-100.0	See PTT Test
PTI Mix w Normal Finana. PTI with Mixing Study FTI-LA Ristocetia CaPactor Thrombin Time Thrombin Time Thrombin Time Thris w Normal Finana (Not individually orderable. Order Lupus Auticoagulant Workspi) Van Willebrand Battery Agn + Factor VIII Van Willebrand Factor Ag Van Willebrand Factor Ag Band Neutrophils. Bandband + Seg Ratio Basophils Alsolute Basophils Alsolute	Partial Thromboplastin Time NAA NIA NIA LA-FIF PIT. Lapus Sensirie, Includes FIFTA Mang Shady Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Non Willebrand Workup Includes. Von Willebrand Workup Includes. Thrombin Time with Heparin Von Willebrand Workup Includes. Emiliary Committee Committee (as applicable) VWFAG NIA BANDR Body find cell differential NIA NIA	Mechanical Cic Detection Plateir Agglerination Light Transmittance Light Transmittance Mechanical Cic Detection Mechanical Cic Detection Mechanical Cic Detection Mechanical Cic Detection See individual tents Limited Cic Detection Limited Cic Detection Limited Cic Detection Limited Cic Detection See individual tents Limited Cic Detection L	Sago Sago Sago Sago Helena Sago Sago Sago Sago Sago Sago Sago Sag	Sec Sec	Heparin Therapeuris Range (HTK): 776 - 91.0 NA	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A OSUWMC, in shouse reference range study performed yearly OSU I and Normal Range Study OSU Lab Normal Range Study See individual tests See individual tests Normal Range Study OSU Indones Study: Blood Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1992 NNA NNA NNA NNA OSU Internal Normal Range Study, October 2018 Söddin, Seven J. Prüharsie Reference Intervali. 78 ed. Ander Pers. 2011	See PTT Yest See PTT Test See PTT Test 20-180.0 See Helena SARP calibrator assayed value (ist number specific) 10-120.0 10-120.0 10-120.0 See individual tests see individual tests sees Sago VWF. Ag Calibrator assayed value (ist number specific) 0.0-100.0 0.0-100.0 0.0-100.0 1-1	See PTT Test
PTT Mix w Normal Plasma PTT with Mixing Study PTT-Lin Ribstoccia CePactor Themshin Time TT Mix w Normal Plasma Not individually orderable. Order Lapsa Anticognatur Workup) TT Mix w Prestamine Sulfate (Not individually orderable. Order Lapsa Anticognatur Workup) Von Willebrand Battery Agn = Factor VIII Von Willebrand Factor Ag Von Willebrand Factor Ag Band Nestrophils BandBand + Seg Ratio BandBand + Seg Ratio BandBand + Seg Ratio BandBand Restrict (Padd) BandBand Restrict (Padd)	Partial Thromboplastin Time NIA NIA NIA LA-FIF, PIT. Lapus Sensirie, Includes FIT-1A Ming Study Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Nottralization Von Willebrand Workup Includes Thrombin Clotting Time Thrombin Time with Heparin Nottralization Von Willebrand Workup Includes No Willebrand Workup Includes N	Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Platest Agglorisation Light Transmission Aggregatory Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection See individual total See individual total Immunoulub/function-photometric measurement system consisting of a Solution promising for	Stago Stago Stago Helena Stago Stago Stago Stago Stago Stago Stago Stago Stago NA NA NA NA Symex	sec	Heparin Therapeutic Range (HTK): 770 - 94 D NA	Outpatient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A N/A N/A OSUWACC, aboute reference range study performed yearly OSU Lab Normal Range Study See individual tests See individual tests NA NA NA NA NA NA OSU Inhouse Study: Blood, Vol 80, 1998-2005, Andrew, 1992. Blood, Vol 70, 165-172, Andrew, 1992. Blood, Vol 70, 165-172, Andrew, NA NA NA NA NA NA Solitateral Normal Range Study, October 2018 Soldin, Seeven J. Peduris Reference Interval.	See PTT Yest See PTT Test See PTT Test See PTT Test 20.0-180.0 See Helman SARP calibrator ansayed what (16 minubes specific) 10.0-120.0 10.0-120.0 See individual tests See individual tests See Stapp VWF- Ag Calibrator ansayed value (16 minubes specific) 0.0-100.0	See PTT Test
PTI Mix w Normal Finana. PTI with Mixing Study FTI-LA Ristocetia CaPactor Thrombin Time Thrombin Time Thrombin Time Thris w Normal Finana (Not individually orderable. Order Lupus Auticoagulant Workspi) Van Willebrand Battery Agn + Factor VIII Van Willebrand Factor Ag Van Willebrand Factor Ag Band Neutrophils. Bandband + Seg Ratio Basophils Alsolute Basophils Alsolute	Partial Thromboplastin Time NAA NIA NIA LA-FIF PIT. Lapus Sensirie, Includes FIFTA Mang Shady Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Non Willebrand Workup Includes. Von Willebrand Workup Includes. Thrombin Time with Heparin Von Willebrand Workup Includes. Emiliary Committee Committee (as applicable) VWFAG NIA BANDR Body find cell differential NIA NIA	Mechanical Cist Detection Light Transmittance Light Transmittance Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection See individual tents Immunitation of the Detection Immunitation of the Cist Detection Immunitation of the Cist Detection Immunitation of the Cist Detection Light Cist Detection	Sago Sago Sago Sago Helena Sago Sago Sago Sago Sago Sago Sago Sag	Sec Sec	Heparin Therapeuris Range (HTK): 776 - 91.0 NA	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A OSUWMC, in shouse reference range study performed yearly OSU I and Normal Range Study OSU Lab Normal Range Study See individual tests See individual tests Normal Range Study OSU Indones Study: Blood Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1992 NNA NNA NNA NNA OSU Internal Normal Range Study, October 2018 Söddin, Seven J. Prüharsie Reference Intervali. 78 ed. Ander Pers. 2011	See PTT Yest See PTT Test See PTT Test 20-180.0 See Helena SARP calibrator assayed value (ist number specific) 10-120.0 10-120.0 10-120.0 See individual tests see individual tests sees Sago VWF. Ag Calibrator assayed value (ist number specific) 0.0-100.0 0.0-100.0 0.0-100.0 1-1	See PTT Test
PTT Mix w/ Normal Finama PTT sitis Mixing Study PTT-LiA Ristocccia CeFactor Throught Time TTMix w/ Normal Finama (Not individually orderside. Order Lapsa Anticoagulant Workspy) TTMix w/ Portonine Sulfate (Not individually orderside. Order Lapsa Anticoagulant Workspy) TMix w/ Portonine Sulfate (Not individually orderside. Order Lapsa Anticoagulant Workspy) Von Willebrand Buttery Agn + Factor VIII Von Willebrand Factor Ag Band Nestrophili. Basselli Relative (Tibid)	Partial Thromboplastin Time NAA NAC NAC NAC NAC NAC NAC NA	Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Planted Agglorization Light Transmissioner Aggregateity Mechanical Cist Detection See adoubted International Cist Detection Immunorun/bidinersis-photometric measurement system consisting of a 5-50m passing through a solution of a Calculation Manual Differential Calculation Manual differential Manual differential	Stage Stage Stage Stage Hickens Stage Stage Stage Stage Stage Stage Stage Stage Stage NA	Sec Sec	Heparin Therapeutic Range (HTK): NA	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A N/A N/A N/A OSUNACE, hower reference range study performed yearly OSU Lab Normal Range Study See individual tests See individual tests N/A N/A N/A N/A N/A N/A N/A N/	See PTT Yest	See PTT Test
PTI Mix w/ Normal Planna PTI sitis Mixing Study PTI sitis Mixing Study PTI sitis Mixing Study PTI sitis Mixing Study Ristoccial CaPactor Throught Time TTMix w/ Normal Planna (Not individually nethrolite Order Lapse Anticongulant Workup) TT Mix w/ Prottomine Sulfate (Not individually nethrolite Order Lapse Anticongulant Workup) This w/ Prottomine Sulfate Von Willebrand Battery Agn + Factor VIII Von Willebrand Factor Ag Based Neutrophilit Based Band + Sag Rettin Based Band + Sag Rettin Basedhik Relative (Tolid) Basephilit Absolute Basephilit Absolute Basephilit Relative (TSF) Blast Absolute Blast Relative (TSF) Blast Absolute Blast Batter (TSF) Blast Absolute	Partial Thromboplastin Time NAA NAA NAA LA-PTF PT. Lapu Sensitive, Include PTF1-A Mining Shaby Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Hepanin Noturlization Von Willebrand Workup Includes PTF. Factor VIII, VWP Autigno VWP AGG NAA NAA NAA NAA NAA NAA NAA	Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Planted Agglorination Light Transmittance Aggregatority Mechanical Cist Detection See adolyshad total Immunofurbidimetri-photometric measurement system consisting of a Softime passing through a solution of Softime passing through a solution of Softime passing through a solution of BANDS/Segs-BANDS/ Manual Differential Para Cystonesy Manual Differential Calculation Calculation Calculation Calculation Calculation Manual Differential	Stage Stage Stage Stage Hickens Stage Stage Stage Stage Stage Stage Stage Stage Stage NIA	Sec Sec	Heparin Therapeuris Range (HTK): 776 - 918 / 10 NA NA NA NA NA NA NA All ages: 0.00 All ages: 0.	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A OSUWACC, no basses reference runge study performed yearly OSU Normal Range Study OSU Lab Normal Range Study See individual tests See individual tests See individual tests OSU Inhouse Study; Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 16-172, Andrew, 1987 N/A N/A N/A N/A N/A N/A N/A N/	See PIT Feet	See PTT Test
PTT Mix w/ Normal Fisams PTT sitis Mixing Study PTT-LA Ristocctia CoFactor Ristocctia CoFactor Throuble Time Throuble Time Thrix w/ Normal Fisams (Not individually orderable. Order Lapas Anticogelast Workspy) Van Willebrand Ruttery Agn + Factor VIII Von Willebrand Ruttery Agn + Factor VIII Von Willebrand Factor Ag Band Neutrophils Bandland + Seg Ratio Basophils Absolute Basophils Absolute Basophils Absolute Basophils Relative (CSF) Bilast Absolute Blast Bedwitz (CSF) Blast Relative (CSF)	Partial Thromboplastin Time NAA NAA NAA LA-FIT PIT Lupu Sensirie, Incheke FIT-IA Mising Shady Von Willebrand Factor Activity Thrombin Chotting Time Thrombin Clotting Time Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Neutralization Neutralization Westerp Incheke (as applicable) VWFAG NIA Body Mad cell differential NIA NIA Spinal fluid cell differential NIA NIA Senial fluid cell differential Body fluid cell differential Body fluid cell differential NIA	Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Platest Agglorisation Light Transmission Segregatory Mechanical Cite Detection Segregatory Mechanical Cite Detection Member Detec	Stage Stage	Sec Sec	Heparin Therapeuris Range (HTK): 776 - 91.0 NA	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A OSUWMC, in-bostne reference ramge study performed yearly OSU I have reference ramge study performed Range Study OSU Lah Normal Range Study See individual tests See individual tests Normal Range Study OSU Indouse Study: Blood Vol 80, 1998-2005, Andrew, 1992. Blood, Vol 70, 16-5172, Andrew, 1992 NA NA NA NA NA NA NA NA NA N	See PIT Feet	See PTT Test
PTI Mix w/ Normal Planna PTI sitis Mixing Study PTI sitis Mixing Study PTI sitis Mixing Study PTI sitis Mixing Study Ristoccial CaPactor Throught Time TTMix w/ Normal Planna (Not individually nethrolite Order Lapse Anticongulant Workup) TT Mix w/ Prottomine Sulfate (Not individually nethrolite Order Lapse Anticongulant Workup) This w/ Prottomine Sulfate Von Willebrand Battery Agn + Factor VIII Von Willebrand Factor Ag Based Neutrophilit Based Band + Sag Rettin Based Band + Sag Rettin Basedhik Relative (Tolid) Basephilit Absolute Basephilit Absolute Basephilit Relative (TSF) Blast Absolute Blast Relative (TSF) Blast Absolute Blast Batter (TSF) Blast Absolute	Partial Thromboplastin Time NAA NAA NAA LA-PTF PT. Lapu Sensitive, Include PTF1-A Mining Shaby Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Hepanin Noturlization Von Willebrand Workup Includes PTF. Factor VIII, VWP Autigno VWP AGG NAA NAA NAA NAA NAA NAA NAA	Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Planted Agglorination Light Transmittance Aggregatority Mechanical Cist Detection See adolyshad total Immunofurbidimetri-photometric measurement system consisting of a Softime passing through a solution of Softime passing through a solution of Softime passing through a solution of BANDS/Segs-BANDS/ Manual Differential Para Cystonesy Manual Differential Calculation Calculation Calculation Calculation Calculation Manual Differential	Stage Stage Stage Stage Hickens Stage Stage Stage Stage Stage Stage Stage Stage Stage NIA	Sec Sec	Heparin Therapeutic Range (HTK): 776 - 91 0 NA	Outputient: >60.0 Ni/A	performed yearly N/A N/A N/A N/A N/A OSUNG: shows reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study OSU Indownes Study: 1987 See indirection OSU Indownes Study: 1987 N/A N/A N/A N/A N/A N/A N/A N/	See PTT Test	See PTT Test See PTT Test See PTT Test See PTT Test 20.0-180.0 13-400 10.0-120.0 10.0-120.0 10.0-120.0 See individual tests schedular tests 3-400 0.0-100.0
PTT Mix w/ Normal Fisams PTT sitis Mixing Study PTT-LA Ristocctia CoFactor Ristocctia CoFactor Throuble Time Throuble Time Thrix w/ Normal Fisams (Not individually orderable. Order Lapas Anticogelast Workspy) Van Willebrand Ruttery Agn + Factor VIII Von Willebrand Ruttery Agn + Factor VIII Von Willebrand Factor Ag Band Neutrophils Bandland + Seg Ratio Basophils Absolute Basophils Absolute Basophils Absolute Basophils Relative (CSF) Bilast Absolute Blast Bedwitz (CSF) Blast Relative (CSF)	Partial Thromboplastin Time NAA NAA NAA LA-FIT PIT Lupu Sensirie, Incheke FIT-IA Mising Shady Von Willebrand Factor Activity Thrombin Chotting Time Thrombin Clotting Time Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Neutralization Neutralization Westerp Incheke (as applicable) VWFAG NIA Body Mad cell differential NIA NIA Spinal fluid cell differential NIA NIA Senial fluid cell differential Body fluid cell differential Body fluid cell differential NIA	Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Planete Agglinization Light Transmission's Aggregated to the Control of the Contro	Stage Stage Stage Stage Hickens Stage N/A	Sec Sec	Heparin Therapeutic Range (HTK): NA	Outputient > 60.0 N/A	performed yearly N/A N/A N/A N/A N/A OSUNACE, shown reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study See individual texts See individual texts N/A N/A N/A N/A N/A N/A N/A N/	See PTT Test	See PTT Test
PTT Mix w/ Normal Finama. PTT sitis Mixing Study. PTT-Lix Ristoccia CeFactor Throught Time TTMix w/ Normal Finama. (Not individually orderable. Order Lapsa Antionagalant Workapy) TMix w/ Protonine Sulfate (Not individually orderable. Order Lapsa Antionagalant Workapy) Van Willebrand Battery Agn + Factor VIII Von Willebrand Factor Ag Band Neutrophili. Basuphil Relative (Total) Basuphils Absolute Basuphils Absolute Basuphils Relative (CSF) Blast Absolute Blast Relative (Phid) Blooky Finid Cell Count	Partial Thromboplastin Time NAA NAA LA-PIT PIT Lupu Sensitive, Include PIT-1A Mining Shaby Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralizers, Neutralizers, Von Willebrand Workup Includes PITF. Factor VIII. WIP Antique, Sensoretin Coffects, and a Von Willebrand Multimerie (an applicability) VWFAG N/A N/A N/A N/A Spinal fluid cell differential Body fluid cell differential	Mechanical Cist Detection Platiest Agglorization Light Transmissione Aggregateity Mechanical Cist Detection See addyshale tests See addyshale tests Immunofurbidimetric-photometric measurement system consisting of a Solinu passing through a soldine of Membrood Solinus passing through a soldine of Membrood Solinus passing through a soldine of Cist Solinus passing through a soldine of Membrood Solinus passing through a soldine of Cist Cist Solinus passing through a soldine of Membrood Solinus passing through a soldine of Cist Solinus passing through a solinus of Cist Solinus pas	Stage Stage Stage Fichera Stage Sta	Sec Sec	Heparin Therapeuris Range (HTK): 776 - 91 0 NA	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A N/A OSUWACC, no basses reference runge study performed yearly OSU Normal Range Study OSU Lab Normal Range Study See individual tests NA NA NA NA NA NA NA NA NA N	See PTT Test	See PTT Test
PTT Mix w Normal Finana FTT sitis Mixing Study FTT-LA Ristoccia CaPactor Ristoccia CaPactor Throubin Time TTMix w Normal Pisona (Not individually orderolds: Order Lupes Anticoagulant Worksup) TTMix w Protunine Sulfate (Not individually orderolds: Order Lupes Anticoagulant Worksup) Von Willebrand Ruttery Agn + Factor VIII Von Willebrand Factor Ag Band Nestrophils Bandlind - Neg Retio Bandlind - Neg Retio Bandlind - Neg Retio Bandlind - Neg Retio Bandlind - Seg Re	Partial Thromboplastin Time NAA NAA LA-PTF PT Lupu Sensitive, Include PTF-1A Mining Shady Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Neutralization Von Willebrand Workup Includer (Neutralization) Von Willebrand Workup Includer (Sa applicability VWFAG NAA NAA NAA NAA NAA NAA NAA NAA Spinal flaid cell differential Body flaid cell differential	Mechanical Cist Detection Plateful Agglorization Light Transmatures Aggregativity Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection Mechanical Cist Detection See advantage See advantage See advantage International Cist Detection Int	Stage Stage Stage Stage Stage Hickena Stage Sta	sec	Heparin Therapeuris Range (HTK): Yid. Yid. Yid. Yid. Yid. See	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A OSUWeC, in-bostne reference ramge study performed yearly OSU Informal Range Study OSU Lab Normal Range Study See individual tests N/A N/A N/A N/A N/A N/A N/A N/	See PIT Feet	See PTT Test
PTT Mix or Normal Plasma PTT with Mixing Study PTT-Lin Ribstoccia CePactor Thrombin Time TT Mix w Normal Plasma Not individually orderable. Order Lapes Anticognatur Workup) TT Mix w Protamine Sulfate Not individually orderable. Order Lapes Anticognatur Workup) TT Mix w Protamine Sulfate Not individually orderable. Order Lapes Anticognatur Workup) Von Willebrand Battery Agn + Pactur VIII Von Willebrand Factor Ag Von Willebrand Factor Ag No Willebrand Factor Ag Band Norderablis Band Band - Seg Ratio Bandblis Relative (Thild) Bandblis Relative (Thild) Bandblis Relative (Thild) Bassphils Relative (CNT) Blists Relative (CNT) Blast Relative (Find) Body Find Cell Count Bloby Find Cell Count Bloby Find Cell Count with Diff Bine Marraw Cultertion CBC, EDIF, Fistelet	Partial Thromboplastin Time NAA NAA LA-PTF PTT - Lays Sensitive, lockeds PTF1-A Mining Study Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Von Willebrand Workup Includes PTF, Factor VIII, WFF Autigno, Von Willebrand Workup Includes PTF, Factor VIII, WFF Autigno, VWFAG NAA BANDR Body flad cell differential N/A Spinul fluid cell differential N/A Spinul fluid cell differential Body fluid cell differential Rich N/A Spinul fluid cell differential Body fluid cell differential Rich N/A Spinul fluid cell differential Rich N/A Body Fluid Battery N/A Body Fluid Battery N/A CBC, Electronic Diff with Placetor	Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Planter Agglorination Light Transmissions Aggregatedly Mechanical Cite Detection See individual tools See individual tools London	Stago Stago Helena Stago Stago Helena Stago NA	Sec Sec	Heparin Therapeutic Range (HTK): 776 - 91.0 NA	Outputient: >60.0	performed yearly N/A N/A N/A N/A N/A N/A OSUNG: shows reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study See indirection OSU Indoorse Study: 1987 N/A N/A N/A N/A N/A N/A N/A N/	See PTT Test	See PTT Test See PTT Test See PTT Test See PTT Test 20.6-180.0 13-400 10.6-120.0 10.6-120.0 10.6-120.0 See individual tests 3-400 0.0-100 0.0-10
PTT-Mix or Normal Plasma PTT-Mix Mixing Study PTT-Lish Mixing Study PTT-Lish Mixing Study PTT-Lish Mixing Study Ristocccian CeFactor Throught Time TTMix w Normal Plasma Not individually orderable. Order Lapse Anticongulant Workup) TT Mix w Protamine Sulfate Not individually orderable. Order Lapse Anticongulant Workup) TMix w Protamine Sulfate Not individually orderable. Order Lapse Anticongulant Workup) Von Willebrand Battery Agn + Factor VIII Von Willebrand Battery Agn + Factor VIII Band Norderable. Order Band Norderable Band Norderabl	Partial Thromboplastin Time NAA NAA LAPTEPTT Lupa Sensitive, lockeds PTT-LA Mining Study Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Von Willebrand Workup Includes PTT, Factor VIII, WFF Antigon, Strate VIII, WFF Antigon, VWFAG NAA BANDR Body Bad cell differential N/A Spinul Build cell differential N/A Spinul Build cell differential Budy Had cell differential Budy Had cell differential Riva Spinul Bud cell differential Budy Had cell differential Riva Spinul Bud cell differential Riva N/A Spinul Bud cell differential Budy Had cell differential Riva N/A Spinul Bud cell differential Riva N/A Budy Flaid Buttery N/A Budy Flaid Buttery N/A Budy Flaid Buttery N/A CER_Extensiv Diff with CER_Extensiv Diff	Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Planter Agglorization Light Transmissioner Aggregate Vision Mechanical Cite Detection See Individual Literature Individual Cite Detection Individual Citerature Indiv	Stage Stage Stage Stage Hickens Stage N/A N/A N/A N/A N/A N/A N/A N/	Sec Sec	Heparin Therapeutic Range (HTK): NA	Outpatient > 60.0 N/A N/A	performed yearly N/A N/A N/A N/A N/A N/A N/A OSUNACE, shown reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study See individual tests N/A N/A N/A N/A N/A N/A N/A N/	See PTT Test	See PTT Test
PTT Mix or Normal Plasma PTT with Mixing Study PTT-Lin Ribstoccia CePactor Thrombin Time TT Mix w Normal Plasma Not individually orderable. Order Lapes Anticognatur Workup) TT Mix w Protamine Sulfate Not individually orderable. Order Lapes Anticognatur Workup) TT Mix w Protamine Sulfate Not individually orderable. Order Lapes Anticognatur Workup) Von Willebrand Battery Agn + Pactur VIII Von Willebrand Factor Ag Von Willebrand Factor Ag No Willebrand Factor Ag Band Norderablis Band Band - Seg Ratio Bandblis Relative (Thild) Bandblis Relative (Thild) Bandblis Relative (Thild) Bassphils Relative (CNT) Blists Relative (CNT) Blast Relative (Find) Body Find Cell Count Bloby Find Cell Count Bloby Find Cell Count with Diff Bine Marraw Cultertion CBC, EDIF, Fistelet	Partial Thromboplastin Time NAA NAA LA-PTF PTT Lupu Semirie, Inches PTT-LA Mising Shady Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Clotting Time Thrombin Clotting Time Thrombin Clotting Time Thrombin Time with Heparin Neutralization Neutralization Neutralization Neutralization Neutralization Neutralization Noutralization Noutralization Noutralization NAA NAA NAA NAA NAA Spinal fluid cell differential NAA ROB Spinal fluid cell differential ROB fluid fluid differential NAA ROB Spinal fluid cell differential ROB fluid fluid cell differential	Mechanical Cist Detection Platefat Agglorination Light Transmittance Aggregatority Mechanical Cist Detection See additional totals Immunofurbidinetric behots total total Immunofurbidinetric behots total The Cistaliance Industrial States and Immunofurbidinetric Cistaliance Industrial Immunofurbidinetric Manual Differential Manual Differential Manual Differential Manual Differential Immunofurbidinetric Counts / Inscircument Immunofurbidinetric Manual Differential Manual Diffe	Stago Stago Helena Stago Stago Helena Stago NA	Sec Sec	Heparin Therapeuris Range (HTK): 776 - 91 0 NA	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A N/A OSUWACC, no bosone reference runge study performed yearly OSU Normal Range Study OSU Lab Normal Range Study See individual tests N/A N/A N/A N/A N/A N/A N/A N/	See PTT Test	See PIT Test
PTT Mix or Normal Plasma PTT with Mixing Study PTT-Lin Ribstoccia CePactor Thrombin Time TT Mix w Normal Plasma Not individually orderable. Order Lapes Anticognatur Workup) TT Mix w Protamine Sulfate Not individually orderable. Order Lapes Anticognatur Workup) TT Mix w Protamine Sulfate Not individually orderable. Order Lapes Anticognatur Workup) To Mix w Protamine Sulfate Not individually orderable. Order Lapes Anticognatur Workup) Von Willebrand Battery Agn + Factor YIII Von Willebrand Factor Ag Work Willebrand Factor Ag Band Norderablish Band Norderablish Band Norderablish Band Sulfate (Spill) Band Band - Seg Ratio Bandblish Relative (Thild) Bandblish Relative (CNT) Blast Relative (CNT) Blast Absolute Bloop Flaid Cell Count Bloop Flaid Cell Count Bloop Flaid Cell Count with Diff Bane Marrow Cultertion Cell Count & Diff. CRY; CSF Bifferential Typh to berepretation	Partial Thromboplastin Time NAA NAA LA-PTF, PTT. Lapus Sensirie, Inchdes PTT-At Mang Shady Von Willebrand Factor Activity Thrombin Chotting Time Thrombin Chotting Time Thrombin Time with Heparin Neutralization Neutralization Neutralization Von Willebrand Workup Includes. Thrombin Time with Heparin Neutralization Neutralization Neutralization Neutralization Non Willebrand Multimeric (as applicable) VWFAG NIA BANDR Bedy flad cell differential N/A N/A Spinal flad cell differential N/A Spinal flad cell differential Body flad of differential N/A Body Flad flattery N/A Body Flad Battery N/A Body Flad Battery N/A CEC, Electronic Diff with Fletchern Computation Spinal Flad Count and Differential	Mechanical Cist Detection Planelet Agglorination Light Transmittance Aggregateity Mechanical Cist Detection See advishable total Innusconhyldimetric-photometric measurement system consisting of a Detection of monochronatic light at total Innusconhyldimetric-photometric measurement system consisting of a Detection of monochronatic light at total Total Innusconhyldimetric-photometric measurement system consisting of a Detection of monochronatic light at total Total Innusconhyldimetric-photometric measurement system consisting of a Detection of monochronatic light of the Total Innusconhyldimetric-photometric Manual Differential United States of the States of States of the States of States of Manual Differential United States of S	Stago Stago Stago Helena Stago Stago Helena Stago N/A	see	Heparin Therapeuris Range (HTK): 776-94.0 NA NA S40.2 40-200 13.0-20.0 13.0-20	Outputient: >60.0	performed yearly N/A N/A N/A N/A N/A N/A N/A OSUNG: shower reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study NA NA NA NA NA NA NA NA NA N	See PTT Test	See PTT Test
PTT Mix w/Normal Pissma PTT sitis Mixing Study PTT-List Ritheretia CeFactor Thrombin Time TTMix w/Normal Pissma (Not individually orderable: Order Lapsa Anticognist Workup) TTMix w/Protamine Sulfate (Not individually orderable: Order Lapsa Anticognist Workup) TTMix w/Protamine Sulfate (Not individually orderable: Order Lapsa Anticognist Workup) TTMix w/Protamine Sulfate (Lapsa Anticognist Workup) TTMix w/Protamine Sulfate Lapsa Anticognist Workup) Town Wilebrand Battery Agn + Factor VIII Von Wilebrand Battery Agn + Factor VIII Band Neatvephils Band Neatvephils Band Neatvephils Band Neatvephils Band Neatvephils Band Neatvephils Band Neatvephils Band Neatvephils Band Neatvephils Band Neatvephil Band Band Cell Count Blast Edulive (TSF) Blast Absolute Blast Batter (Phid) Body Fluid Cell Count with Diff Bune Marraw Cultertion (Assist) CERC, EDIF, Pistelet CERC, Fatelets Ceystals, Fluid	Partial Thromboplastin Time NAA NAA LA-PTF PTT Lupus Sensitive, Includes PTT-AA Misney Shady Von Willebrand Factor Activity Thrombin Chotting Time Thrombin Chotting Time Thrombin Chotting Time Thrombin Time with Heparin Noturtalization Von Willebrand Workup Includes Thrombin Time with Heparin Noturtalization Von Willebrand Workup Includes Willebrand Malineric (as applicable) VWFAG N/A BANDIR Body find cell differential N/A N/A Spinal fluid cell differential N/A Spinal fluid cell differential Body fluid cell differential N/A Spinal fluid cell differential N/A Body Fluid Battery N/A Body Fluid Battery N/A Spinal fluid cell differential Spinal Fluid Cell Count and Differential N/A Spinal Fluid Cell Count and Differential N/A Spinal Fluid Cell Count and Differential N/A	Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Planete Agglorination Light Transmission's Agreementy Mechanical Cite Detection See individual Cite Detection Manual Differential Calculation Manual Differential Menual Differential Menual Differential Hency tenter Count / In its instrument Hency tenter Count / In its instrument Hency tenter Count / In its individual numbytes See individual numbytes See individual numbytes See individual numbytes Manual Differential Lunational quots in fluid sider Manual Differential Lunational quots in fluid sider Manual Differential Lunational Greenial misseury Manual Differential Lunational Greenial misseury Line See individual numbytes See individua	Stage Stage Stage Stage Hickens Stage N/A	see	Heparin Therapeutic Range (HTK): 776 - 91 0 NA	Outputient: >60.0	performed yearly N/A N/A N/A N/A N/A N/A N/A OSUNG: shower reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study NA NA NA NA NA NA NA NA NA N	See PTT Test	See PIT Test
PTT Mix or Normal Plasma PTT with Mixing Study PTT-Lin Ribstoccia CePactor Thrombin Time TT Mix w Normal Plasma Not individually orderable. Order Lapes Anticognatur Workup) TT Mix w Protamine Sulfate Not individually orderable. Order Lapes Anticognatur Workup) TT Mix w Protamine Sulfate Not individually orderable. Order Lapes Anticognatur Workup) To Mix w Protamine Sulfate Not individually orderable. Order Lapes Anticognatur Workup) Von Willebrand Battery Agn + Factor YIII Von Willebrand Factor Ag Work Willebrand Factor Ag Band Norderablish Band Norderablish Band Norderablish Band Sulfate (Spill) Band Band - Seg Ratio Bandblish Relative (Thild) Bandblish Relative (CNT) Blast Relative (CNT) Blast Absolute Bloop Flaid Cell Count Bloop Flaid Cell Count Bloop Flaid Cell Count with Diff Bane Marrow Cultertion Cell Count & Diff. CRY; CSF Bifferential Typh to berepretation	Partial Thromboplastin Time NAA NAA LA-PTF, PTT. Lapus Sensirie, Inchdes PTT-At Mang Shady Von Willebrand Factor Activity Thrombin Chotting Time Thrombin Chotting Time Thrombin Time with Heparin Neutralization Neutralization Neutralization Von Willebrand Workup Includes. Thrombin Time with Heparin Neutralization Neutralization Neutralization Neutralization Non Willebrand Multimeric (as applicable) VWFAG NIA BANDR Bedy flad cell differential N/A N/A Spinal flad cell differential N/A Spinal flad cell differential Body flad of differential N/A Body Flad flattery N/A Body Flad Battery N/A Body Flad Battery N/A CEC, Electronic Diff with Fletchern Computation Spinal Flad Count and Differential	Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Mechanical Cite Detection Planete Agglatination Light Transmission's Agreementy Mechanical Cite Detection See addeduct to the Cite of t	Stago Stago Stago Helena Stago Stago Helena Stago N/A	Sec Sec	Heparin Therapeutic Range (HTK): NA	Outpatient > 60.0 N/A N/A	performed yearly N/A N/A N/A N/A N/A N/A N/A OSUNMC, aboute reference range study performed yearly OSU Lab Normal Range Study See individual tests N/A N/A N/A N/A N/A N/A N/A N/	See PTT Test	See PTT Test
PTT Mix wi Normal Plasma PTT with Mixing Study PTT-Lin Ristocctia CePactor Throubin Time TT Mix wi Normal Plasma Not individually orderable. Order Lapes Anticognatur Workup) TT Mix wi Protamine Sulfate Not individually orderable. Order Lapes Anticognatur Workup) TT Mix wi Protamine Sulfate Not individually orderable. Order Lapes Anticognatur Workup) To Mix wi Protamine Sulfate Not individually orderable. Order Lapes Anticognatur Workup) Von Willebrand Battery Agn + Factur VIII Von Willebrand Factor Ag Work Willebrand Factor Ag Band Nondread - Seg Ratio Band Nondread - Seg Ratio Band Nondread - Seg Ratio Band Rod - Seg Ratio Band Sundread - Seg Ratio Band Su	Partial Thromboplastin Time NAA NAA LA-PTF PTT Lupus Sensitive, Includes PTT-AA Misney Shady Von Willebrand Factor Activity Thrombin Chotting Time Thrombin Chotting Time Thrombin Chotting Time Thrombin Time with Heparin Noturtalization Von Willebrand Workup Includes Thrombin Time with Heparin Noturtalization Von Willebrand Workup Includes Willebrand Malineric (as applicable) VWFAG N/A BANDIR Body find cell differential N/A N/A Spinal fluid cell differential N/A Spinal fluid cell differential Body fluid cell differential N/A Spinal fluid cell differential N/A Body Fluid Battery N/A Body Fluid Battery N/A Spinal fluid cell differential Spinal Fluid Cell Count and Differential N/A Spinal Fluid Cell Count and Differential N/A Spinal Fluid Cell Count and Differential N/A	Mechanical Cite Detection Platest Agglorization Light Transmission Supergeometry Mechanical Cite Detection See individual Cite Detection See individual Cite Detection See individual Cite Detection Immunoulubilismics'-photometric measurement system consisting of a Solution Season of monochanical light at 54th part of the Cite Cite Cite Cite Cite Cite Cite Cit	Stago Stago Stago Stago Helera Stago	Sec Sec	Heparin Therapeutic Range (HTK): NA	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A N/A OSUWAC, abottoes reference runge study performed yearly OSU Lon Normal Range Study OSU Lab Normal Range Study See individual tests See individual N/A N/A N/A N/A N/A N/A N/A N/A	See PTT Test	See PTT Test
PTT Mix w Normal Plasma PTT with Mixing Study PTT-Lin Ristoccian CePactor Transhin Time TT Mix w Normal Plasma Not individually orderable. Order Lapse Anticoagnatu Workup) TT Mix w Protamine Sulfate Not individually orderable. Order Lapse Anticoagnatu Workup) TT Mix w Protamine Sulfate Not individually orderable. Order Lapse Anticoagnatu Workup) TO Mix w Protamine Sulfate Not individually orderable. Order Lapse Anticoagnatu Workup) Von Willebrand Battery Agn + Factur VIII Von Willebrand Factor Ag Workelprogram Pactur VIII Band Note Study Band Note Study Band Study (Supplied Study Band Study Ba	Partial Thromboplastin Time NAA NAA LA-PTF PTT. Lapus Sensirie, Rockes PTT-A Mang Sandy Von Willebrand Factor Activity Thrombin Chotting Time Thrombin Chotting Time Thrombin Chotting Time Thrombin Time with Heparin Neutralization NAA Backenin Calcium and a Von Raincenin Calcium (as applicable) VWFAG NIA BANDR Body flad cell differential N/A N/A Spinal flad cell differential N/A Spinal flad cell differential N/A Body flad del differential N/A Body Flad del differential N/A Body Flad del differential N/A CEC: Exercise Diff with Pletches Company Spinal Flad Cell Count and Differential N/A Spinal Flaid Cell Count and Differential N/A Spinal Flaid Cell Count and Differential	Mechanical Cist Detection Platefar Agglorination Light Transmittance Aggregately Mechanical Cist Detection See androkalal tools Innuscript Mechanical Cist Detection Detection of mechanical glist at tools Detected of mechanical glist and bear of mesochronical glist at tools Detected of mesochronical glist and bear of mesochronical glist at tools Detected of mesochronical glist and Detection Innuscript Memory Detection particles. Memory Detection Memory Deferencial Memory Detection Memory Deferencial Memory Detection Memory Deferencial Memory Deference Me	Stage Stage	see	Heparin Therapeutic Range (HTK): 776-94.0 NA NA S40.2 40-200 13.0-20.0 1	Outputient: >60.0	performed yearly N/A N/A N/A N/A N/A N/A N/A OSUNG: shower reference range study performed yearly OSU Normal Range Study OSU Lab Normal Range Study NA NA NA NA NA NA NA NA NA N	See PIT Feet	See PTT Test
PITAITS of Normal Planna PITAITS of Normal Planna PITAIN Ristocetia CePactor Throughin Time This was Normal Planna This was Normal Planna Not individually orderable. Order Lapas Anticogniant Workup) This wife Protamine Sulfate Not individually orderable. Order Lapas Anticogniant Workup) To Mix wife Protamine Sulfate Not individually orderable. Order Lapas Anticogniant Workup) Von Willebrand Battery Agn + Factor VIII Von Willebrand Battery Agn + Factor VIII Band Nortrophilis Coll Count Coll Count Coll Count Coll Count Coll Count & Diff. CST; CSP Office Told Count Only CSF Fluid Count Only	Partial Thromboplastin Time NAA NAA LA-PTF PTT. Lapus Sensirie, Rockes PTT-A Mang Sandy Von Willebrand Factor Activity Thrombin Chotting Time Thrombin Chotting Time Thrombin Chotting Time Thrombin Time with Heparin Neutralization NAA Backenin Calcium and a Von Raincenin Calcium (as applicable) VWFAG NIA BANDR Body flad cell differential N/A N/A Spinal flad cell differential N/A Spinal flad cell differential N/A Body flad del differential N/A Body Flad del differential N/A Body Flad del differential N/A CEC: Exercise Diff with Pletches Company Spinal Flad Cell Count and Differential N/A Spinal Flaid Cell Count and Differential N/A Spinal Flaid Cell Count and Differential	Mechanical Cist Detection Platefar Agglorination Light Transmittance Aggregately Mechanical Cist Detection See androkalal tools Innuscript Mechanical Cist Detection Detection of mechanical glist at tools Detected of mechanical glist and bear of mesochronical glist at tools Detected of mesochronical glist and bear of mesochronical glist at tools Detected of mesochronical glist and Detection Innuscript Memory Detection particles. Memory Detection Memory Deferencial Memory Detection Memory Deferencial Memory Detection Memory Deferencial Memory Deference Me	Stage Stage	Sec Sec	Heparin Therapoutic Range (HTK): 710 - 91,0 NA	Outputient: >60.0	performed yearly N/A N/A N/A N/A N/A N/A N/A OSUNG: shower reference range study performed yearly OSU I alm Normal Range Study OSU Lab Normal Range Study NA NA NA NA NA NA NA NA NA N	See PTT Test	See PIT Test
PTI Mix w/Normal Pisams PTI sids Mixing Study The Mix w/Normal Pisams (Not individually norbrokle, Orbet Lapas Antiongulant Workup) TT Mix w/ Protunine Sulfate (Not individually norbrokle, Orbet Lapas Antiongulant Workup) Von Willebrand Battery Aga + Factor VIII Von Willebrand Factor Ag Band Nortrophils Band Battery Aga + Factor VIII Not Willebrand Factor Ag Band Nortrophils Band Band Study Band Band S	Partial Thromboplastin Time NAA NAA LA-PIT PIT. Lapu Sensitive, Include PIT-1A Mining Shaby Von Willebrand Factor Activity Thrombin Clotting Time Thrombin Time with Hepanin Neutralization Von Willebrand Workup Includes PIT. Factor VIII, WIP Antique, Sensoretin Coffects, and a Von Wildebrand Multimeric (as applicable) VWFAG NAA NAA NAA NAA NAA NA NAA Spinal flaid cell differential Body flaid Cell Count Hemogram Spinal Flaid Cell Count and Differential NAA Spinal Flaid Cell Count NA Spinal Flaid Cell Count	Mechanical Cist Detection Platiest Agglorization Light Transmissioner Aggregativity Mechanical Cist Detection See adoxhal tens Immunofurbidineris-ip-hotometric measurement system consisting of a 550mp passing through a solution of Storage passing through a solution of Calculation Manual Differential Calculation Calculation Calculation Manual Differential Manual Differential Mensual Differential Unional Different	Stage Stage Stage Stage Fichera Stage Stag	sec	Heparin Therapeuris Range (HTK): 776 - 91 0 NA	Outputient: >60.0 N/A N/A N/A N/A N/A N/A N/A N/	performed yearly N/A N/A N/A N/A N/A N/A N/A OSUNACE, beause reference range study performed yearly OSU Lab Normal Range Study OSU Inhouse Study, Blood, Vol 80, 1998-2005, Audrew, 1987 N/A N/A N/A N/A N/A N/A N/A N/	See PTT Test	See PIT Test

Essimonkila Balatina (CSE)	Spinal fluid cell differential	Manual Differential	N/A	%	N/A	N/A	N/A	0-100	0-100
Eosinophils Relative (CSF) Eosinophils Relative (Fluid)	Body fluid cell differential	Manual Differential	N/A	%	N/A N/A	N/A N/A	N/A	0-100	0-100
Extended Reticulocyte Panel	Panel includes: Ret%, Ret#, IRF and RET-HE	Flow Cytometry, Calculation	Sysmex	Varies	Varies	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	Varies	Varies
Hairy Cells	N/A	Manual Differential	N/A	% x10³/uL	All ages: 0.0	N/A	N/A	0.0-100.0	0.0-100.0
Hairy Cells Absolute	N/A	Calculation	N/A	-OR-	All ages: 0.00	N/A	N/A	0.00-440.00	0.00-dilute to obtain numeric result
Hematocrit	нст	Cumulative Pulse Height Detection	Sysmex	%	≥18years: Male: 39.6-48.8 Female 34.9-44.3	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	0.1-75.0	0.1-dilute to obtain numeric result
Hematocrit, Fluid Hemoglobin	Fluid HCT, Fluid PCV HGB	Manual Spun Hematocrit Photometrically measured	N/A Sysmex	% g/dL	N/A ≥18 years: Male: 13.4-16.8 Female: 11.4-15.2	N/A >12y: <7.0 and >22.0 8d-12y: <8.0 and >22.0 0d-7d: <11.0 and >22.0	N/A OSU Internal Normal Range Study. October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	5.0-60.0 0.2-26.0	5.0-60.0 0.2-dilute to obtain numeric result
Immature Granulocytes %	N/A	Flow Cytometry	Sysmex	%	N/A	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	0.0-100.0	0.0-100.0
Immature Granulocytes Absolute	IG	Calculation	Sysmex	x10 ³ /uL -OR- K/uL	≥18 years Male: ≤0.07 Female: ≤0.08	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	Electronic: 0.04-440.00	Electronic: 0.04-dilute to obtain numeric result
Immature Platelet Fraction	IPF	Calculation	Sysmex	%	≥18 years: Male: 0.0-9.0 Fernale: 0.0-8.6	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	0.0-100.0	0.0-100.0
Immature Reticulocyte Fraction	IRF	Calculation	Sysmex	%	≥18 years: Male: 0.2-16.3 Female: 1.1-16.2	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	0.0-100.0	0.0-100.0
Lymphocytes Relative (CSF)	Spinal fluid cell differential	Manual Differential	N/A	%	<3m: 35-50 >3m 40-80	N/A	Body Fluids 3rd ed. Kjeldsbreg, Knight 1993	0-100	0-100
Lymphocytes %	N/A	Flow Cytometry/ Manual differential	Sysmex	%	N/A	N/A	N/A	0.0-100.0	0.0-100.0
Lymphocytes Absolute	N/A	Calculation	Sysmex	x10 ³ /uL •OR- K/uL	≥18 years: Male: 0.83-3.57 Female: 1.16-3.51	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	Electronic: 0.04-440.00 <u>Manual</u> : 0.00-440.00	Electronie: 0.04-dilute to obtain numeric result Manual: 0.00-dilute to obtain numeric result
Lymphocytes Relative (Fluid)	Body fluid cell differential N/A	Manual Differential	N/A	%	N/A	N/A N/A	N/A N/A	0-100	0-100 0.0-100.0
Lymphoma Cells Lymphoma Cells Absolute	N/A	Manual Differential Calculation	N/A	x10³/uL -OR-	All ages: 0.0 All ages: 0.00	N/A	N/A	0.0-100.0	0.00-dilute to obtain numeric result
Lymphoma Cells Relative (CSF)	Spinal fluid cell differential	Manual Differential	N/A	K/uL %	N/A	N/A	N/A	0-100	0-100
Lymphoma Cells Relative (Fluid)	Body fluid cell differential	Manual Differential	N/A	%	N/A	N/A N/A	N/A N/A	0-100	0-100
Malaria Prep	Parasite Screen / ID Blood, MPB	Giemsa Stain	N/A	N/A	NOPO - No parasitic organism seen, including plasmodium organisms	N/A	N/A	N/A	No parasitic organism seen, including plasmodium organism / Positive for
Malignant Cells Relative (CSF)	Spinal fluid cell differential	Manual Differential	N/A	%	N/A	N/A	N/A	0-100	Plasmodium species 0-100
Malignant Cells Relative (Fluid)	Body fluid cell differential	Manual Differential	N/A	%	N/A	N/A	N/A	0-100	0-100
Manual Retic	N/A	Manual/Miller Disk	N/A	%	≥18 years: Male: 0.68-2.64 Female: 0.74-2.54	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	0.25-30.00	0.25-30.00
мсн	Red Cell Indices	HGB x 10/RBC	Sysmex	pg	≥18 years: Male: 26.1-33.3 Female: 25.9-33.9	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	N/A	N/A
мснс	Red Cell Indices	HGB x 100/HCT	Sysmex	g/dL	≥18 years: Male: 31,9-36.5 Female: 31,4-35.9	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	N/A	N/A
MCV	Red Cell Indices	HCT x10/RBC	Sysmex	ſL.	≥18 years: Male: 79.0-94.5 Female: 79.6-97.7	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	N/A	N/A
Mesothelial Cells Relative (Fluid)	Body fluid cell differential	Manual Differential	N/A	%	N/A	N/A	N/A	0-100	0-100
Metamvelocytes	N/A	Manual Differential	N/A	% x10 ³ /uL	N/A ≥18 years	N/A	N/A OSU Internal Normal Range Study, October 2018	0.0-100.0	0.0-100.0
Metas Absolute	N/A	Calculation Flow Cytometry/	N/A	-OR- K/uL	Male: ≤0.07 Female: ≤0.08	N/A	Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	0.00-440.00	0.00-dilute to obtain numeric result
Monocytes % Monocytes / Macrophages Relative	N/A Spinal fluid cell differential	Manual differential Manual Differential	Sysmex N/A	%	N/A <3m 50-90	N/A N/A	N/A Body Fluids 3rd ed. Kjeldsbreg, Knight 1993	0.0-100.0	0.0-100.0
(CSF) Monocytes / Macrophages Relative		Manual Differential	N/A	%	>3m 15-45 N/A	N/A N/A	N/A	0-100	0-100
(Fluid) Monocytes Absolute	N/A	Calculation	Sysmex	x10³/uL -OR-	≥18 years: Male: 0.24-0.93 Female:	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals.	Electronic: 0.04-440.00 <u>Manual:</u> 0.00-440.00	Electronic: 0.04-dilute to obtain numeric result Manual:
MPV	N/A	Derived from the PLT histogram.	Sysmex	K/uL fL	0.22-0.87 ≥18 years: Male: 8.7-12.3 Female:	N/A	7th ed., AACC Press, 2011. OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals.	0.00-440.00 N/A	0.00-dilute to obtain numeric result N/A
Myelocytes	N/A	Manual Differential	N/A	%	8.5-12.2 N/A	N/A	7th ed., AACC Press, 2011. N/A	0.0-100.0	0.0-100.0
Myclos Absolute	N/A	Calculation	N/A	x10³/uL -OR- K/uL	≥18 years Male: ≤0.07 Female: ⊴0.08	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	0.00-440.00	0.00-dilute to obtain numeric result
Neutrophils %	N/A	Flow Cytometry/ Manual differential	Sysmex	%	N/A	N/A	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	0.0-100.0	0.0-100.0
Neutrophils Relative (CSF) Neutrophils Relative (Fluid)	Spinal fluid cell differential Body fluid cell differential	Manual Differential Manual Differential	N/A N/A	%	<3m: 0-8 >3m: 0-6 N/A	N/A N/A	Body Fluids 3rd ed. Kjeldsbreg, Knight 1993 N/A	0-100 0-100	0-100 0-100
Neutrophils Relative (Fluid) NRBC	N/A	Flow Cytometry	Sysmex	/100 WBC	N/A ≥18 years: ≤0.2	N/A	Sysmex XN-9000 IFU (North American Edition) Code No. AC794819	0.0-600.0	0.0-600.0
NDDG	D 1 4		****				Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.		
NRBCs Relative (Fluid) Nucleated RBCs Relative (CSF)	Body fluid cell differential Spinal fluid cell differential	Manual Differential Manual Differential	N/A N/A	%	N/A N/A	N/A N/A	N/A N/A	0-100 0-100	0-100 0-100
Other Cells Other Cells Absolute	N/A N/A	Manual Differential Calculation	N/A	% x10 ³ /uL -OR-	All ages: 0.0 All ages: 0.00	N/A N/A	N/A N/A	0.0-100.0	0.0-100.0 0.00-dilute to obtain numeric result
Other Cells Relative (CSF)	Spinal fluid cell differential	Manual Differential	N/A	K/uL %	N/A	N/A	N/A	0-100	0-100
Other Cells Relative (Fluid) Peripheral Smear for Pick up by	Body fluid cell differential N/A	Manual Differential Manual	N/A N/A	% N/A	N/A N/A	N/A N/A	N/A N/A	0-100 N/A	0-100 N/A
Physician for Review Plasma Cells	N/A N/A	Manual Differential	N/A N/A	%	All ages: 0.0	N/A N/A	N/A N/A	0.0-100.0	0.0-100.0
Plasma Cells Absolute	N/A	Calculation	N/A	x 10³/uL -OR- K/uL	All ages: 0.00	N/A	N/A	0.00-440.00	0.00-dilute to obtain numeric result
Plasma Cells Relative (CSF) Plasma Cells Relative (Fluid)	Spinal fluid cell differential Body fluid cell differential	Manual Differential Manual Differential	N/A N/A	%	N/A N/A	N/A N/A	N/A N/A	0-100 0-100	0-100 0-100
Platelet Count Platelet Count -	N/A	Electronic Resistance Detection	Sysmex	x10 ³ /uL	≥18 years: Male:	<30 and >1,000	OSU Internal Normal Range Study, October 2018	5-5,000	5-dilute to obtain numeric result
Platelet Count - fluorescent Prolymphs	N/A N/A	Flow Cytometry Manual Differential	N/A	-OR- %	146-337 All ages: 0.0	Oncology: N/A	Soldin, Steven J. Pediatric Reference Intervals. 7th N/A	0.0-100.0	0.0-100.0

March Marc					x10 ³ /uL					
Martine 10	Prolymphs Absolute	N/A	Calculation	N/A		All ages: 0.00	N/A	N/A	0.00-440.00	0.00-dilute to obtain numeric result
Marcian Marc	Promyelocytes	N/A	Manual Differential	N/A		N/A	N/A	N/A	0.0.100.0	0.0-100.0
						≥18 years				
March Marc					K/uL	Female: ≤0.08		7th ed., AACC Press, 2011.		
			Iris instrument Hemocytometer Counts /	RRL, JWC: N/A CCL: Iris						
Materia	KBC Fluid	Body Itala celi codin		RRL: N/A	/uL	≥18 years:	N/A		3-30,000	3-unite to enupone
Marie Mari	RDW	Red Cell Indices	Representative of CV% of the	Sysmex	%	10.9-14.3 Female:	N/A	Soldin, Steven J. Pediatric Reference Intervals.	N/A	N/A
Marie Mari				_		Male:		OSU Internal Normal Range Study, October 2018		
Part	Red Blood Cell Count	RBC	Electronic Resistance Detection	Sysmex		4.38-5.83 Female: 3.91-5.04	N/A	Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.	0.05-8.60	0.05-dilute to obtain numeric result
Marie Part						≥18 years: Male:			<u>XN</u> : 0.0100-0.7200	XN; 0.0100-dilute to obtain numeric
Marie Mari		27/4	allic by ppo	0			277	OSU Internal Normal Range Study, October 2018	XN-L:	result
March Marc	Retic Absolute	1674	Cardannii Retvi X RDC	Systilex		Manual:	NA	Soldin, Steven J. Pediatric Reference Intervals. 7th ed., AACC Press, 2011.		result
Marie Mari						Male: 0.0317-0.1377			0.0000-8.6000	Manual: 0.0000-dilute to obtain numeric result
Mathematical No. Professional No. Profess						0.0324-0.1142				
Marie Mari	Retic Count	N/A	Flow Cytometry	Sysmex	%	Male:	N/A		0.25-30.00	0.25-30.00
Marche M	Active Count		1-11-5/	-,	-	Female: 0.74-2.54		7th ed., AACC Press, 2011.		
Market M	Retic HGB Equivalent	RET-HE	Calculation	Sysmex	Pg	Male:	N/A		N/A	N/A
Marient Roman Marient Roma						28.8-39.9		7th ed., AACC Press, 2011.		
Marticus						>85Y: <30				
Part	Sedimentation Rate, Automated	ESR	Westergren	Mechatronics	mm/hr	0-49Y: <15	N/A	Clinical Diagnosis and Management by Laboratory	1-140	1-140
Part						Female: >85Y: <42		overnous (23rd ed.). St. Louis, MO: Elsevier Inc. pg. 532		
Page						50-85Y: <30 0-49Y: <20				
		ANC		Syemey		Male:	N/A		0.04-440.00	0.04-dilute to obtain numeric result
Processor Proc	Segs + Bands Absolute		WBC x (NE% + Bands%)			Female: 1.64-7.28		7th ed., AACC Press, 2011.	0.00-440.00	Manual: 0.00-dilute to obtain numeric result
	Sperm pH	YFER, YSEMB	pH paper	N/A	N/A		N/A	WHO laboratory manual for the Examination and Processing of Human Semen. 5th Ed		
Processing Pro			Qualitative, visually read immunochromatographic assay for							
Probabilities Probabilitie	Synovasure PJI, Synovial Fluid		the detection of human host response proteins, Alpha Defensins 1-3, in the	CD Diagnostics, Inc	N/A	Negative	N/A	Package Insert	N/A	Positive/Negative
No. Common Comm			joint replacement who are being							
March Marc	Synovial Lining Cells Relative	Body fluid cell differential		N/A	%	N/A	N/A	N/A	0-100	0-100
No.				CCL: Iris	/nI	<1Y: <31				
Who find class The Committee of St. Com			Hemocytometer Counts /	CCL: Iris	(a)				2.2.500	
Part	INC Fluid	Body Italu Celi Codin	Iris instrument	RRL: N/A					3-2,300	3-unite to enupoin
Trace-Come Note of place Votes Note	White Blood Count	WBC	Flow Cytometry	Sysmex		Male:			0.30-440.00	0.30-dilute to obtain numeric result
Betein No. 1 Security interference of the indexes of Life Security of CE Security of Secur					K/uL	Female	<0.50 and >35.00	7th ed., AACC Press, 2011.		
Billion No. Control Section No. Control Section No. Control Section No.	Urine Screen	Urine dipstick	Various	Siemens Clinitek	N/A	Various	Various	Various	Various	Various
Proceed Proced			Microscopic Examination of Urine Sediment: All Labs	CCL: Sysmex or Beckman						Absent
Page	Bacteria	N/A	CCL, James Lab, RRL		NA	Absent	N/A	Ormanysis and Body Pillid, Ringsrud 1995	N/A	
Size Company			The peroxidase-like activity of			Nombin				
Appearance Carlo Carlo Carlo Carlo Carlo NA Carlo Carlo NA Carlo Carlo NA Carlo Carlo NA Carlo NA Carlo NA Carlo NA Carlo Carlo Carlo Carlo Carlo Carlo Carlo Carlo NA Carlo Carlo NA Carlo Carlo NA Carlo Ca	Blood Urine	N/A	disopropylbenzene dihydroperoxide and 3.3',5,5'-tetramethylbenzidine to	Siemens Clinitek	NA	Manufacturer's sensitivity is 0.015-	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	
Clair Charge and the permitted prices of the permitted			green.			0.062 mg/dL hemoglobin				
Market Viside MA		Clarity	scattering of light		N/A	Class	N/A	Limber and Date Phild Discound 1996	MA	Class Charles Tookid
Manual and reflections of Manual and reflections of Manual Actions Man	Appearance	Clarity		JWC: N/A	NA	Clear	N/A	Urmatysis and Body Filia, Ringsrud 1995	N/A	Clear, Cloudy, Turnid
Common Continue NA Microscope Examination of Use Ext., June, MADE/SCIC, NA NA NA NA NA Unsulyin and Body Flad, Ringered 1995 NA Person	Color	N/A	Manual and reflectance spectrophotometer		N/A	Yellow	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	Yellow, Orange, Red, See Comment
Clase of Uniter Class Common Color CCC Color CCCC Color CCC Color CCC Color CCC Color CCC Color CCC Color CCC Col			Microscopic Evamination of Urina							
Bysiline Case NA Microscopic Extension NA Mi	Crystals -Urine	N/A	Sediment: All Labs	RRL, James, MMMP, SSCBC, JWC: N/A	N/A	N/A	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	Present
Character Uniter NA CCL Internal Library For This test is but of an adole segmental expert restration. One organic formation of plotters and an adole segmental expert restration. One organic and process and and phylogene proceeds from the restration of plotters and phylogene proceeds from the phylogene phylogene proceeds from the phylogene phy			Glucose oxidase catalyzes the							
Clarene Urine NA NA Na Sieman Clinick mg/d. Modification of gloring process from the cardinal dysteps process and the cardinal dysteps process from the cardinal dysteps process from the cardinal dysteps process from the cardinal dysteps p			acid and hydrogen peroxide.							
Glacese Urine NiA Significant of Specime and and formation of glocome and and glocome and			test is based on a double sequential							
Sement Ciriae Ni			glucose oxidase, catalyzes the							
Collector Crase N.A Seguine, Collector Company of the containing of the distinctive price and demolyticated by hydrogen price and complete and the price of the containing of the containi			hydrogen peroxide from the oxidation			Negative				
methylaticals by hydrogra. personals. MMAP, SSGIC: Provides contyry—the Provision of hydrogra personals with a proximism solid contyreast for reaction of hydrogra personals with a proximism solid contyreast for proximism c	Glucose Urine	N/A	peroxidase, catalyzes the oxidative	Siemens Clinitek	mg/dL	Manufacturer's sensitivity level is 75- 125 mg/dL	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	Negative, 100, 250, 500, ≥1000
catalyses for reactions of hydrogen considered by the control of hydrogen control of h			methykatechol by hydrogen peroxide.							
transport to caller the chonesput of the			MMMP, SSCBC: Peroxidase catalyzes the reaction of hydrogen							
Hyaline Cast NA Meroscopic Examination of Urine Science: All Labs Urine Particle Courses: A 2000 CCL NE Courses Agron CCL No A Manufactures's semainty by soci is 5-15 magnific sectoscotic seed of the foreign of problem into seed over the f			peroxide with a potassium iodide chromogen to oxidize the chromogen							
Hyaline Cast N/A Microscopic Examination of Uses Schemer, All Labs Usine Particle Counter, Q200 CCL. N/A Microscopic Examination of Uses Schemer, All Labs Usine Particle Counter, Q200 CCL. N/A Microscopic Examination of Uses Schemer, All Labs Usine Particle Counter, Q200 CCL. N/A Microscopic Examination of Uses Schemer, All Labs Usine Particle Counter, Q200 CCL. N/A Microscopic Examination of Usine Schemer, All Labs Usine Particle Counter, Q200 CCL. N/A Microscopic Examination of Usine Schemer, All Labs Usine Particle Counter, Q200 CCL. N/A Microscopic Examination of Usine Schemer, All Labs Usine Particle Counter, Q200 CCL. N/A Microscopic Examination of Usine Schemer, All Labs Usine Particle Counter, Q200 CCL. N/A Microscopic Examination of Usine Schemer, All Labs Usine Particle Counter, Q200 CCL. N/A Microscopic Examination of Usine Schemer, All Labs Usine Mode of No. A N/A Microscopic Examination of Usine Schemer, All Labs Sche			brown.							
Hyaline Cast NA Microscopts Extracted Contract (2009; CCL Limit Particle Counter, Q2009; CCL Wine Particle Counter, Q2009; CCL Wine Particle Counter, Q2009; CCL Wine Particle Counter, Q2009; CCL NA Acetoscerts acid resets with infrapromastic to produce a marroon color color of the physiologis of the discontinuous color color in limit and programs of the physiologis of the contracted program and said ease to liberary shipting whethater is mainting in \$1.5 \text{ Manufacturer's sensitivity is \$1.5 \text{ N/A} } Manufacturer's sensitivity is \$0.05 \text{ N/A} } Manufacturer's sensitivity is \$0										
Ketones Urine NA Acctoaceric acid reacts with aniroprosate to produce a marron color Earlesses contained in grandscytes catalyze the hydrodysis of the h		N/A	Sediment: All Labs	RRL, James, MMMP, SSCBC,	/lpf	0-2	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	3-5/lpf
Acctoractic neil resets with anterpressive to produce a marroon color N/A Manufacturer's sensitivity level is 5.10 N/A Urinalysis and Body Flaid, Ringered 1995 N/A Large (Rangered 1995 Large	Hyaline Cast		Urine Particle Counter- iQ200: CCL	J. C. LOA						11-20/lpf
Ketunes Urine NA nirrogrounds to produce a marroon color The provides the physiophy of the discretion with a finite physiophy of the discretion of the physiophy of the discretion of the physiophy of the discretion of the physiophy of the discretion of produce a purple of the physiophy of the discretion of produce a purple of the physiophy of the discretion of produce a purple of the physiophy of the discretion of produce a purple of the produce a purple of the physiophy of the discretion of produce a purple of the physiophy of the discretion of produce a purple of the physiophy of the discretion of the physiophy of the discretion of produce a purple of the physiophy of the discretion of the physiophy of the physiophy of the discretion of the physiophy of the physiophy of the discretion of the physiophy of the physiophy of the discretion of the physiophy of the phy	Hyaline Cast								-	Negative,
Enterance continued in granulocytes catalyze the hydrodysis of the the hydrodysis	Hyaline Cast		Acetoacetic acid prants with			Negative				Trace,
Leukscyte Esterase N/A Significe	· .	N/A	nitroprusside to produce a maroon	Siemens Clinitek	N/A	Manufacturer's sensitivity level is 5-10	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	Small (15 mg/dL), Moderate (40 mg/dL),
Leukeyte Keterase NA profession from the contractive was with a diagramma and the product a pumple. Na pumple which then reasons with a diagramma was product a pumple. The providate discontinue and the product a pumple. The providate discontinue was a pumple of the product and product a pumple of the product and the product a pumple of the product and the product and product a pumple of the product and the product a pumple of the product and the product and product a pumple of the product and the prod		N/A	nitroprusside to produce a maroon color.	Siemens Clinitek	N/A	Manufacturer's sensitivity level is 5-10	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	Small (15 mg/dL), Moderate (40 mg/dL), Large (280 mg/dL), Unable to analyze
discrotima tale produce a purple color The providence description of the reaction of discreption the reaction of discreption the reaction of discreption discreption of the reaction of discreption d	· .	N/A	nitroprusside to produce a maroon color. Esterases contained in granulocytes catalyze the hydrolysis of the	Siemens Clinitek	N/A	Manufacturer's sensitivity level is 5-10 mg/dL acetoacetic acid	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	Small (15 mg/dL), Moderate (40 mg/dL), Large (280 mg/dL), Unable to analyze due to interfering substance
Myoglobia Urine Wine Myoglobia Screening L'ine	Ketones Urine		nitroprusside to produce a maroon color. Esterases contained in granulocytes catalyze the hydrolysis of the derivatized pyrrole amino acid ester to liberate 3-hydroxy5-sphenyl pyrrole which then reacts with a			Manufacturer's sensitivity level is 5-10 mg/dL acetoacetic acid Negative Manufacturer's sensitivity is 5-15				Small (15 mg/dL), Moderate (40 mg/dL), Large (≥80 mg/dL), Unable to analyze due to interfering substance Negative, Trace, Small, Moderate,
Myuglobia Urine Urine Myoglobin Screening Urine Myoglobin Urine Urine Myoglobin Screening Urine	Ketones Urine		nitroprusside to produce a maroon color. Esterases contained in granulocytes catalyze the hydrolysis of the derivatized pyrrole amino acid ester to liberate 3-hydroxy5-5-plenyl pyrrole which then reacts with a diazonium sat to produce a purple			Manufacturer's sensitivity level is 5-10 mg/dL acetoacetic acid Negative Manufacturer's sensitivity is 5-15				Small (15 mg/dL), Modernte (40 mg/dL), Large (≥80 mg/dL), Unable to analyze due to interfering substance Negative, Trace, Small, Moderate,
produce a contra dom orange to	Ketones Urine		nitroprusside to produce a marson color. Esterases contained in granulesy-tes catalyre the hydrohysis of the derintited pyrrole amino sed ester to liberate 3-hydroxy-5-pharyl pyrrole which then races with a diazonium salt to produce a purple color. The peroxidase-like activity of hemoglobic natalyses the reaction of			Manufacturer's sensitivity level is 5-10 mg/df. acetoacetic acid Negative Manufacturer's sensitivity is 5-15 white blood cells/hpf				Small (1 Smgidl.), Moderate (0 mgidl.), Large (280 mgidl.), Unable to analyze due to interfering substance Negative, Trace, Small, Moderate, Large
	Kennes Urine Leukocyte Esterase	N/A	nitroprusside to produce a marcon color. Esterases contained in granulocytes castlyce the hydrolysis of the derivatized pyrrole amino said ester pyrrole which then reach with a diazonium sait to produce a purple color. The pertudiane, the carbon of disopropy the content of disopropy the core of disopropy the carbon	Siemens Clinitek	N/A	Manufacturer's sensitivity level a 5-10 mg/dl. acetoacetic acid Negative Manufacturer's sensitivity is 5-15 white blood cells hpf Negative Manufacturer's sensitivity is 0.015-0062 mc/dl. hemoshobis and	N/A	Urinslysis and Body Floid, Ringored 1995	N/A	Small (1 Smgidl.), Moderate (0 mgidl.), Large (800 mgidl.), Utashe to unalyze due to interfering substance Negative, Trace, Small, Moderate, Large Negative, Trace, Small, Moderate, Large

Nitrites Urine	N/A	At the acid pH of the reagent area, nitrite in the urine reacts with p- arsanilic acid to form a Diaz onium compound which couples with 1,2,3,4-etrahydrobenzo(h)quinolin-3- ol to produce a pink color.	Siemens Clinitek	NA	Negative Manufacturer's sensitivity is 0.06-0.1 mg/dL nitrite ion	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	Negative, Positive
Occult Blood, Fecal- Immunological	FIOB	Immunoussay utilizing rabbit polyclonal antiboides to detect	OC- Auto SENSOR iO	N/A	Negative	N/A	N/A	N/A	Negative, Positive
Occult Blood, Gastric	Gastroccult	presence of hemoglobin in feces. Developing solution (stabilized mixture of hydrogen peroxide and denatured alcohol) creates a reaction between hemoglobin and guaine to produce a blue color.	Gastroccult Beckman	N/A	Negative	N/A	N/A	N/A	Negative, Positive
Occult Blood, Stool	Occult Blood, Fecal Hemoccult	Developing solution (stabilized mixture of hydrogen peroxide and denatured alcohol) creates a reaction between hemoglobin and guainc to produce a blue color.	Hemoccult Beckman	N/A	Negative	N/A	N/A	N/A	Negative, Positive
Other Casts	N/A	Microscopic Examination of Urine Sediment: All Labs Urine Particle Counter- iQ200: CCL	CCL: Beckman RRL, James, MMMP, SSCBC, JWC: N/A	Лрf	N/A	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	When reported: 0-2/lpf 3-5/lpf 6-10/lpf 11-20/lpf >20/lpf
pH Urine	N/A	Double indicator principle to cover the range of urinary pH range. Colors range from orange through yellow and green to blue.	Siemens Clinitek	N/A	5.0-7.0	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	CCL, RRL, James: 5.0 - ≥9.0 SSCBC, MMMP: 5.0 - ≥8.5 JWC: 5.0 - ≥8.5
Protein Urine	N/A	Based on the protein-error-of- indicators principle where at a constant pH, the development of any green color is due to the presence of protein.	Siemens Clinitek	mg/dL	Negative Manufacturer's sensitivity is 15- 30mg/dL albumin	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	Negative, Trace, 30mg/dL, 100mg/dL, ≥300mg/dL
RBC Casts	RBC Casts	Microscopic Examination of Urine Sediment: All Labs Urine Particle Counter- iQ200: CCL	CCL: Beckman RRL, James, MMMP, SSCBC, JWC: N/A	ЛрГ	Absent	Any seen	Urinalysis and Body Fluid, Ringsrud 1995	N/A	When reported: 0-2/hpf 3-5/hpf 6-10/lpf 11-20/lpf >20/hpf
RBC Urine	N/A	Microscopic Examination of Urine Sediment: All Labs Urine Particle Counter-UF5000: CCL, James Lab, RRL Urine Particle Counter-iQ200: CCL	CCL: Sysmex or Beckman James Lab, RRL, Sysmex MMMP, SSCBC, JWC: N/A	ЛэрГ	0-2	N/A	Urimalysis and Body Fluid, Ringsrud 1995	N/A	0-2/hpf 3-5/hpf 6-10/hpf 11-25/hpf >25/hpf
Renal Tubular Cells	N/A	Microscopic Examination of Urine Sediment: All Labs Urine Particle Counter- iQ200: CCL	CCL: Beckman RRL, James, MMMP, SSCBC, JWC: N/A	/hpf	Absent	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	When Reported 0-2/hpf 3-5/hpf (1+) 6-10/hpf (2+) 11-20/hpf (3+) >20/ hpf (4+)
Specific Gravity Urine	N/A	CCL, James Lab, RRL: Fiber optic refractive index method All Labs: pKa change of pretreated polyelectrolyte in relation to ionic concentration	Siemens Clinitek	N/A	1.001-1.035	N/A	Urinalysis and Body Fluid, Ringsrud 1995	CCL Clinitek Novus: 1.001-1.045 RRL, James, SSCBC, MMMP, JWC Clinitek Advantus/Status+. ≤1.005, 1.010, 1.015, 1.020, 1.025, ≥1.030	CCL Clinitek Novus: 1.001-1.045 RRL, James SSCBC, MMMP, JWC Clinitek Advantus/Status+: ≤1.005, 1.010, 1.015, 1.020, 1.025, ≥1.030
Squamous/Epithelial Cells	N/A	Microscopic Examination of Urine Sediment: All Labs Urine Particle Counter-UF5000i: CCL, James Lab, RRL Urine Particle Counter-iQ200: CCL	CCL: Sysmex or Beckman James Lab, RRL, Sysmex MMMP, SSCBC, JWC: N/A	/hpf	0-2/hpf 3-5/hpf (1+)	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	0-2/hpf 3-5/hpf (1+) 6-10/hpf (2+) 11-20/hpf (3+) >20/ hpf (4+)
Trichomonas	N/A	Microscopic Examination of Urine Sediment: All Labs Urine Particle Counter- iQ200: CCL	CCL: Beckman RRL, James, MMMP, SSCBC, JWC: N/A	N/A	Absent	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	When reported: Absent, Present
Urinalysis	U/A with Microscopic	Various	Siemens Clinitek, Sysmex and/or Beckman	N/A	Various	Various	Various	Various	Various
Urinalysis Reflex to Culture	UTI workup for general population	Various	Siemens Clinitek, Sysmex and/or Beckman	N/A	Various	Various	Various	Various	Various
Urine Dipstick with Reflex Microscopy	UASR	Various	Siemens Clinitek, Sysmex and/or Beckman if it is Positive	N/A	Various	Various	Various	Various	Various
Urobilinogen Urine	N/A	Ehrlich Reaction, in which p- diethylaminobenzaldehyde in conjunction with a color enhancer reacts with urobilinogen in a strongly acid medium to produce a pink-red color.	Siemens Clinitek	E.U.4IL	0.2, 1.0	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	0.2, 1.0, 2.0,4.0, 28.0
WBC Casts	N/A	Microscopic Examination of Urine Sediment: All Labs Urine Particle Counter- iQ200: CCL	CCL: Beckman RRL, James, MMMP, SSCBC, JWC: N/A	/lpf	Absent	Any seen	Urinalysis and Body Fluid, Ringsrud 1995	N/A	0-2/lpf 3-5/lpf 6-10/lpf 11-20/lpf >20/lpf
WBC/Renal Tubular Epithelial Cast	N/A	Microscopic Examination of Urine Sediment: All Labs Urine Particle Counter- iQ200: CCL	CCL: Beckman RRL, James, MMMP, SSCBC, JWC: N/A	/lpf	Absent	Any seen	Urinalysis and Body Fluid, Ringsrud 1995	N/A	When reported: 0-2/lpf 3-5/lpf 6-10/lpf 11-20/lpf >20/lpf
WBC Urine	N/A	Microscopic Examination of Urine Sediment: All Labs Urine Particle Counter-UF5000: CCL, James Lab, RRL Urine Particle Counter-iQ200: CCL	CCL: Sysmex or Beckman James Lab, RRL, Sysmex MMMP, SSCBC, JWC: N/A	ЛэрГ	0.5	N/A	Urimalysis and Body Fluid, Ringsrud 1995	N/A	0-5/hpf 6-10/hpf 11-20/hpf >20/hpf
Yeast /Fungi	N/A	Microscopic Examination of Urine Sediment: All Labs Urine Particle Counter- iQ200: CCL	CCL: Beckman RRL, James, MMMP, SSCBC, JWC: N/A	N/A	Absent	N/A	Urinalysis and Body Fluid, Ringsrud 1995	N/A	Absent, Present
Acetone, Blood Amikacin Level, Trough	N/A N/A	GC-FID Turbidimetric immunoassay	Agilent GC Beckman	mg/dL mcg/mL	<10 Therapeutic Range:	≥10	N/A OSU	10-400 3.0-50.0	10-400 3.0-150.0
(Pre Drug Level) Amikacin Level, Peak	N/A	Turbidimetric immunoassay	Beckman	meg/mL	< 6.0 Therapeutic: Range	≥60.0	Pharmacy OSU	3.0-50.0	3.0-150.0
(Post Drug Level) Amikacin Level, Random	Amikin	Turbidimetric immunoassay	Beckman	meg/mL	30.0-60.0 Therapeutic Peak: 30.0-60.0	≥60.0	Pharmacy OSU	3.0-50.0	3.0-150.0
		y			Trough: < 6.0		Pharmacy		
Amphetamine, Urine, Confirmation	Amphetamine, methamphetamine, adderall	LCMS/MS	Agilent QQQ 6420	ng/mL	< 25 ng/mL	N/A	N/A	Amphetamine: 25-5000 ng/mL Methamphetamine: 25-5000 ng/mL Amphetamines Interpretation: Positive or None Detected (Positive if 1 or more drugs detected)	25-25,000 ng/mL
Amphetamine / Methamphetamine	Amphetamines Screen - Urine	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Emit II Plus Amphetamines Assay	Negative / Presumptive Positive / Presumptive Positive. Confirmation to follow.	Negative	N/A	N/A	Cutoff: 500 ng/mL	N/A
Amphetamine/Methamphetamine, Meconium	Amphetamines Screen - Meconium	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Emit II Plus Amphetamines Assay	Negative / Presumptive Positive. Confirmation to Follow.	Negative	N/A	N/A	Cutoff: 1000 ng/g	N/A
Amphetamines, Meconium, Confirmation	N/A	LC/MS/MS	SCIEX 3200 QTRAP	None Detected / Positive	None Detected	N/A	N/A	Cutoff Amphetamine: 100 ng/g Methamohetamine: 100 ng/g	N/A
Barbiturates	Barbiturates Screen - Urine	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Emit II Plus Barbiturate Assay	Negative / Presumptive Positive / Presumptive Positive. Confirmation to follow.	Negative	N/A	N/A	Methamphetamne: 100 ng/g Cutoff: 200 ng/mL	N/A
Barbiturates Screen, Serum	N/A	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Thermo Scientific DRI Barbiturate	Negative / Presumptive Positive	Negative	N/A	N/A	Cutoff: 1000 ng/mL	N/A
Barbiturates, Meconium	N/A	Enzyme multiplied immunoassay	Serum Tox Assay Beckman Coulter DxC700AU; Emit II Plus Barbiturate Assay	Negative / Presumptive Positive	Negative	N/A	N/A	Cutoff: 400 ng/g	N/A
Barbiturates, Umbilical Cord	N/A	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Emit II Plus Barbiturate Assay	Negative / Presumptive Positive	Negative	N/A	N/A	Cutoff: 200 ng/mL	N/A
Benzodiazepines	Benzodiazepines Screen - Urine	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Emit II Plus Benzodiazepine Assay	Negative / Presumptive Positive / Presumptive Positive. Confirmation to follow.	Negative	N/A	N/A	Cutoff: 200 ng/mL	N/A
Benzodiazepine, Meconium	N/A	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Emit II Plus Benzodiazepine	Negative / Presumptive Positive. Confirmation to Follow.	Negative	N/A	N/A	Cutoff: 400 ng/g	N/A
Benzodiazepine Confirmation, Meconium	N/A	LCMSMS	Assay SCIEX 3200 QTRAP	None Detected / Positive	None Detected	N/A	N/A	Cutoff Alpracolum: 25 ng/g alpha-hydroxyalpracolum: 125 ng/g 7-aminochanspam: 50 ng/g Diazepam: 120 ng/g Mikazolum: alpha-hydroxymidazolum Nordinzapum: 50 ng/g Lozazpam: 100 ng/g Crazepam: 100 ng/g Temuzepam: 50 ng/g	N/A

Benzodiazepines, Urine, Confirmation	N/A	LCMSMS	SCIEX 3200 QTRAP	None Detected, 7- Aminocleaszepum; 7- Aminocleaszepum; 7- Amio Munitarzepum; Alpha- hydroxyalparzolum; Alpha- hydroxyalparzolum; Alpha- hydroxyalparzolum; Alpha- Diszepum; Flamirarepum; Flamzepum; Lerazepum; Midazolum; Nodularepum; Oxazepum; Temazepum; Triazolum	None Detected	N/A	N/A	Caself 7-animicolanaryum 200 agind. 7-animicolanaryum 200 agind. 7-animicolanaryum 200 agind. 7-animicolanaryum 200 agind. Alpha-bydus yagindanin 400 agind. Alpha-bydus 100 agind. Alpha-bydus 200 agind. Terma-pase 100 agind. Terma-pase 100 agind.	N/A
Buprenorphine	Buprenorphine Screen - Urine	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Emit II Plus Buprenorphine Assay	Negative / Presumptive Positive / Presumptive Positive. Confirmation to follow.	Negative	N/A	N/A	Cutoff: 5 ng/mL	N/A
Buprenorphine, Meconium	Suboxone	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Emit II Plus Buprenorphine Assay	Negative / Presumptive Positive	Negative	N/A	N/A	Cutoff: 10 ng/g	N/A
Buprenorphine/Norbuprenorphine , Urine, Confirmation	Suboxone, Buprenorphine metabolite	LC/MS/MS	Agilent QQQ 6420	ng/mL	< 5.0 ng/mL	N/A	N/A	Buprenorphine: 5.0 -5,000.0 ng/mL Norbuprenorphine: 5.0 - 5,000.0 ng/mL	Buprenorphine: 5.0 -25,000.0 ng/mL Norbuprenorphine: 5.0 - 25,000.0 ng/mL
Cannabinoids (Marijuana)	THC Screen - Urine	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Emit II Plus Cannabinoid Assay	Negative / Presumptive Positive / Presumptive Positive. Confirmation to follow.	Negative	N/A	N/A	Cutoff: 50ng/mL	N/A
Cannabinoids, Meconium	THC Screen meconium, marijuana screen THC Screen meconium,	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Emit II Plus Cannabinoid Assay Beckman Coulter DxC700AU;	Negative / Presumptive Positive	Negative	N/A	N/A	Cutoff: 100 ng/g	N/A
Cannabinoids, Umbilical Cord Carboxy THC, Urine,	marijuana screen N/A	Enzyme multiplied immunoassay GC-MS	Emit II Plus Cannabinoid Assay Agilent GC/MS	Negative / Presumptive Positive ng/mL	Negative < 5.0 ng/mL	N/A N/A	N/A N/A	Cutoff: 20 ng/mL 5.0-500.0 ng/mL	N/A 5.0-500.0 ng/mL
Confirmation			Beckman Coulter DxC700AU;	Negative / Presumptive Positive /	-				
Cocaine Cocaine Confirmation, Urine	Cocaine Screen - Urine	Enzyme multiplied immunoassay LC/MS/MS	Emit II Plus Cocaine Metabolite Assay Agilent QQQ 6420	Presumptive Positive. Confirmation to follow.	Negative	N/A N/A	N/A	Cutoff: 150 ng/mL Benzoylecgonine: 25-5,000 ng/mL	N/A Benzoylecgonine: 25-25,000 ng/mL
			Beckman Coulter DxC700AU;	ng/mL	< 25 ng/mL			Cocaine: 25-5,000 ng/mL	Cocaine: 25-25,000 ng/mL
Cocaine, Meconium	Coke	Enzyme multiplied immunoassay	Emit II Plus Cocaine Metabolite Assay	Negative / Presumptive Positive. Confirmation to Follow.	Negative	N/A	N/A	Cutoff: 300 ng/g	N/A
Cocaine, Meconium, Confirmation Creatinine	N/A Creatinine - Urine Adulteration	LC/MS/MS Kinetic modified Jaffe	SCIEX 3200 QTRAP Beckman Coulter DxC700AU;	None Detected / Positive mg/dL	None Detected ≥20.0	N/A N/A	N/A SAMSHA	Cutoff Cocaine: ng/g Benzoylecgonine: 50 ng/g 1.0-300.0 mg/dL	N/A 1.0-300.0 mg/dL
Cyclic Citrullinated Peptide Ab	Screen Anti-CCP	Chemiluminescent microparticle immunoassay	Creatinine Abbott	U/mL	<5.0	N/A	Abbott	0.5-200.0	0.5-1,200.0
Cyclosporine Level, Trough (Pre Drug Level)	CSAN	immunoassay Chemiluminescent microparticle immunoassay	Abbott	ng/mL	Therapeutic Range: 70-320	N/A	OSU Pharmacy	30-1,500	30-3,000
Cyclosporine Level, 2HR	CSAN2	Chemiluminescent microparticle immunoassay	Abbott	ng/mL	Therapeutic Range: 320 - 960	N/A	OSU Pharmacy	30-1,500	30-3,000
Drugs Detected, Umbilical Cord	Drug screen umbilical cord	LCMSMS	SCIEX 3200 QTRAP	6-Monoscotylnosrphine Or 7, Aminoclostrogene Or Aphra- hydrosvalencolum Or Andra- hydrosvalencolum Or Andra- hydrosvalencolum Or Ampetamine Or Benzoylesgenine Or Buprencophine Or Cocane Or Buprencophine Or Cocane Or Diphentyloramine Or EDDF- methalose Or EDDF- methalose Or EDDF- methalose Or EDDF- methalose Or Or Edphedires Presidosphedires Or Or Edphedires Presidosphedires Or Or Eddf- methalose Or Malanquine Or Morphine Or Nalbophine Or Nalbophine Or Nalbophine Or Nalbophine Or Nalbophine Or Or Malencome Or Morpherencophine Allocane Or Northerencophine Or Northerophine Or Oxacepain Or Northerophine Or Oxacepain Or Nycodene Or Oxacepain Or Oxycodene Or Oxacepain Or Oxycodene Or Oxacepain Termazepain Or Tramadel Or Zubpidem	Negative	N/A	N/A	Cutoff (ug/g): Ablancacce/bascaphine (14): Antimesce/bascaphine (14): Antimesce/bascaphine (14): Antimesce/bascaphine (14): Antimesce/bascaphine (14): Bettooyleegaine (16): Bet	N/A
Ethanol (Alcohol), Urine	Alcohol-Ethyl	Enzymatic	Beckman Coulter DxC700AU; Emit II Plus Ethyl Alcohol Assay	mg/dL	<10	N/A	N/A	10-600 mg/dL	10-600 mg/dL
Alcohol (Ethanol), Blood	Ethanol, Alcohol-Ethyl	Enzymatic	Beckman Coulter DxC700AU; Emit II Plus Ethyl Alcohol Assay	mg/dL	<10	≥300	N/A	10-600 mg/dL	10-600 mg/dL
Ethyl Alcohol, Blood Ethylene Glycol, Blood,	Alcohol-Ethyl, ETOH N/A	GC-FID GC-FID	Agilent GC Agilent GC	mg/dL mg/dL	<10 <10	≥300 ≥10	N/A N/A	10-400 mg/dL 10-250 mg/dL	10-400 10-250
Quantitative Confirmation Ethylene Glycol, Blood, Screen	Ethylene Glycol Level	Enzymatic UV	Beckman Coulter DxC700AU; Catachem DiscretPak Ethylene	None Detected, Presumptive	None Detected	≥ 10 mg/dL	N/A	Cutoff: 10 mg/dL	N/A
with Reflex to Confirmation Everolimus, Trough (Pre Drug	Afinitor	Particle-enhanced turbidimetric	Glycol Reagent Kit Beckman	Positive. Confirmation to follow. ng/mL	Therapeutic range not established	N/A	Microgenies Corp. Thermo Scientific QMS	2.0-20.0	2.0-40.0
Level) Fentanyl	Zortress N/A	immunoassay Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; ARK Fentanyl II Assay	Negative / Presumptive Positive / Presumptive Positive . Confirmation to follow.	Negative	N/A	Everolimus IFU N/A	Cutoff: 1 ng/mL	N/A
Fentanyl, Meconium	N/A	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; ARK Fentanyl II Assay	Negative / Presumptive Positive. Confirmation to Follow.	Negative	N/A	N/A	Cutoff: 2 ng/g	N/A
Fentanyl, Meconium, Confirmation	N/A	LC/MS/MS	SCIEX 3200 QTRAP	None Detected / Positive	None Detected	N/A	N/A	Cutoff Fentanyl: 25 ng/g	N/A
Fentanyl, Urine, Confirmation	Fentanyl Urine Confirmation	LC/MS/MS	Agilent QQQ 6420	ng/mL	< 2.5 ng/mL	N/A	N/A	Norfentanyl: 25 ng/g Fentanyl: 2.5-5,000 ng/mL Norfentanyl: 2.5 - 5,000 ng/mL	Fentanyl: 2.5-25,000 ng/mL Norfentanyl: 2.5-25,000 ng/mL
Gentamicin Level, Peak (Post Drug Level)	N/A	Enzyme immunoassay	Beckman	meg/mL	3.0-15.0 (Therapeutic Range)	≥20.0	OSU Pharmacy	0.3-10.0	0.3-20.0
Gentamicin Level, Trough (Pre Drug Level)	N/A	Enzyme immunoassay	Beckman	mcg/mL	<1 year: <1.6 > 1 year: ≤1.0 (Therapeutic Range)	<1 year: ≥1.6 > 1 year: >1.0	OSU Pharmacy	0.3-10.0	0.3-20.0
Hemoglobin A1C Isopropanol, Blood	HA1CI 2-propanol	Turbidimetric immunoassay GC-FID	Beckman Agilent GC	% mg/dL	4.7-5.6 <10	N/A ≥10	Textbook N/A	4.0-15.0 10-400 mg/dL	4.0-15.0 10-400
Lidocaine Level	N/A	Enzyme immunoassay	Beckman	meg/mL	Therapeutic Range: 1.5-5.0	>6.0	OSU Pharmacy	0.5-12.0	0.5-36.0
Methadone	Methadone Screen- Urine	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Emit II Plus MethadoneAssay	Negative / Presumptive Positive / Presumptive Positive. Confirmation to follow.	Negative	N/A	N/A	Cutoff: 300ng/mL	N/A
Methadone, Meconium	N/A	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Emit II Plus MethadoneAssay	Negative / Presumptive Positive. Confirmation to Follow.	Negative	N/A	N/A	600 ng/g cutoff Cutoff	N/A
Methadone, Meconium, Confirmation	N/A	LC/MS/MS	SCIEX 3200 QTRAP	None Detected / Positive	None Detected	N/A	N/A	Methadone: 50 ng/g EDDP: 25 ng/g	N/A
Methadone Confirm, Urine	N/A	LC/MS/MS	Agilent QQQ 6420	ng/mL	< 25 ng/mL	N/A	N/A	Methadone: 25-5,000 ng/mL EDDP: 25-5,000 ng/mL	Methadone: 25-25,000 ng/mL EDDP: 25-25,000 ng/mL
Methanol. Blood Methotrexate Level	Alcohol-Methyl N/A	GC-FID Homogeneous enzyme immunoussay	Agilent GC Beckman	mg/dL umol/L	<10 Due to different protocols using this drug, contact the primary attending	≥10 N/A	N/A OSU	10-400 mg/dL 0.04-1.20	10-400 0.04-1,200.00
Methotrexate Level Nicotine Screen Urine	N/A Cotinine	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Thermo Scientific DRI Cotinine	umol/L Negative / Positive	drug, contact the primary attending physician Negative	N/A N/A	Pharmacy N/A	0.04-1.20 Cutoff: 500ng/mL	0.04-1,200.00 N/A
Opiate	Opiate Screen - Urine	Enzyme multiplied immunoassay	Assay Beckman Coulter DxC700AU; Emit II Plus Opiate Assay	Negative / Presumptive Positive / Presumptive Positive.	Negative	N/A	N/A	Cutoff Clinical: 300ng/mL	N/A
Opiate, Meconium	Morphine screen, Codeine screen, Heroin screen	Enzyme multiplied immunoassay	Beckman Coulter DxC700AU; Emit II Plus Opiate Assay	Confirmation to follow. Negative / Presumptive Positive. Confirmation to Follow.	Negative	N/A	N/A	Workplace: 2000 ng/mL Cutoff: 600 ng/g	N/A
Opioids, Meconium, Confirmation	N/A	LCMS/MS	SCIEX 3200 QTRAP	None Detected / Positive	None Detected	N/A	N/A	Cutoff 6-Monoacetyl morphine: Codeine: 500 ng/g Dihydrocodeine: 100 ng/g Hydrocodone: 100 ng/g Hydromorphone: 100 ng/g Morphine: 100 ng/g 6-Monoacetylmorphine: 5-5,000	N/A 6-Monoacetylmorphine 5-25,000
Opioids, Urine, Confirmation	N/A	LC/MS/MS	Agilent QQQ 6420	ng'mL	6-Monoacetylmorphine < 5 ng/mL. Codeine, Morphine, Hydrocodone, Hydromorphone, and Tramadol < 25 ng/mL.	N/A	N/A	ng/mL Codeine 25-5,000 ng/mL Morphine 25-5,000 ng/mL Hydrocodone 25-5,000 ng/mL Hydromorphone 25-5,000 ng/mL Tramadol 25-5,000 ng/mL	ng/mL Codeine 25-25,000 ng/mL Morphine 25-25,000 ng/mL Hydrocodone 25-25,000 ng/mL Hydromorphone 25-25,000 ng/mL Tramadol 25-25,000 ng/mL

	Oxidants-Urine Adulteration		Beckman Coulter DxC700AU:						1
Oxidants Oxidants Confirmation	Screen N/A	Colorimetric Colorimetric	Sciteck SVT Oxidants Reagent Sciteck Diagnostics AdultaCheck	Negative / Positive	Negative Negative	N/A N/A	N/A N/A	Cutoff: 50 mcg/mL Cutoff: 5 mg/dL Oxidants	N/A N/A
Oxidants Confirmation	N/A	Cotonmetre	6 Beckman Coulter DxC700AU;	Negative / Presumptive Positive /	rvegative	N/A	N/A	Cutoff: 5 mg/dL Oxidants	N/A
Oxycodone	Oxycodone Screen- Urine	Enzyme multiplied immunoassay	Thermo Scientific DRI Oxycodone	Presumptive Positive. Confirmation to follow.	Negative	N/A	N/A	Cutoff: 100ng/mL Oxycodone: 25-5,000 ng/mL	N/A Oxycodone: 25-25,000 ng/mL
Oxycodone, Urine, Confirmation	N/A	LC/MS/MS	Agilent QQQ 6420 Beckman Coulter DxC700AU;	ng/mL	< 25 ng/mL	N/A	N/A	Oxymorphone: 25-5,000 ng/mL Noroxycodone: 25-25,000 ng/mL	Oxymorphone: 25-25,000 ng/mL Noroxycodone: 25-25,000 ng/mL
Oxycodone, Meconium	Oxycontin	Enzyme multiplied immunoassay	Thermo Scientific DRI Oxycodone	Negative / Presumptive Positive	Negative	N/A	N/A	Cutoff: 200 ng/g	N/A
Pentobarbital Level	Nembutal	Gas chromatography	Agilent GC	ug/mL	Intracranial pressure therapy: 30-40	>45	OSU Pharmacy	5-50	5-50
pH	pH - Urine Adulteration Screen pH - Urine Adulteration	Colorimetric	Beckman Coulter DxC700AU; Sciteck SVT pH Reagent	N/A	4.5-9.0	N/A	SAMSHA	3.0-9.0	3.0-9.0
pH Confirmation	Confirmation	pH meter	Corning	N/A	4.5-9.0	N/A	SAMSHA	3.0-11.0	3.0-11.0
Phencyclidine	PCP Screen - Urine	Enzyme multiplied immunoassay Chemiluminescent microparticle	Beckman Coulter DxC700AU; Emit II Plus Phencyclidine Assay Abbott	Negative / Presumptive Positive / Presumptive Positive. Confirmation to follow.	Negative 0.6-2.4	N/A >3.0	N/A OSU	Cutoff: 25ng/mL 0.5-40.0	N/A 0.5-40.0
Phenytoin Free Level	Dilantin, Free	immunoassay	Abbott	mcg/mL	(Therapeutic Range) Bone Marrow Transplant:	>3.0	Pharmacy	0.5-40.0	0.3-40.0
Sirolimus (Rapamycin) Level, Random	Rapamycin	Chemiluminescent microparticle immunoassay	Abbott Reichert Technologies TS Meter	ng/mL	4.0-12.0 Therapeutic: 5.0-30.0	N/A	OSU Pharmacy	2.0-30.0	2.0-60.0
Specific Gravity	N/A	Refractometry	D Clinical Refractometers	N/A	1.003-1.030 Bone Marrow Transplant:	N/A	SAMSHA	1.000-1.045	1.000-1.045
Tacrolimus, Random	Prograf	Chemiluminescent microparticle immunoassay	Abbott	ng/mL	4.0-12.0 Therapeutie: 5.0-15.0	N/A	OSU Pharmacy	2.0-30.0	2.0-60.0
Toxicology Diversion Serves	N/A	LCMSMS	SCIEX 3200 QTRAP	6-monoacetylmophine Or 7, aminochonacepum Or Charlespum Or Displexocidente Or Electrica Cyclesia Or Codeine Or Codeine Or Codeine Or Codeine Or Restraine Or Haracepum Or Philosocidente Or Networkson Or Flamines Or Lezazapum Or Nationacepum Or Northaracepum Or Oxycoloxide Or Oxysomephone Oxysome	Negative	N/A	NA	Cutoff (agirda.) 6. Monuscery biomylera (2007). Aminochamira zegorat (25), 7. Aminochamira zegorat (25), 7. Aminochamira zegorat (25), 7. Aminochamira zegorat (25), 7. Aminochamira (25), 4. Aminochamira (25), 4. Aprachamira (25), 4. Aprach	N/A
Valproic Acid, Free	FVPA	Chemiluminescent microparticle immunoassay	Abbott	mcg/mL	5-35 (Therapeutic Range)	>40	OSU Pharmacy	2-150	2-150
Valproic Acid, Total	VPA	TOX: Chemiluminescent microparticle immunoassay	TOX: Abbott RRL: Beckman	meg/mL	50-120 (Therapeutic Range)	>150	Applied Clinical Pharmacokinetics, 2001 Clinical Pharmacokinetics, 1995;29:442-50	4-150	4-750
Cytogenetic Studies	Cytogenetics, karyotype Chromosome Analysis	Manual	N/A	N/A	See report	N/A	N/A	N/A	N/A
MDS FISH Panel	Panel Components: D5S23:D5S721/CSF1R, 5p15.2 / 5q33.34 D7ZI/D75486, 7 centromere / 7q31 D8Z2/D20S108,8 centromere / 20q12	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 1q25.2 (ABL2)	ABL2 rearrangement, ABL2, Abelson gene 2, 1q25.2	Fluorescent in situ Hybridization (FISH)	N/A	%	N/A	N/A	N/A	N/A	N/A
CG 9q34.11-q34.13 (ABL1)	ABL1 rearrangement, ABL1, Abelson gene 1, CG 9q34.11-9q34.13	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 9p11-q11 (D9Z4)	9 centromere, CEP 9, 9 cen, D9Z4, 9p11-q11	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 7p11.1-q11.1 (D7Z1)	7 centromere, CEP 7, 7 cen, D7Z1, 7p11.1-q11.1	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 7p11.1-q11.1, 7q31 (D7Z1- D7S486)	7q-, -7, 7q31, 7centromere, D7Z1, 7p11.1-q11.1, D7S486, 7q31	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 15p11.1-q11.1 (D15Z4)	CEP15, 15 cen, 15 centromere, D15Z4, 15p11.1-q11.1	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 20q12, 8p11.1-q11.1 (D20S108- D872)	20q-, +8, 8 centromere, CEP 8, D8Z2, 8p11.1-q11.1 & D20S108, 20q12	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CLL FISH Panel	Panel Components: ATM, 11q22.3 TP53, 17p13.1 D12Z3, 12 centromere D13S319. 13u14.3	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 2p16.1, 2q32.1 (REL-DIRC1)	REL, 2p16.1, DIRC1, 2q32.1	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 6q21, 6q23 (SEC63-MYB)	SEC63, 6q21, myeloblastosis, MYB, 6q23	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 9p21, 9p11-q11 (CDKN2A- D9Z4)	CDKN2A, cyclin dependent kinase inhibitor 2A, 9p21, 9 centromere, D9Z4, 9p11-q11	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 12p11.1-q11, 13q14.3, 13q34 (D12Z3-D13S319-LAMP1)	12-13, 12 centromere, trisomy 12, del 13, 13q-, D12Z3, 12p11.1- q11.1, D13S319, 13q14.3, LAMP1, 13q34,	Fluorescent in situ Hybridization	N/A	96	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
MYELOMA FISH PANEL	Panel Components: CDKN2C, 1p32.3 CKS1B, 1c21 CEP 7, 7p11.1-q11.1 CEP 9, 9p11-q11 CEP15, 15p11.1-q11.1 ATM, 1q22.3 TP53, 17p13.1 RB1, 1sq14.2 LAMP1, 1sq84 GHICCND1, 14q32.3/1q13 GHICCND1, 14q32.3/1q13	Fluorescent in situ Hybridization	N/A	56	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 1p32.3, 1q21 (CDKN2C- CKS1B)	lp, 1q, CDKN2C, 1p36.3, CKS1B, 1q21	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 3q27 (BCL6)	BCL6 rearrangement, B-cell lymphoma 6, BCL6, 3q27	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 5q33-34,5p15.2 (CSF1R- D5S23:D5S721)	5p-5q, -5, 5q-, D5S23:D5S721, 5p15.2, CSF1R, 5q33-34, colony	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 8q24.2 (MYC)	stimulating factor MYC rearrangement, CMYC, MYCC, MYC, 8q24	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293-	N/A	N/A	N/A	N/A
CG 11q22.3, 17p13.1	ATM-TP53, ATM, 11q22.3,		N/A	%	9898 for current reference range See report or contact lab at 614-293-	N/A	N/A	N/A	
(ATM-TP53) CG 12p13.2-21q22	TP53, 17p13.1 ETV6-RUNX1 translocation,	Fluorescent in situ Hybridization			9898 for current reference range See report or contact lab at 614-293.				N/A
(ETV6-RUNX1)	t(12;21), TEL-AML1, ETV6, 12p13, RUNX1, 21q22	Fluorescent in situ Hybridization	N/A	%	9898 for current reference range	N/A	N/A	N/A	N/A
CG 13q14.2, 13q34 (RB1-LAMP1) CG 14q32.3-11q13.3	13q-, del13, -13, RB1, 13q14.2, LAMP1, 13q34 translocation (11;14), t(11;14), Mantle cell lymphoma FISH,	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range See report or contact lab at 614-293-	N/A	N/A	N/A	N/A
(IGH-CCND1)	MCL FISH, CCND1, cyclin D1, 11q13, IGH, 14q32.3	Fluorescent in situ Hybridization	N/A	%	9898 for current reference range	N/A	N/A	N/A	N/A
CG 8p11.1-q11.1,8q24 (D8Z2- MYC)	8 centromere, +8, D8Z2, 8p11.1- q11.1, MYC single color, 8q24	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 2p24,2p11-2q11 NMYC - D2Z1	NMYC amp, NMYC, neuroblastoma, MYCN, 2p24.1, 2 centromere, 2p11.1-q11.1	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A

				1				I	I
CG 11p15.4 (NUP98)	NUP98 rearrangement, nucleoporin 98, NUP98, 11p15.4	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
Xp22.33-Yp11.32 (P2RY8)	P2RY8 rearrangement, P2Y8, P2Y receptor, purinoceptor 8, P2RY8, Xp22.33 - Yp11.32	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 1q23-19p13.3 (PBX1-TCF3)	PBX1-TCF3 translocation, t(1;19), pre-B-cell leukemia transcription factor 1, PBX1, 1q23, transcription factor 3, TCF3, 19p13.3,	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 5q32 (PDGFRB)	PDGFRB rearrangement, platelet derived growth factor beta,	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 15q24-17q21 (PML-RARA)	PDGFRB, 5q32 t(15;17), PML-RARA, APL FISH, promyelocytic leukemia, PML, 15q24, retinoic acid receptor alfa,	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 17q21 (RARA)	RARA, 17q21 RARA rearrangement, retinoic acid receptor alfa, RARA, 17q21	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 21q22 (RUNX1)	RUNX1 rearrangement, runt- related transcription factor 1, AML1, acute myeloid leukemin	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
	marker 1, RUNX1, 21q22.12 RUNX1T1-RUNX1 translocation,								
CG 8q21.3-21q22 (RUNX1T1- RUNX1)	t(8;21), ETO-AML1, ETO, eight- twenty-one, RUNX1T1, 8q21.3, runt-related transcription factor 1, RUNX1, 21q22	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
4q12 (SCFD2-LNX-PDGFRA- KIT)	PDGFRA rearrangement, 4q tricolor, CHIC2, platelet derived growth factor alpha, SCFD2-LNX- PDGFRA, 4q12	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 14q32.13-q32.2 (TCL1)	TCL1 rearrangement, inv(14), T- cell leukemia/lymphoma protein 1, TCL1, 14q32	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 7q34 (TRB)	TRB rearrangement, TCRB, T- cell receptor beta, TRB, 7q34	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG Xp11.1-q11.1, Yq12 (DXZ1- DYZ1)	XY, opposite sex BMT FISH, X centromere, Xpl1.1-q11.1, Yq, Yq12	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 7p11.1-q11.1, 7q22, 7q36 (D7Z1-CUX1-CUL1)	7q-, -7, 7centromere, D7Z1, 7p11.1-q11.1, CUX1, cut like homeobox 1, CDP, CULT1, 7q22, CUL1, culling 1, 7q36	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 2p23.2-p32.1 (ALK)	ALK rearrangement, anaplastic lymphoma kinase, ALK, 2p23	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 19q13.3 (BCL3)	BCL3 rearrangement, B-cell leukemia/lymphoma 3, BCL3, 19p13	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 22q11.2-9q34.1 (BCR-ABL1)	BCR-ABL1, t(9:22), Philadelphia chromosome, Ph+ FISH, Abelson 1, ABL1, 9q34, breakpoint cluster region, BCR, 22q11.2	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 11q22-18q21.3 (BIRC3-MALT1)	BIRC3-MALT1 translocation, t(11;18), API2-MLT, baculoviral IAP repeat containing 3, BIRC3, 11q21, mucosa-associated lymphoid tissue lymphoma	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
	translocation protein 1, MALT1, 18q21 CBFB, core binding factor beta				See report or contact lab at 614-293-				
CG 16q22 (CBFB)	rearrangement, inv(16), t(16;16), 16q2 CBFB-MYH11, inv(16), t(16;16),	Fluorescent in situ Hybridization	N/A	%	9898 for current reference range	N/A	N/A	N/A	N/A
CG 16q22-16p13.1 (CBFB-MYH11)	inverted 16, translocation 16-16, myosin heavy chain 11, MYH11, 16p13, core binding factor, CBFB, 16q22	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 4p11-q11,10p11.1-q11.1 (D4Z1- D10Z1)	4 centromere, CEP4, 4 cen, +4, 4p11-q11, 10 centromere, CEP10, 10 cen, +10, 10p11.1-q11.1	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG Xp22.33-Yp11.32 (CRLF2)	CRLF2 rearrangement, cytokine receptor like factor 2, CRLF2, Xp22.33/YP11.32	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 6p22-9q34 (DEK-NUP214)	DEK-NUP214 translocation, DEK, 6p22.3, nucleoporin 214, NUP214, 9q34.12-9q34.13	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 5q31, 5p15.2 (EGR1-D5823:D58721)	5p-5q, 5q-, -5, D5S23:D5S721, 5p15.2, EGR1, early growth response 1, 5q31	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 12p13.2 (ETV6)	ETV6 rearrangement, ETS variant transcription factor 6, TEL, ETV6, 12p13	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 22q12 (EWSR1)	EWSR1 rearrangement, Ewing's sarcoma, EWS, EWS-FLI1, EWSR1, 22q12	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 8p11.2, 8p11.1-q11.1 (FGFR1- D8Z2)	FGFR1 rearrangement, fibroblast growth factor receptor 1, FGFR1, 8p11.23, 8 centromere, 8p11.1- q11.1	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 13q14 (FOXO1)	FOXO1 rearrangement, FKHR, Foxhead box O, alveolar rhabdomyosarcoma, 13q14	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 14q32.3 (IGH)	IGH rearrangement, immunoglobulin heavy locus, IGH, 14q32.3	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 14q32.3-6p21 (IGH-CCND3)	IGH-CCND3 translocation, t(6;14), IGH, 14q32.3, CCND3, cyclin D3, 6p21	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 14q32.3-18q21.3 (IGH-BCL2)	IGH-BCL2 translocation, t(14;18), IGH, 14q32.3, B-cell leukemia/lymphoma 2, BCL2,	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 14q32.3-4p16.3 (IGH-FGFR3)	18q21.3 IGH-FGFR3 translocation, t(4;14), IGH, 14q32.3, FGFR3, fibroblast growth factor 3, 4p16	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 14q32.3-16q23 (IGH-MAF)	IGH-MAF translocation, t(14;16), IGH, 14q32.3, musculoaponeurotic fibrosarcoma, MAF, c-MAF, 16q23	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 14q32.3-20q12 (IGH-MAFB)	IGH-MAFB translocation, t(14;20), IGH, 14q32.3, leucine zipper transcription factor β, MAFB, 20q12	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 14q32.3-8q24,8p11.1-q11.1 (IGH-MYC/D8Z2)	IGH-MYC translocation, t(8;14), Burkitt lymphoma FISH, IGH, 14q32.3, MYC, 8q24, 8 centromere, 8p11.1-q11.1	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 2p11.2 (IGK)	IGK rearrangement, Immunoglobulin kappa, IGK, 2p11.2	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 9p24 (JAK2)	JAK2 rearrangement, JTK10, Janus kinase 2, JAK2, 9p24	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 11q23 (KMT2A)	KMT2A rearrangement, MLL, mixed lineage leukemia, lysine methyltransferase 2A, KMT2A, 11q23	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CG 3q26.2 (MECOM)	MECOM rearrangement, EVII, MDS1 and EVII complex locus, MECOM, 3q26.2	Fluorescent in situ Hybridization	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
Pediatric MDS FISH Panel	Panel Components: D5S23:D5S721/CSF1R 5p15.2 / 5q33-34 D7Z1/D7S486 7 centromere /7q31 D8Z2 - 8 centromere	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
Pediatric MDS w/ EGR1 FISH Panel	Panel Components: D5823:D58721/EGR1, 5p15.2 / 5q31 D7Z1/D78486, 7 centromere / 7q31 D8Z2, 8 centromere	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
MDS w/ EGR1 FISH Panel	Panel Components: D5S23:D5S721/EGR1, 5p15.2 / 5q31 D7ZI/D7S486, 7 centromere / 7q31 D8Z2/D20S108, 8 centromere / 20q12	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A

MPD FISH Panel	Panel Components: PDGFRA ba, 4q12 PDGFRB ba, 5q32 FGFR1 ba, 8p12 JAK2 ba, 9p24 BCR/ABL1, 22q11.2/9q34	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
CLL Extended FISH Panel	Panel Components: ATM, 11q22.3 TP53, 17p13.1 D1223, 12 centromere D13S319, 13q14.3 MYC ba, 8q24 CDKN2A, 9p21	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
Mycloma IGH Reflex FISH Panel	Panel Components: IGH/FGFR3, 14q32.2/4p16 IGH/MAF, 14q32.3/16q23 IGH/MAFB, 14q32.3/20q12	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
Eosinophil AEL-CEL FISH Panel	Panel Components: PDGFRA ba, 4q12 PDGFRB ba, 5q32 FGFR1 ba, 8p12	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
NHL B-Cell FISH Panel	ETV6 ba, 12p13 Panel Components: BCL6 ba, 3q27 MYC ba, 8q24	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
NHL T-Cell FISH Panel	IGH/BCL2, 14q32.3/18q21 Panel Components: TRB ba, 7q34 TCL1 ba, 14q32.13-32.2	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
ALL FISH Panel	Panel Components: 4 centromere 10 centromere BCR/ABL1, 22q11.2/9q34 KMT2A ba, 11q23 ETV6/RUNX1, 12p13/21q22	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
AML FISH Panel	Panel Components: MECOM ba, 3q26 RINXITI/RINXI, 8q21.3/21q22 KMT2A ba, 11q23 PML/RARA, 15q24/17q21 CBFB ba, 16q22 TP33/CEP 17, 17p13.1/17 centromere	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
17p13.1, 17p11.1-q11.1 (TP53 - D17ZI)	TP53, tumor protein 53, del17p, - 17, 17p13.1, CEP17, 17 centromere, 17p11.1-17q11.1, D17Z1	Fluorescent in situ Hybridization (FISH)	N/A	%	See report or contact lab at 614-293- 9898 for current reference range	N/A	N/A	N/A	N/A
Acid Fast Bacilli Culture and Smear	Acid Fast Culture	Culture; Susceptibility testing performed based on established lab guidelines	Bactec/Bruker Daltonics MicroFlex	N/A	Collect time is required for each specimen submission. Normal is negative. Collect time is required for each	Presence of Acid-Fast Bacilli	N/A	N/A	N/A
Acid Fast Bacilli Smear	AFB Smear	Smear	N/A	N/A	specimen submission. Normal is negative.	Presence of Acid-Fast Bacilli	N/A	N/A	N/A
Acinetobacter Culture Actinomyces, Screen	N/A N/A	Surveillance Culture Gram stain	Vitek N/A	N/A N/A	Negative Negative	N/A N/A	N/A N/A	N/A N/A	N/A N/A
Affirm Test (Vaginitis DNA Probe)	Affirm	Nucleic Acid Hybridization	BD Microprobe Processor	N/A	Candida = negative Gardnerella = negative	N/A	N/A	N/A	Negative / Positive
ED Only Anaerobe ID	Anaerobic Identification	Culture Culture; Susceptibility testing	Bruker Daltonics MicroFlex	N/A	Trichomonas = negative N/A	N/A	N/A	N/A	N/A
Anaerobic Culture	Anaerobe Culture	performed based on established lab guidelines	Bruker Daltonics MicroFlex	N/A	Collect time is required for each specimen submission	N/A	N/A	N/A	N/A
Atypical Bacterial Pneumonia, PCR	Atypical Bacterial Pneumonia Panel	PCR	BioFire	N/A	Not Detected	N/A	Package Insert	N/A	Not Dected / Detected
Autoclave Spore Check	Autoclave Spore Check Assert	Steam sterilization Smear; Culture; Susceptibility testing	N/A	N/A	Negative	N/A	N/A	N/A	Negative / Positive
Bacterial Culture and Direct Smear, Lesion, Tissue, Device	Routine Culture and Smear	performed based on established lab guidelines	N/A	N/A	No growth	See critical call list for organisms requiring notification.	Validation	N/A	N/A
Bacterial vaginosis Panel	BV	TMA - transcription-mediated amplification	Hologic Panther Aptima kit	N/A	Negative	N/A	Package Insert; Clinical Data	N/A	Negative, Positive
Beta Strep, Vaginal Screen	Group B Streptococcus Testing by PCR	Concentration in LIM broth for > 18 hours followed by real-time PCR testing for GBS DNA sequence	BD MAX	N/A	Negative	N/A	Validation	N/A	Negative / Positive
Beta Strep, Vaginal Screen, Reflex Susceptibility for Penicillin Allergy BK Virus DNA PCR, Quant,	GBS, Streptococcus agalactiae	Concentration in LIM broth for > 18 hours followed by real-time PCR testing for GBS DNA sequence	BD MAX	N/A	Negative	N/A	Validation	N/A	Negative / Positive
Urine BK Virus DNA Qn, PCR, Plasma	N/A BKBP	Real-Time PCR Real-Time PCR	3M Integrated Cycler 3M Integrated Cycler	copies/mL copies/mL	<500 <500	N/A N/A	Validation Validation	500-10,000,000,000	500-endpoint 500-5,000,000
Blood Culture, AFB, Mycobacteria	Blood, acid fast	Culture; Susceptibility testing performed based on established lab guidelines	Bruker Daltonics MicroFlex	N/A	Reference Range-Negative Collect time is required for each	Growth	N/A	N/A	N/A
Blood Culture, Fungus	N/A	Culture; Susceptibility testing performed based on established lab guidelines	Bruker Daltonics MicroFlex	N/A	specimen submission. Reference Range-Negative. Collect time is required for each specimen submission	Growth	N/A	N/A	N/A
Blood Culture, Pediatric	N/A	Culture; Susceptibility testing performed based on established lab guidelines	BioMerieux Virtuo/Bruker Dultonics MicroFlex	N/A	No growth	Growth	N/A	N/A	N/A
Blood Culture	N/A	Culture; Susceptibility testing performed based on established lab guidelines	Bruker Dahonics MicroFlex, BioMerieux Virtuo, Vitek	N/A	No growth	All first time positive blood cultures are called with organism morphology details. Any additional positives after 48 hours requires an additional call. If Gram negative resistance marker or vanA, vanB is detected on Nanosphere an additional call is made.	N/A	N/A	N/A
Blood Product Protocol Blood, Transfusion Reaction	N/A Transfusion Reaction, Blood	Culture	BioMerieux Virtuo BioMerieux Virtuo	NA NA	Negative Negative	Growth Growth	N/A N/A	N/A N/A	N/A N/A
BMTCDP	Product Culture BMT C. diff by PCR	PCR Culture; Susceptibility testing	BD Max	N/A	Negative	N/A	Package insert; in-house validation; literature	N/A	Negative / Positive
Body Fluid Culture and Direct Smear	Sterile fluid culture	Culture; Susceptibility testing performed based on established lab guidelines	Vitek/Bruker Dultonics MicroFlex	N/A	N/A	N/A	N/A	N/A	N/A
Candida/ Trichomonas Panel	CV/TV	Transcription-mediated amplification	Hologic Panther Aptima kit	N/A	Not Detected	N/A	Package Insert; Clinical Data	N/A	Not Detected/ Detected
C difficile 2 Step	N/A	Rapid membrane enzyme immunoassay	Techlab	N/A	Negative	N/A	Package insert	N/A	Negative / Positive
Candida auris Screen by PCR CAPD Fluid Bacterial Culture	Candida auris Screen N/A	Real-Time PCR Culture; Susceptibility testing performed based on established lab	DiaSorin Vitek/Bruker Daltonics MicroFlex	N/A N/A	Not Detected Collect time is required for each	Detected N/A	PI; Literature N/A	N/A N/A	Not Detected/ Detected N/A
Catheter Tip Culture	N/A	guidelines Culture	Vitek/Bruker Daltonics MicroFlex	N/A	specimen submission. Negative. Vascular Catheter tip cultures are interpreted in conjunction with blood culture results.	Growth	N/A	N/A	N/A
Chlamydia and Gonorrhea Amplified	Chlamydia trachomatis & Neisseria gonorrhoeae NAAT Testing	TMA - transcription-mediated amplification	Hologic Aptima Combo 2 Assay on Panther	N/A	with blood culture results. Not Detected	N/A	Package Insert	N/A	N/A
CMV by PCR, Quantitative, Blood	CMV Viral Load, CMV PCR	Real-Time PCR	Abbott	IU/mL	<50	N/A	Literature / History	50-156,000,000	50-156,000,000
EBV by PCR, Quantitative, Blood	EBV Viral Load, EBV PCR	Real-Time PCR	3M Integrated Cycler	IUmL	<1,000	≥10,000	Validation	1,000-5,000,000	1,000-5,000,000
EBV Rapid PCR, CSF Only	EBV PCR, EBV CSF	Real-Time PCR	3M Integrated Cycler	IU/mL	Not Detected	≥10,000	Validation	1-10,000	Not Detected, Detected <10,000, Detected >10,000
Fungal Susceptibility Testing	N/A	TREK panel Culture; Susceptibility testing	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Fungus Culture	N/A	performed based on established lab guidelines	N/A	N/A	Collect time is required for each specimen submission. No growth.	Growth	N/A	N/A	N/A
Fungus Culture (Skin, Hair, Nails)	N/A	Culture	N/A	N/A	Collect time is required for each specimen submission.	N/A	N/A	N/A	N/A
Fungus Smear	Calcofluor White fluorescent stain	Smear Smear when indicated; Culture;	N/A	N/A	Negative	Positive for fungal elements	N/A	N/A	N/A
Genital Culture, Bacterial	Vaginal, Cervical, Urethral	Susceptibility testing performed based on established lab guidelines	Vitek/Bruker Daltonics MicroFlex	N/A	Normal flora or no growth, depending on site	See critical call list for organisms that require a call.	N/A	N/A	N/A
Gram Stain	N/A	Smear	N/A	N/A	Negative	See Critical Call procedure for list of sources that are called to	N/A	N/A	N/A
H. Pylori Urea Breath Test	UBT for H. pylori, BreathID	Infrared Spectrophotometry	Meridian BreathID Smart	N/A	Cut-off value is 5 for adults for children 3-17 years	physician/nurse N/A	Package Insert	N/A	Negative / Positive
Hepatitis B DNA	HBV Viral Load	Real-Time PCR	Abbott	IU/mL	<10	N/A	Validation/ Package Insert	10-1,000,000,000	10-1,000,000,000
Hepatitis C by PCR, Quant	HCV Viral Load	Real-Time PCR	Abbott	(log IU/mL) IU/mL	(<1.00) <12	N/A	Validation/ Package Insert	(1.00-9.00) 12-100,000,000	(1.00-9.00) 12-100,000,000
Hepatitis C by PCR, Quant HIV Viral Load RNA PCR Quant	HIV Viral Load	Real-Time PCR	Abbott	(log IU/mL) copies/mL	(<1.08) <40	N/A N/A	Validation/ Package Insert	(1.08-8.00) 40-10,00,000	(1.08-8.00) 40-10,000,000
HSV by PCR, Fluid/Lesion	Herpes Simplex Virus 1 and 2 Testing by PCR	Real-Time PCR	DinSorin	(log copies/mL) N/A	(<1.60) Not Detected	Positive in CSF	Package Insert / Literature	(1.60-7.00) N/A	(1.60-7.00) Detected / Not Detected
	Changes CCR								Detected / Not Detected
Immunocompromised Respiratory Panel	BioFire RP2.1	Film Array PCR	BioFire	N/A	Not Detected	N/A	Package Insert / Literature	N/A	Influenza A Only: Detected, Indeterminate, Not Detected

					T.				
Influenza A/B Rapid Molecular	Rapid Flu	Isothermal Nucleic Acid Amplification	Abbott	N/A	Not Detected	N/A	Alere-I Influenza A+B package insert	N/A	Detected / Not Detected / Indeterminate
Influenza A/B, RSV by PCR	Flu PCR, RSV PCR Fecal Leukocytes, Stool for	PCR	3M Integrated Cycler Alere	N/A	Not Detected	N/A	Validation	N/A	Detected/ Not Detected
Lactoferrin, Qualitative, Stool	WBCs	Immunochromatographic	LEUKO EZ VUE	N/A	Negative	N/A	Package Insert	N/A	Negative / Positive
Legionella Culture	N/A	Culture	Bruker Daltonics MicroFlex	NA	Collect time is required for each specimen submission.	N/A	N/A	N/A	N/A
Legionella Environ	Environmental Culture for Legionella	Culture	Bruker Daltonics MicroFlex	N/A	Collect time is required for each specimen submission.	N/A	N/A	N/A	N/A
Lower Respiratory Culture, Bacterial	RES	Culture; Susceptibility testing performed based on established lab guidelines	Bruker Daltonics MicroFlex	N/A	normal flora	N/A	N/A	N/A	N/A
M Tuberculosis Complex by PCR	TB PCR, MTB, M. tuberculosis	Real-Time PCR	GeneXpert	N/A	Not Detected	Detected	Package Insert / Reference Materials	N/A	Not Detected / Detected
Macrosconic: Arthropod	Arthropod	Macroscopic Exam	N/A	N/A	Negative, Artifact (not arthropod)	N/A	N/A	N/A	N/A
Meningitis / Encephalitis Panel, CSF	BioFire Meningitis / Encephalitis Panel	Film Array PCR	BioFire	N/A	Not Detected	Detected	Package Insert	N/A	Detected / Not Detected
MRSA Screening Culture Panel, Nares, Axilla, Groin/Wound	MRSA Screen	Culture	N/A	N/A	Negative for MRSA	N/A	N/A	N/A	N/A
Molecular Enteric Panel, Stool	Gastrointestinal Panel	Molecular - real time PCR	BD MAX	N/A	Negative	N/A	N/A	N/A	Negative / Positive
Molecular Stool Parasite Panel	O&P	Real-Time PCR	BD MAX	N/A	Negative	N/A	Package insert; Microbiology Reference material	N/A	Negative / Positive
Neisseria-gonococcus Screen	GC Screen	Culture on selective agar for N.	N/A	N/A	Negative	N/A	N/A	N/A	N/A
0.11.5 150	Dermatophyte Identification	gonorrhoea and N. meningitidis Culture	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Outside Fungal ID Outside Mycobacterial ID	Mold Identification Yeast Identification		Bruker Daltonics MicroFlex					N/A	N/A N/A
Pinworm Exam	N/A	Culture Microscopic exam	Bruker Daltonics MicroFlex N/A	NA N/A	NA Negative	NA N/A	N/A N/A	N/A N/A	N/A N/A
Plesiomonas/Aeromonas Screen, Stool	Aeromonas / Plesiomonas Screen	Culture	Vitek/Bruker Dultonics MicroFlex	N/A	Negative	N/A	N/A	N/A	N/A
POCT Chlamydia trachomatis and Neisseria gonorrhoeae (CTNG)	binx io GC and Chlamydia	PCR	Binx io	N/A	Not Detected	N/A	Package Insert	N/A	Detected / Not Detected
		Tissue is weighed, serially diluted.							
Quantitative Tissue Culture	N/A	and cultured for exact colony count.	Vitek/Bruker Dultonics MicroFlex	colony forming units/gram	No growth	N/A	N/A	N/A	N/A
Rapid HIV-1/HIV-2 Ab With P24 Antigen	Rapid HIV, Alere Determination HIV 1/2 Ag/Ab Combo	Qualitative Immunoassay / Immunochromatographic test for simulianeous and qualitative detection of free HIV-1 p24 antigen and antibodies to HIV-1 and HIV-2	Alere Determine	N/A	All: nonreactive	N/A	Package Insert	N/A	Reactive / Nonreactive / Presumptive Reactive
Rapid Malaria	Plasmodium	Immunochromatographic membrane assay that uses monoclonal antibodies to qualitatively detect Plasmodium fakiparum antigen and pan-makirial antigen (an antigen shared by Plasmodium species causing human malaria)	Abbott Binax NOW	N/A	Negative for Plasmodium antigens	N/A	Package Insert	Limit of detection 100 parasites per microliter	Positive for Plasmodium antigen
Rapid Strep A, Molecular	Rapid Strep, Strep A	Molecular in vitro diagnostic test utilizing isothermal nucleic acid	Abbott	N/A	Negative	N/A	N/A	N/A	Negative / Positive
Rectal Screening for Cipro	Ciprofloxacin Resistance	amplification Culture							
Resistance	Screening	Culture Isothermal Nucleic Acid	N/A	N/A	N/A	N/A	N/A	N/A	N/A Detected /
SARS-COV-2 RAPID	Rapid COVID	Amplification	Abbott	N/A	Not Detected	N/A	Abbott ID NOW Rapid Covid package insert	N/A	Not Detected
Novel Coronavirus PCR	COVID-19 Vancomycin Resistant	Real Time PCR	DiaSorin	N/A	Not Detected Negative for Vancomycin Resistant	N/A	N/A	N/A	Detected / Not Detected
Screen VRE Screen, Yeast	Enterococcus Screen N/A	Culture on selective agar. Culture	N/A Bruker Daltonics MicroFlex	N/A N/A	Enterococcus. Negative	N/A N/A	N/A N/A	N/A N/A	N/A N/A
Screen: MRSA - Baby	NICU MRSA Respiratory Staphylococcus	Culture	N/A	N/A	Negative	N/A	N/A	N/A	N/A
Screen: MRSA/MSSA	Screen, Staph Screen	Real-Time PCR	BD MAX	N/A	Negative	N/A LOOP Specimens will be called	Package Insert	N/A	N/A
Sterility Check	N/A	Culture	Vitek/Bruker Dultonics MicroFlex	N/A	Negative	to the coordinator	N/A	N/A	N/A
Strep Pneumoniae Antigen, Urine	N/A	Immunochromatographic membrane assay.	Binax NOW	N/A	Negative	N/A	Binax NOW Package Insert	N/A	Negative / Positive
Susceptibility	Susceptibility and Identification	N/A	Vitek/Bruker Daltonics MicroFlex	N/A	N/A	N/A	N/A	N/A	N/A
Upper Respiratory Culture, Bacterial	Throat Culture, RESN	Culture	Bruker Daltonics MicroFlex	N/A	normal flora	N/A	N/A	N/A	N/A
Urine Culture	N/A	Culture; Susceptibility testing performed based on established lab	N/A	CFU/mL	Culture includes colony count. Collect time is required for each specimen	N/A	N/A	N/A	N/A
Varicella Zoster By PCR, Skin	VZVPCR	guidelines Real Time PCR	DiaSorin	N/A	submission. Not Detected	N/A	Package Insert / Literature	N/A	Detected / Not Detected
ABO / RH(D) Typing	Blood Type, ABORH	Agglutination	Manual: N/A	N/A	A, B, O, or AB and Rh positive or Rh	N/A	N/A	N/A	N/A
			Automated: Ortho Manual: N/A	N/A	Negative A, B, O, or AB and Rh positive or Rh	N/A	N/A	N/A	N/A
ABORH Type Reconfirmation ABORH Not Valid for Transfusion	Confirmatory Type Blood Type, ABOD	Agglutination Agglutination	Automated: Ortho Manual: N/A	N/A	negative A, B, O, or AB and Rh positive or Rh	N/A	N/A	N/A	N/A
Antibody ID	N/A	Agglutination	Automated: Ortho N/A	N/A N/A	negative N/A	N/A	N/A N/A	N/A N/A	N/A N/A
Antibody Screen	Indirect Antiglobulin Test, ABS	Agglutination	Manual: N/A Automated: Ortho	N/A	Negative / Positive	N/A	N/A	N/A	N/A
Antibody Titer	ABTIT	Agglutination	N/A	N/A	Reciprocal of serial dilution	All antigens but K have a critical value of 32, K has a critical value	Alloimmunization Committee	N/A	N/A
[LAB275] Antigen Typing, Red Cell	N/A	Agglutination	N/A	N/A	Negative / Positive	of 8 N/A	N/A	N/A	N/A
Autoadsorption, RBC	N/A	N/A	N/A	N/A	N/A For type- A, B, O, or AB and Rh	N/A	N/A	N/A	N/A
Baby Type and DAT (Direct Antiglobulin Test)	HEELS, Heelstick Evaluation	Agglutination	N/A	N/A	positive or Rh Negative, Antibody Screen Positive or Negative, DAT	Positive DAT	N/A	N/A	N/A
Cold Agglutinin Titer	N/A	Agglutination	N/A	N/A	Positive or Negative Reciprocal of serial dilution	N/A	N/A	N/A	N/A
Cord Blood Evaluation				N/A	For type- A, B, O, or AB and Rh positive or Rh Negative, DAT Positive			N/A	N/A
	N/A	Agglutination	N/A		or Negative Compatible, Incompatible, Least	Positive DAT	N/A	1474	11/25
Crossmatch	N/A	Agglutination	N/A	N/A	companies, incompatible, Least				
Direct Antiglobulin Test (DAT)	DAT, Direct Antiglobulin				incompatible	N/A	N/A	N/A	N/A
Donor unit retype		Agglutination	N/A	N/A	incompatible Negative / Positive	N/A	N/A	N/A	N/A
Donor unit retype	Reconfirmation of donor units	Agglutination Agglutination	Manual: N/A Automated: Ortho	N/A N/A	incompatible Negative / Positive A, B, O, or AB and Rh positive or Rh Negative	N/A N/A	N/A N/A	N/A N/A	N/A N/A
Eluate	Elution, RBC	Agglutination Agglutination	Manual: N/A Automated: Ortho N/A	N/A N/A	incompatible Negative / Positive A, B, O, or AB and Rh positive or Rh Negative N/A	N/A N/A New antibody identified in Ekate	N/A N/A N/A	N/A N/A N/A	N/A N/A N/A
Eluate Fetal Screen Workup RHOIG Evaluation	Elution, RBC N/A Rhogam Evaluation	Agglutination Agglutination Agglutination Agglutination Agglutination	Manual: N/A Automated: Ortho N/A Immucor N/A	N/A N/A N/A N/A	incompatible Negative / Positive A, B, O, or AB and Rh positive or Rh Negative N/A Negative / Positive N/A	N/A N/A New antibody identified in Eluate N/A N/A	N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A
Eluate Fetal Screen Workup RHOIG Evaluation Transfusion Reaction Battery	Elution, RBC N/A Rhogam Evaluation N/A	Agglutination Agglutination Agglutination Agglutination Agglutination Agglutination	Manual: N/A Automated: Ortho N/A Immucor N/A N/A N/A Manual: N/A	N/A N/A N/A N/A N/A	incompatible Negative / Positive A, B, O, or AB and Rh positive or Rh Negative N/A Negative / Positive N/A N/A N/A For type-A, B, O, or AB and Rh	N/A N/A New antibody identified in Eluate N/A N/A All transfusion reactions	N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A
Eluate Fetal Screen Workup RHOIG Evaluation	Elution, RBC N/A Rhogam Evaluation	Agglutination Agglutination Agglutination Agglutination Agglutination	Manual: N/A Automated: Ortho N/A Immucor N/A N/A N/A N/A Automated: Ortho	N/A N/A N/A N/A	incompatible Negatine / Positive A, B, O, or AB and Rh positive or Rh Negative N/A Negative / Positive N/A N/A N/A For type-A, B, O, or AB and Rh positive or Rh Negative, Ambody Secreen Positive or Negative or Negative.	N/A N/A New antibody identified in Eluate N/A N/A	N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A
Eluate Fetal Screen Workup RHOIG Evaluation Transfusion Reaction Battery	Elution, RBC N/A Rhogam Evaluation N/A	Agglutination Agglutination Agglutination Agglutination Agglutination Agglutination	Manual: N/A Automated: Ortho N/A Immucor N/A N/A N/A Manual: N/A	N/A N/A N/A N/A N/A	incompatible Negative / Positive A, B, O, or AB and Rh positive or Rh Negative N/A Negative / Positive N/A Negative / Positive N/A For type- A, M, O, or AB and Rh positive or Rh Negative or Rh Sector Positive Sector Positive For type- A, B, O, or AB and Rh positive or Rh Negative, Authorly Sector Positive or Negative For type- A, B, O, or AB and Rh positive or Rh Negative.	N/A N/A New antibody identified in Eluate N/A N/A All transfusion reactions	N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A
Eluate Fetal Screen Workup RHOIG Evaluation Transfusion Reaction Battery Type and Screen Type and Screen Type and Screen Type and Screen-Not for Transfusion	Elution, RBC N/A Rhogam Evaluation N/A N/A N/A	Agglutination Agglutination Agglutination Aspolutination Aspolutination Applutination Agglutination Agglutination Agglutination	Manual: N/A Automated: Ortho N/A Immuscor N/A N/A Manual: N/A Automated: Ortho Manual: N/A	N/A N/A N/A N/A N/A N/A N/A N/A	incompatible Negative / Positive A, B, O, or AB and Rh positive or Rh Negative N/A Negative / Positive N/A Negative / Positive N/A For type-A, B, O, or AB and Rh positive or Rh Negative or Negative Server Positive or Negative For type-A, B, O, or AB and Rh positive or Rh Negative, Antibody Serverse Positive or Negative For type-A, B, O, or AB and Rh	N/A N/A N/A New antibody identified in Elaste N/A N/A All transfosion reactions N/A N/A N/A	N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A
Eluate Fetal Screen Workup RHOIG Evaluation Transflusion Reaction Battery Type and Screen Type and Screen	Elution, RBC N/A Rhogam Evaluation N/A N/A	Agglutination Agglutination Agglutination Anglutination Anglutination Anglutination Agglutination Agglutination Agglutination Agglutination	Manual: N/A Automated: Ortho N/A Immuscor N/A N/A Manual: N/A Automated: Ortho Manual: N/A Automated: Ortho	N/A N/A N/A N/A N/A	incompatible Negative / Positive A, B, O, or AB and Rh positive or Rh Negative / No. NS. NS. NS. NS. NS. NS. For type-A, B, O, or AB and Rh positive or Rh Negative, anthody Secret Negative or Negative, anthody Secret Negative, anthody Secret Negative or Rh Negative, anthody Secret Negative or Negative	N/A N/A New antibody identified in Ehate N/A N/A All transfusion reactions N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A	N/A
Eluste Fetal Screen Workup BROIG Evaluation Transfusion Reaction Battery Type and Screen Type and Screen Type and Screen	Elution, RBC N/A Rhogam Evaluation N/A N/A N/A	Agglutination Agglutination Agglutination Aspolutination Aspolutination Applutination Agglutination Agglutination Agglutination	Manual: N/A Automated: Ortho N/A Immuscor N/A N/A Manual: N/A Automated: Ortho Manual: N/A Automated: Ortho Manual: N/A Automated: Ortho	N/A N/A N/A N/A N/A N/A N/A N/A	incompatible Negative Positive A. R. Q. or All and Expositive or Ex- Negative Negative Note Positive Note	N/A N/A N/A New antibody identified in Elaste N/A N/A All transfosion reactions N/A N/A N/A	N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A
Eluste Fetal Screen Workup RHIGG Evaluation Transfusion Reaction Battery Type and Screen Type and Screen-Net for Transfusion Type and Screen-Preadmission	Elation, RBC N/A Rhogam Evaluation N/A N/A N/A	Agglariation Two-Six State-both Immunosasy Two-Six State-both Immunosasy	Manual: N/A Antonated: Ortho N/A Immoor N/A Immoor N/A N/A N/A N/A Manual: N/A Antonated: Ortho Manual: N/A Automated: Ortho Manual: N/A Automated: Ortho	N/A N/A N/A N/A N/A N/A N/A N/A N/A	incompatible Negative Positive A. R. O. or All and Eth positive or Eth Negative Negative Positive NA Negative Positive NA	N/A N/A New antibody identified in Elaste N/A N/A All transfusion reactions N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A	N/A
Eluste Fetal Screen Weekep BRHOGE Neuhation Transchoine Reaction Bettery Type and Screen Type and Screen Type and Screen-Not for Transchoine Type and Screen - Preadminsion Type and Screen - Preadminsion AFP Tumor Marker	Elution, RBC N/A N/A Rhoam Toubartien N/A N/A N/A N/A AFPTMR, AFP	Agglerisation Two-Site Stanlock Immunosassy Chemilantoscent	Manual: NA Manual: NA NIA Inmosor Ortho NIA Inmosor NIA NIA NIA NIA Automated: Ortho Manual: NIA Automated: Ortho Manual: NIA Automated: Ortho Siemens Atellica IM	N/A N/A N/A N/A N/A N/A N/A N/A	incompatible Nagather (Postaire A. B. O. or All and Rh positive or Rh Name (Postaire NA Name (Postaire NA Name (Postaire NA Name (Postaire NA For type. A. B. O., or All and Rh positive or Rh Negather, Anthochy Server (Postaire or Rh Postaire or R	N/A N/A N/A N/A N/A N/A All transferious reactions N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A	N/A
Elaste Fetal Screen Workshop BRIGHG Evolutation Transitions Reserves Type and Screen APP Tumor Marker Addonterone	Elution, RBC N:A Rloam Fountrien N:A N:A N:A N:A N:A AFPTMR, AFP	Aggleination Aggleination Aggleination Analytication Analytication Analytication Analytication Aggleination Aggleination Aggleination Aggleination Two Six Starbock Immunosusty Chemilaninescent Immunosusty Multiples flow immunosusty Multiples flow immunosusty	Manual N/A Automatic Ortho N/A Inmuscor Inmuscor N/A N/A N/A N/A N/A Manual N/A Automatic Ortho Manual N/A Automatic Ortho Siemens Atellica IM DisSerin Linion XL	N/A N/A N/A N/A N/A N/A N/A N/A	incompatible Negative Positive A. B. O. or All and El positive or Elb. Negative Positive N/A N. A. B. O. or All and Ell positive or Elb. N/A N. A. S. Or All and Ell. For type. A. B. O. or All and Ell. positive or Ell. Negative, Authorby Seron Positive or Negative For type. A. B. O. or All and Ell. positive or Ell. Negative, Authorby Seron Positive or Negative All Depositive or Ell. Seron Positive or Negative All Depositive or Ell. Lighty for type. A. B. O. or All and Ell. Lighty for type. Seron Positive or Negative All Depositive or Negative Seron Positive or Negative All Depositive or Ell. Lighty for Ell. Lighty f	N/A N/A New antibody identified in Ehase N/A All transfusion reactions N/A N/A N/A N/A N/A N/A N/A N/	N/A N/A N/A N/A N/A N/A N/A N/A	N/A	N/A
Elaste Fetal Screen Warkup RHOGE Neshastim Transchaine Recution Battery Type and Screen Type and Screen And Fetal Type and Screen And Fetal Transchaine Type and Screen - Prendmission AFP Tumor Marker Aldosterone ANA Multiples Screen	Elution, RBC N:A N:A Rhound Substitute N:A N/A N/A N/A N/A AFPTME, AFP ALDOS	Aggleisation Aggleisation Aggleisation Andefination Andefination Andefination Aggleisation Aggleisation Aggleisation Aggleisation Aggleisation Two Six Sach-six Immunosasy Chemiluminescent Immunosasy Chemiluminescent Immunosasy Multiples flow immunosasy Multiples flow immunosasy Indirect Immunosasy	Manuel NiA Automated: Ortho NiA Inmotor Inmotor NiA Inmotor NiA NiA NiA Automated: Ortho Manuel NiA Automated: Ortho Manuel NiA Automated: Ortho Siemens Atellica Ibd DiaSorin Linion XL Bisquer 2200	N/A N/A N/A N/A N/A N/A N/A N/A	incompatible Nagather Positive A. B. O, or All and Et positive or Eth Nagather Nagather Nagather Positive NA Nagather Positive NA Na Nagather Positive Nagather Positive Nagather Positive Server Positive Nagather Nagather For type A. B. O, or All and Eth positive or Eth Negather, Authorby Server Doubter or Negather For type A. B. D. or All and Eth positive or Eth Negather Server Positive or Negather Server Positive Negather Server Negather Server Negather Server Negather Server	N/A N/A N/A New antibody identified in Elaste N/A N/A N/A N/A N/A N/A N/A N/	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A
Eluste Fetal Screen Wurkupp RHOGE Neuhaufun Transchulen Reaction Battery Type and Screen Type and Screen. Not for Transchulen Type and Screen. Not for Transchulen Type and Screen. Preadmission AFP Tumor Marker Aldosterone ANA Multiplex Screen ANA Multiplex Screen ANA Multiplex Screen	Elution, RBC NIA NIA NIA NIA NIA NIA NIA AFPTMR, AFP ALDOS NIA NIA	Agglatisation Agglatisation Agglatisation Anderination Anderination Agglatisation Agglatisation Agglatisation Agglatisation Agglatisation Agglatisation Two Sits Sachwich Immunoussay Chemilaminescent Immunoussay Chemilaminescent Immunoussay Multiples flow immunoussay Multiples flow immunoussay Indirect	Manual: NiA Antononici: Ortho NiA Immoor NiA Immoor NiA NiA NiA NiA Automated: Ortho Manual: NiA Automated: Ortho Manual: NiA Automated: Ortho Manual: NiA Automated: Ortho DisSerin Linion XL Bissplex: 2200 Bisplex: 2200	N/A N/A N/A N/A N/A N/A N/A N/A	incompublic Negative Positive A. R. O. or All and Els positive or Ris Nather State of the State of the State of the State of Stat	N/A N/A N/A New autibody identified in Elaste N/A All transfinion reactions N/A N/A N/A N/A N/A N/A N/A N/	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A
Enate Feed Screen Workup RHOGE CAMBATE Translations Reservin Ballers Type and Screen. As Screen Type and Screen. Translation Type and Screen. Preadmission APP Tunner Marker Addoctrone ANA Multiples Screen Market ANA Multiples Screen HA ANA Multiples Screen HA ANA Multiples Screen HA	Elution, RBC NA Rhourn Evaluation N/A N/A N/A N/A AFPTMR, AFP ALDOS N/A N/A ANAB	Aggleriation Two-Six Study-sich Immunosasy Chemilaninescent Immunosasy Multiplet flow immunosasy Multiplet flow immunosasy Infere Immunosas	Manual NiA Automated Ortho NiA Immoor Immoor NiA NiA Manual NiA Automated: Ortho Manual NiA Automated: Ortho Manual NiA Automated: Ortho James NiA Automated: Ortho James NiA Automated: Ortho James NiA James	N/A N/A N/A N/A N/A N/A N/A N/A	incompatible Negative Positive A. B. O. or All and Rb positive or Rb. Nather Positive NA. Nather Positive NA. Nather Positive NA. For type. A. B. O., or All and Rb. For type. A. B. O., or All and Rb. positive or Rb. Negative, Anthocky positive or Rb. Negative, Anthocky positive or Rb. Negative, Anthocky Serven Positive or Negative For type. A. B. O. or All and Rb. positive or Rb. Negative, Anthocky Serven Positive or Negative All Lipsight formula Negative in Normal Negative in Normal Negative in Normal	N/A N/A New antibody identified in Elaste N/A N/A N/A All transfinest reactions N/A N/A N/A N/A N/A N/A N/A N/	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A
Elaste Fetal Screen Workship BRIGHG Evolutation Transitionis Risterion Battery Type and Screen And Fore APP Tumor Marker Aldosterone ANA Multiple's Screen ANA Multiple's Screen ANA Multiple's Screen BA ANA Screen BA ANA Screen BA ANA Screen BA	Elution, RBC N:A NIA Rboam Fodultion N/A N/A N/A N/A AFPTMR, AFP ALDOS N/A N/A N/A N/A N/A N/A N/A N/	Agglatisation Agglatisation Agglatisation Anderination Anderination Agglatisation Agglatisation Agglatisation Agglatisation Agglatisation Agglatisation Two Sits Sachwich Immunoussay Chemilaminescent Immunoussay Chemilaminescent Immunoussay Multiples flow immunoussay Multiples flow immunoussay Indirect	Manual NiA Automated Ortho NiA Immedia Immedia NiA Manual NiA Automated: Ortho Immedia	N/A N/A N/A N/A N/A N/A N/A N/A	incompatible Negative (Positive A. B. O, or All and RB positive or Rb. NA Nature (Positive NA Nature (Nature (Natu	N/A New antibody identified in Elante N/A N/A All transferior reactions N/A N/A N/A N/A N/A N/A N/A N/	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A
Eliste Feel Scree Workup Feel Scree Workup RHOOf Chustada Transfolion Better Type and Screen-Not for Transfolion Type and Screen-Preadmission AFF Tunner Marker Addisterone ANA Multiples Screen ANA Multiples Screen HA ANA Screen HA ANA Streen HA ANA Streen And Micronomal Antibody	Elution, RBC NIA NIA NIA NIA NIA NIA NIA NI	Agglatisation Two-Site State-based Immunossasy Chemilaminescent Immunossasy Multiples flow immunossasy Multiples flow immunossasy Multiples flow immunossasy Indirect Immunoflatorecoccue Antibody Indirect Immunoflatorecoccue Indirect Immunosasy Oceanification Indirect Immunosasy Indi	Manual NiA Automatic Ortho NiA Immoor Immoor NiA NiA Manual NiA Automatic Ortho Manual NiA Automatic Ortho Manual NiA Automatic Ortho Manual NiA Automatic Ortho Immoor Im	N/A N/A N/A N/A N/A N/A N/A N/A	incompublic Negative Protaire A. B. O. or All and Rh positive or Rh Nather Protaire NA Nather Protaire NA Nather Protaire NA For type A. B. O. or All and Rh For type A. B. O. or All and Rh For type A. B. O. or All and Rh positive or Rh Negative Anthochy Server Protaire or Rh Segative Anthochy Server Protaire or Segative A. B. O. Segative Anthochy Server Protaire or All and Rh Segative Anthochy Segative	N/A New antibody identified in Elaste N/A N/A N/A N/A All transfinest reactions N/A N/A N/A N/A N/A N/A N/A N/	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A
Elaste Fetal Serces Workshop BRIGGE Contention Transitions Reserves Type and Serces Type and S	Elution, RBC NIA NIA NIA NIA NIA NIA NIA AFPTMR, AFP ALDOS NIA NIA ANAB NIA ANAB NIA ANAB ANAB AMA	Aggleitation Aggleitation Aggleitation Andefination Andefination Andefination Andefination Aggleitation Aggleitation Aggleitation Aggleitation Aggleitation Two Sits Starb-tick Immunossay Chemiluminescent Immunossay Multiples flow immunossay Multiples f	Manual NA Automated Ortho NA Inmuseor Inmuseor NA NA Manual NA Automated: Ortho Manual NA Automated: Ortho Manual NA Automated: Ortho Inmuseor Inmu	N/A N/A N/A N/A N/A N/A N/A N/A	incompublic Negative Positive A. B. O. or All and Rb positive or Rb. No. All and Rb positive or Rb. No. All and Rb positive or Rb. No. All and Rb. No. All and Rb. No. All and Rb. For type. A. B. O. or All and Rb. For type. A. B. O. or All and Rb. positive or Rb. Negative. Anthooly Kerna Positive or Negative Positive or Rb. Negative. Anthooly Serna Positive or Negative Carlo Topics. Negative in Normal Negative in Normal Negative Normal Negative Negative	N/A N/A New autibody identified in Ehaste N/A N/A N/A All transfinion resistions N/A N/A N/A N/A N/A N/A N/A N/	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A
Elisate Feel Screen Workship RIHOGE Chausthate Transitions Reserved Type and Screen-Not for Transfusion Type and Screen-Not for Transfusion Type and Screen-Preadmission AFP Tumor Marker Aldosterone ANA Multiples Screen ANA Multiples Screen With Reflect ANA Screen IF A Anti Mitrochondrial Antibody Anti Mestrophil Cytoplannic Antibody Anti Neutrophil Cytoplannic Antibody Anti Screen IF A Anti Mitrochondrial Antibody Anti Neutrophil Cytoplannic Antibody Anti Screen IF A Anti Mitrochondrial Antibody Anti Screen IF A Anti Mitrochondrial Antibody	Elution, RBC N/A N/A N/A N/A N/A N/A N/A N/	Aggleitation Two Sit Stateback Immunossay Chemilaminescent Immunossay Chemilaminescent Immunossay Multiples flow immunossay Multiples flow immunossay Infered Immunossa	Manual NiA Automatic Ortho NiA Inmotion	N/A N/A N/A N/A N/A N/A N/A N/A	incompublic Negative Positive A. R. O. or All and Els positive or Ris NA Na Member Positive NA Na Negative Positive NA For type A. R. O. or All and Els For type A. R. O. or All and Els For type A. R. O. or All and Els For type A. R. O. or All and Els For type A. R. O. or All and Els For type A. R. O. or All and Els For type A. R. O. or All and Els For type A. R. O. or All and Els Screen Positive or Negative Nogative of Negative Anabody Screen Positive or Negative Nogative of Negative Nogative of Negative Negative Negative Negative Normal Negative in Normal Negative in Normal Negative in Normal Negative Negative Negative Negative Negative Negative Negative	N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A
Eliste Fetal Screen Workspin RIGHOE Christolian Transfesion Reserves Type and Screen Type and	Elution, RBC N/A	Agglatiation Two-Sits State-based internaceasay Chemilaminescent Immunossay Chemilaminescent Immunossay Multiplet flow immunossay Multiplet flow immunossay Multiplet flow immunossay Multiplet flow immunossay Indirect Immunoflowrescence Anthology Indirect Flowerscent Antholy Indirec	Manual NiA Automatic Ortho NiA Immoor Immoor NiA Manual NiA Automatic Ortho Immoor	N/A N/A N/A N/A N/A N/A N/A N/A	incompublic Negative Positive A. B. O. or All and Ris positive or Ris NA Native Positive NA Na Negative Positive NA For type. A. B. O., or All and Ris For t	N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A
Elaste Fetal Scree Workup RIGHGE Voluntation Franchises Recention Batter Type and Screen APA Material APF Tumor Marker AND Material Anti Microsomal Antibody Anti Neutrophil Cytoplannic Antibody Anti Neutrophil Cytoplannic Antibody Anti Paterial Antibody Anti Smooth Mascle Antibody Anti Smooth Mascle Antibody	Elution, RBC NIA NIA NIA NIA NIA NIA NIA NI	Agglatisation Agglatisation Agglatisation Anglatisation Anglatisation Anglatisation Agglatisation Agglatisation Agglatisation Agglatisation Agglatisation Agglatisation Agglatisation Two Sits Sardwidth Immunoussy Chemilamineneus Immunoussy Chemilamineneus Immunoussy Chemilamineneus Immunoussy Malighes flow transmoussy Malighes flow transmoussy Malighes flow transmoussy Indirect Immunoussy Indirect Immuno	Manual NA Automated Ortho N/A Interested Ortho N/A Interested Ortho N/A Interested Ortho N/A NA Manual NA Automated: Ortho Manual NA Automated: Ortho Manual NA Automated: Ortho Manual NA Automated: Ortho Siemens Atellica IM DisSerin Linion XL Bisplex 2200 Werfer/ Inova	N/A N/A N/A N/A N/A N/A N/A N/A	incomputable Negather (Positive A. B. O, or All and RB positive or Rb. NA Nature (Positive NA Nature (Nature (N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A

Column						Male TESTF =				
Column	BKR Free Testosterone	N/A	Calculation	Siemens Atellica IM	TESTF = ng/dL	2.29-20.70 Female TESTF =	N/A	Siemens Atellica IM Reference Interval Verification Study 2023	N/A	N/A
Property	Calaitania	CALCIT CALCT	Two-Step Sandwich Immunoassay	Simon Audin B4		Male: ≤13.38	N/A	Siemens Calcitonin Package Insert	1 00 1 000 00	1 00 100 000 00
March Marc									· ·	
Column	Chromatin Antibody	N/A	Multiplex flow immunoussay	Bioplex 2200			N/A	Package insert, textbook		Negative / Positive
Column			(CLIA)						N/A	
Column	CMV IgM Ab	CMVM	(CLIA)	DiaSorin Liaison XL	U/mL	Negative is Normal	N/A		N/A	Negative/ Indeterminate/ Positive
Column C		CPEP, CpS		Siemens Atellica IM	ng/mL	0.81-3.85	N/A		0.05-25.00	0.05-5,000.00
Control Cont	Insulin Glucose Tolerance Battery):	CPM5M		Siemens Atellica IM	ng/mL	0.81-3.85	N/A		0.05-25.00	0.05-5,000.00
Company	C-Peptide Tolerance (Part of the Insulin Glucose Tolerance	CPZERO		Siemens Atellica IM	ng/mL	0.81-3.85	N/A		0.05-25.00	0.05-5,000.00
Column	0 Minutes C-Peptide Tolerance (Part of the	CDUTANA .		C 45 M		0.01.207	27/4		0.05.25.00	0.05.5.000.00
Company	2 Minutes C-Peptide Tolerance (Part of the	CPEP2M		Siemens Ateilica IM	ngmL	0.81-3.85	N/A	·	0.05-25.00	0.05-5,000.00
March Marc	Insulin Glucose Tolerance Battery): 5 Minutes	CPEP5M	Two-Site Sandwich Immunoassay Chemiluminescent	Siemens Atellica IM	ng/mL	0.81-3.85	N/A	Siemens C-Peptide Package Insert 10997742_EN Rev. 03, 2021-06	0.05-25.00	0.05-5,000.00
March Control March Control March Control March	Insulin Glucose Tolerance Battery): 10 Minutes	CP10M	Two-Site Sandwich Immunoassay Chemiluminescent	Siemens Atellica IM	ng/mL	0.81-3.85	N/A	Siemens C-Peptide Package Insert 10997742_EN Rev. 03, 2021-06	0.05-25.00	0.05-5,000.00
Column	Insulin Glucose Tolerance Battery):	CP30M		Siemens Atellica IM	ng/mL	0.81-3.85	N/A	Siemens C-Peptide Package Insert 10997742_EN Rev. 03, 2021-06	0.05-25.00	0.05-5,000.00
Mathematical Math										
March Marc						Female: 25.90-460.20		Siemens DHEAS Package Insert 11200382_EN		
Column						Negative: ≤4				
Miles Mile	1.5					Positive: ≥10				,
March 100	dsDNA Antibody EBV VCA IgG Ab	N/A EBVG	Multiplex flow immunoussay Multiplex flow immunoussay	Bioplex 2200 Bioplex 2200		Negative is Normal Negative is Normal	N/A N/A	Package insert, textbook Package Insert		Negative / Indeterminate / Positive Negative / Indeterminate / Positive
The color	EBV VCA IgM Ab ENA Battery	EBVM	Multiplex flow immunoussay	Bioplex 2200	N/A	Negative is Normal	N/A	Package Insert		Negative / Indeterminate / Positive
Column	(SSA, SSB, Sm, RNP)			-		_				
Company										Enzyme Activity Absent, Enzyme
Company Comp	, , ,			-				_		Activity Indeterminate, Enzyme Activity Present
Programme			,			Female: \$6.88		Package insert [LIAISON® hGH ([REF] 310340),		Negative / Positive
Professor Prof						Male: ≤1.23		EN - 200/007-914, 06 - 2016-10]		
Part										
Processor					ing-ur.	-1.0				
Property	Hemoglobin, Fetal	HF	HPLC	Variant II	%	Hemoglobin A: ≥95.0	N/A	Package Insert, Textbook	1.0-40.0	1.0-40.0
March Marc	Hemoglobinopathy Eval	Abnormal HGB Detection, HEPB		Variant II	%	Hemoglobin F: <1.0 Hemoglobin C: 0.0	N/A	Package Insert, Textbook	N/A	N/A
	Hep A Ab, Total (IgG+IgM)	HAABG	Competitive Direct Chemiluminescent Immunoassav	Siemens Atellica IM	N/A	Negative is Normal	N/A	Package Insert	N/A	Negative/ Positive
The State Association Control	Hep B Core Ab, Total (IgG+IgM)	HBCBG	2-Wash Antigen Sandwich	Siemens Atellica IM	N/A	Negative is Normal	N/A	Package Insert	N/A	Negative/ Positive
Pages Pages 10 10 10 10 10 10 10 1	Hen B Surf Ast Neutralization		Specific Antibody Neutralization							
Page			2-Step IgM-Capture Immunoassay							
Page	Hepatitis B Surface Antibody	HBSAB		Siemens Atellica IM	N/A	Negative is Normal	N/A	Package Insert	N/A	Negative/Positive
Part	Hepatitis B Surface Antigen	HBSAG	Immunoassav	Siemens Atellica IM	N/A	Negative is Normal	N/A	Package Insert	N/A	Negative/ Positive
			Chemiluminescent Immunoassay	DiaSorin Liaison XL Siemens Atellica IM				Package Insert Package Insert		
	Hepatitis C Antibody	HCAB	Indirect Sandwich Immunoassay	Siemens Atellica IM	N/A	Negative is Normal	N/A	Package Insert	N/A	Negative/ Positive
March 1970	HIV-1/HIV-2 Differentiation	HIV12C	Immunochromatographic Assay	Bio-Rad Genius	N/A	Nonreactive is normal	N/A	Package Insert	N/A	Nonreactive / Reactive
March Marc	HPV, High Risk, DNA	High Risk HPV with Genotyping	PCR	Roche Cobas x 480	N/A	Negative is Normal	N/A		N/A	Negative / Positive
The content of the	HSV 1 And 2 IgG Antibody	HSVG12	Multiplex flow immunoassay	Bioplex 2200	N/A	Negative is Normal	N/A	Insert	N/A	Negative / Indeterminate / Positive
	HSV IgM Antibody		ELISA - Manual	Gold Standard	N/A	Negative is Normal	N/A		N/A	Negative / Positive / Equivocal
Marcin Control Food Prof.	Immunofixation, Serum	Electrophoresis with Immunofixation and serum total	Capillary Electrophoresis	Sebia Capillarys 3	N/A	N/A	N/A	Package Insert	N/A	N/A
Section Part	Immunoglobulin IgE		2-site Sandwich Direct	Siemens Atellica IM	IU'mL	≤165.3	N/A	Reference Range Study 11.3.2016	2.5-3000.0	2.5-3000.0
									0.5-300.0	
Post	Insulin Tolerance (Part of the Insulin Glucose Tolerance	INSULI	Two-Site Sandwich Immunoassay	Siemens Atellica IM	uIUmL	3.0-25.0		Siemens Insulin Package Insert 10997752_EN Rev.	0.5-300.0	
Bartistic Commission Comm	-5 Minutes Insulin Tolerance (Part of the Insulin Glucose Tolerance	INSUL2	Two-Site Sandwich Immunoassay	Siemens Atellica IM	uIUmL	3.0-25.0	N/A	Siemens Insulin Package Insert 10997752_EN Rev.	0.5-300.0	0.5-1.500.0
Manufaction Commissioner Commi	0 Minutes Insulin Tolerance (Part of the									
Security	Battery): 2 Minutes Insulin Tolerance (Part of the	INSUL3	Chemiluminescent	Siemens Atellica IM	uIUmL	3.0-25.0	N/A	05, 2021-06	0.5-300.0	0.5-1,500.0
No.	Insulin Glucose Tolerance Battery): 5 Minutes	INSUL4		Siemens Atellica IM	uIU/mL	3.0-25.0	N/A		0.5-300.0	0.5-1,500.0
	Insulin Glucose Tolerance Battery): 10 Minutes	INSUL5		Siemens Atellica IM	uIU/mL	3.0-25.0	N/A	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0	0.5-1,500.0
	Insulin Glucose Tolerance Battery):	INSUL6	Chemiluminescent	Siemens Atellica IM	uIU/mL	3.0-25.0	N/A	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0	0.5-1,500.0
		Somatomedin C, IGF1	One-step sandwich	DiaSorin Linison XL	ng/mL	Age Dependent	N/A	Package Insert	10.0-1,000.0	10.0-1,000.0
Negret Petr Chate Immunos/boths Text Chairs Text Statement Tex			Two-site sandwich immunoassay							
Immunophobile Refule Immunophobile Perc Chairs Turbifinetty The Bindry See Cyclife Park A	Kappa Free Light Chains	Immunoglobulin Free Chains	Turbidimetry	The Binding Site Optilite	mg/L	3.9-26.0	N/A	2017 OSU Study	2.9-127.0	0.6-63,500.0
Legionela University Legionela Livinory Ag	Lambda Free Light Chains	Immunoglobulin Free Chains		The Binding Site Optilite The Binding Site Optilite						N/A 1.3-139,000.0
No. Chemistic continuous Disfort Linko N. No.	Legionella Serogroup 1 Urinary		EIA	Binax Kit	N/A	Negative is Normal	N/A	Package Insert	N/A	Negative / Positive
Mescendar Pot Internets No. 1 Internetional No. 1 No.	Lvme Ab									
Mumps 1gG Ah. Immune Status Mumps Ah. 1gG Multiples flow immunoususy Bioples 2200 N/A Poutine N/A Bio-Pec-2000 MMRV 1gG Procedure March 2010 N/A Seguite an Normal N/A Negative in Normal N/A N/A Negative in Normal N/A N/A Negative in Normal N/A N/A Negative in Normal N/A N/A Negative in Normal N/A N			immunoassay							
Net-deperoidar Artificities NA Maleight Immorfiles Assay Protein Electrophoresis Protein Electrophoresis Protein Electrophoresis Protein Electrophoresis Protein Electrophoresis Protein Electrophoresis Serum Electrophore	· ·									Negative-The absence of detectable IgC
Protein Electrophoresis Scrum Electrophoresis Schia Capillarys 3 grid. Adds 11. 0.24 grid. Adds 12. 0.24 grid.				-						class antibodies to measles, mumps,
PH		Serum Electrophoresis, PSE, Serum Protein Electrophoresis with Reflex to Immunofixation				Albumin: 3.5-5.0 g/dL Alpha 1: 0.2-0.4 g/dL Alpha 2: 0.5-1.0 g/dL Beta: 0.5-1.1 g/dL Gamma:				
Quantitative BPR	PTH Intact					14.0-72.0				
Communities of the Communities	Quant. Cryptococcus Antigen, Blood	N/A		Immuno-Mycologics Inc.	N/A	Negative is Normal	N/A	Package Insert	N/A	1:2 - ≥1:2560
Linglate	Quantitative RPR	N/A	Macroscopic nontreponemal flocculation	ASI	Nonreactive / Reactive	Nonreactive is Normal	N/A	Package insert	N/A	1:1 - ≥1:2048
240: 25-45.1	Renin	Renin, Direct		DiaSorin Linison XI.	pg/mL	\$40: 3.6-81.6 <u>Supine</u> : <41: 3.2-33.2	N/A	Package insert	2.1-300.0	2.1-3,000.0
RNP Antibody RNPT Multiplex flow immunoussay Bioplex 2200 N/A Negative is Normal N/A Package insert, textbook N/A Negative / Positive	Ribosomal P Antibody	RIBOPT	Multiplex flow improposes	Bionley 2200	N/A	≥40: 2.5-45.1	N/A	Packner insert terribook	N/A	Negative / Peritina
RPR Rapid Plasma Reagin auconscipus, assure promissis ASI Nontreactive / Reactive Nonreactive is Normal N/A Package insert N/A 1:1-2:12048						pure is rectiling	17/7	A THE PARTY OF THE		
<u>.</u>	RNP Antibody	RNPT	Multiplex flow immunoussay	Bioplex 2200	N/A				N/A	Negative / Positive

	pr	Macroscopic nontreponemal			v	****			,
RPR - Baby	RPR, Neonatal	flocculation Macroscopic nontreponemal	ASI	Nonreactive / Reactive	Nonreactive is Normal	N/A	Package insert	N/A	1:1 - ≥1:2048
RPR with Titer	RPR, Therapy	flocculation	ASI	Nonreactive / Reactive	Nonreactive is Normal	N/A	Package insert	N/A	1:1 - ≥1:2048 Negative-The absence of detectable IoGs
Rubella Immune Status IgG Antibody	RUBAB	Multiplex flow immunoassay	Bioplex 2200	Negative / Positive	Positive	N/A	BioPlex2200 MMRV IgG Procedure March 2010	N/A	Negative-The absence of detectable IgG- class antibodies to measles, mumps,
Rubeola IgG Ab (Immune Status)	RUBOIB	Multiplex flow immunoassay	Bioplex 2200	Negative / Positive	Positive	N/A	BioPlex2200 MMRV IgG Procedure March 2010	N/A	Negative-The absence of detectable IgG- class antibodies to measles, mumps,
SARS-COV-2 Spike Protein Antibody	SARS-CoV-2, COVID-19 lgG	Chemiluminescence immunoassay (CLIA)	DiaSorin Liaison XL	AU/mL	Negative is normal	N/A	Package insert	1.85-800.00	1.85-800.00
Sex Hormone Binding Globulin	SHBG	Sandwich Immunoassay	Siemens Atellica IM	nmol/L	Male: 10.00-57.00 Female	N/A	Siemens IMMULITE 2000 SHBG (PIL2KSH-20, 2018-03-15)	1.60-180.00	1.60-360.00
		Modified Nalbandian Procedure-	SickleScreen® Sickling		(non-pregnant): 18.00-144.00				
Sickle Cell Screen Sm Antibody	Sickle Hemoglobin Solubility Smith Antibody	Solubility Multiplex flow immunoussay	Hemoglobin Screening Kit Bioplex 2200	N/A N/A	Negative is Normal Negative is Normal	N/A N/A	Package insert, textbook Package insert, textbook	N/A N/A	Negative / Positive Negative / Positive
Sm/RNP Antibody	N/A	Multiplex flow immunoassay	Bioplex 2200	N/A	Negative is Normal	N/A	Package insert, textbook	N/A	Negative / Positive
SS-A/RO Antibody SS-B/LA Antibody	SSA Antibody SSB Antibody	Multiplex flow immunoassay Multiplex flow immunoassay	Bioplex 2200 Bioplex 2200	N/A N/A	Negative is Normal Negative is Normal	N/A N/A	Package insert, textbook Package insert, textbook	N/A N/A	Negative / Positive Negative / Positive
Syphilis Ab w/Reflex RPR	Syphilis IgG/IgM Antibody with Reflex RPR	Direct sandwich assay	Siemens Atellica IM	N/A	Nonreactive is Normal	N/A	Package insert	N/A	Nonreactive / Equivocal / Reactive
Toxoplasma IgG Antibody	TOXOG	Sandwich Direct Chemiluminescent Immunoassay	Siemens Atellica IM	N/A	Negative is Normal	N/A	Package Insert	N/A	Negative/Positive
Urine Immunofixation - 24 Hour	Monoclonal Prot Immfx, Urine - 24 Hour, UIMFXB (This is a panel that includes urine electrophoresis, urine	Electrophoresis	Sebia Hydrasys 2	N/A	Negative is Normal	N/A	Package Insert	N/A	N/A
Urine Immunofixation, Random	immunofixation and 24 Hr urine total protein.) Monoclonal Prot Immfx, Urine - Random, UIMFXR (This is a panel that includes urine	Electrophoresis	Sebin Hydrasys 2	N/A	N/A	N/A	Package Insert	N/A	N/A
Varicella IgG Ab (Immune Status)	electrophoresis and urine immunofixation.) VZISB	Multiplex flow immunoussay	Bioplex 2200	N/A	Positive is Normal	N/A	BioPlex2200 MMRV IgG Procedure March 2010	N/A	Negative / Indeterminate / Positive
Vitamin D	Vitamin D, Total	Immunoassay Chemiluminescent	DiaSorin Liaison XL	ng/mL	30.0-100.0	N/A	Diasorin	4.0-150.0	4.0-150.0
(25-Hydroxy, Total) Vitamin D,	1,25 Dihydroxy Vitamin D	In vitro chemiluminescent	DiaSorin Liaison XL	pg/mL	20.0-79.0	N/A	Package Insert	5.0-180.0	5.0-540.0
(1,25 Dihydroxy)	.,,,	immunoassay		F9	200,000				In loss, FISH: Detected, Not Detected,
1P19Q (Glioma) FISH	lp/19q - FISH	Fluorescent In Situ Hybridization	Bioview	N/A	Not Detected	N/A	N/A	N/A	Not Indicated, Indeterminate 19q loss, FISH: Detected, Not Detected, Not Indicated, Indeterminate
FISH, 3p (tumor), Sign-out	3p/3q - FISH	Fluorescent In Situ Hybridization	Bioview	N/A	Not Detected	N/A	N/A	N/A	Chr 3p loss: Detected, Not Detected, Not Indicated, Indeterminate
ALK Rearrangement BCL2 FISH	ALK - FISH BCL2 - FISH	Fluorescent In Situ Hybridization Fluorescent In Situ Hybridization	Bioview Bioview	N/A N/A	Negative Negative	N/A N/A	N/A N/A	N/A N/A	Positive/Negative Positive/Negative
BCL6 FISH	BCL6 - FISH	Fluorescent In Situ Hybridization	Bioview	N/A	Negative P190 transcript:	N/A	N/A	N/A	Positive/Negative
BCR/ABL, T(9;22), QUANT	BCRSCR, BCR-ABL, t(9;22), CML	Real Time PCR	7500 Fast Dx	% BCR-ABLI/ABLI	Not Detected P210 transcript: Not Detected BCR-ABL1/ABL1 %: 0.000	N/A	N/A	0.000-100.000	0.000-100.000
C9orf72 Hexanucleotide Repeat Analysis	N/A	Fragment analysis with reflex to agarose gel electrophoresis for expanded alleles >145 repeat	Asuragen	# of Hexanucleotide repeats	2-19	N/A	Testing control specimens and published literature	+/- 1 hexanucleotide repeat for normal range	2 repeats through thousands of hexanucleotid repeats
Hairy Cell Leukemia BRAF V600 Mutation	B-RAF, BRAF V600E	Pyrosequencing	Applied Biosystems GeneAmp PCR System +-Qiagen Pyromark	N/A	LABBRAF: Not Detected LABBRAFHC, LABBRAFBM: <5%, Not Detected	N/A	N/A	0-100	BRAF Mutation: Detected, Not Detected, Not Indicated, Indeterminate
BTK and PLCG2, Comprehensive Mutation Profiling	BTK and PLCG2 Full Sequencing	Next Generation Sequencing	Ion Torrent S5	N/A	Not Detected	N/A	N/A	0-100	Detected/Not detected
BTK Resistance Mutation	BTKR C481S	Allele-specific digital droplet polymerase chain reaction	BioRad	%	<0.1%, Not Detected	N/A	Validation	0-100	Detected/Not detected
Calr Mutation Analysis,		(AS-ddPCR) Fluorescent fragment analysis,	Applied Biosystems GeneAmp						
Myeloproliferative Neoplasm MPN	Calreticulin Mutation Detection	sequence analysis (non-NGS),	PCR System + Genetic Analyzer	N/A	Not detected	N/A	N/A	N/A	Detected/Not detected
FISH, CCND1 (cyclin D1) Rearrangement,	CCND1 - FISH	Fluorescent In Situ Hybridization	Bioview	N/A	Negative	N/A	N/A	N/A	Positive/Negative
Sign-out	MEC, mucoepidermoid	Fluorescent In Situ Hybridization	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MAML2 Rearrangement CEBPA Mutation	CEBP alpha, CEBPAa	Sequence analysis (non-NGS),	Applied Biosystems GeneAmp	N/A	Not detected	N/A N/A	N/A N/A	N/A	N/A Detected/Not detected
		fluorescent fragment analysis	PCR System + Genetic Analyzer		And detected				
FISH. DDIT3 (CHOP) Rearrangement	CHOP - FISH, DDIT3 - FISH	Fluorescent In Situ Hybridization	Bioview	N/A	Negative	N/A	N/A	N/A	Positive/Negative
Comprehensive Hematology Panel with Germline Assessment	550+ Gene Panel, Extended NGS Heme Panel	Next Generation Sequencing	Illumina NextSeq	N/A	Negative for pathogenic mutation at the target VAF level	N/A	N/A	N/A	N/A
Comprehensive Tumor Genomic	Large panel NGS Tumor NGS								
Profile with MSI Status	TMB, CTPNGS	Next Generation Sequencing	Illumina NextSeq	N/A	N/A	N/A	N/A	N/A	N/A
FISH, MET Amplification, Sign-out	CMET - FISH	Fluorescent In Situ Hybridization	Bioview	N/A	Not detected	N/A	N/A	N/A	Detected/Not detected
Colon Cancer Mutation Panel,	COLMOL	Next Generation Sequencing	Ion Torrent S5	N/A	Not detected	N/A	N/A	N/A	Detected/Not detected
Sign-out				- AA	. voi acticita	.474	.v/A	s 4/74	APERCAGANIAN GENERAL
EGFR Mutation Analysis (exons 19 & 21),	Epidermal growth factor receptor, L858R, exon 19, exon 21	Fluorescent fragment analysis, restriction fragment length	Applied Biosystems GeneAmp PCR System + Genetic Analyzer	N/A	Not detected	N/A	N/A	N/A	Detected/Not detected
Sign-out FISH, EGFR Amplification	EGFR - FISH	polymorphism Fluorescent In Situ Hybridization	Bioview	N/A	Not detected	N/A	N/A	N/A	Detected, Not Detected, Not Indicated,
(glioma), Sign-out									Indeterminant
Extended RAS Mutation Panel, Sign-out FISH, EWSR1 Rearrangement,	XRAS EWSR1 - FISH	Pyrosequencing Fluorescent In Situ Hybridization	Pyromark Bioview	N/A N/A	Not detected Negative	N/A N/A	N/A N/A	0-100 N/A	Detected, Not Detected, Not Indicated Positive/Negative
Sign-out		Fluorescent in Situ Hybridization Fluorescent Capillary Fragment			Negative Not detected		10/4		Not detected
Factor V Mutation FACV Leiden	Leiden, G1691A, R506Q	analysis, restriction fragment length polymorphism	Applied Biosystems GeneAmp PCR system + Genetic Analyzer Applied Biosystems GeneAmp	N/A	Heterozygous + Homozygous +	N/A	Gene Reviews	N/A	Heterozygous + Homozygous +
FLT3, ITD & TK Mutation Hematologic Neoplasm/Disorder	FLT3 LMPNGS, MYLNGS,	PCR and capillary electrophoresis	PCR System + Genetic Analyzer	N/A	Not detected	N/A	N/A	N/A	Detected/Not detected
Hematologic Neoplasm/Disorder Mutation Panel Hereditary Hemochromatosis,	T-cell mutation, T-LGL mutation, CLL mutation panel	Next Generation Sequencing	LifeTech S5	N/A	N/A	N/A	N/A	0.5% VAF	0.5-100.0% VAF
(Gene Analysis, Common Variants)	HFE, C282Y, H63D, Iron Overload Disease	PCR	Applied Biosystems GeneAmp PCR System + Genetic Analyzer	N/A	N/A	N/A	N/A	N/A	N/A
FISH, HER2,	HER-2, HER2/neu.	Fluorescent In Situ Hybridization	Bioview	N/A	N/A	N/A	N/A	N/A	GI: Positive, Negative, Indeterminant
Sign-out Huntington's Disease	Huntington chorea, HTT Gene	Polymerase chain reaction, fluorescent capillary fragment analysis	Applied Biosystems GeneAmp PCR System + Genetic Analyzer	N/A	Normal Allele; Normal Mutable Allele; HD Allele with reduced penetrance; HD Allele with full	N/A	Gene Reviews	N/A	Breast: Positive, Negative Normal Allele; Normal Mutable Allele; HD Allele with reduced penetrance; HD Allele with full penetrance
IDH1 and IDH2 Mutations	IDH1	Pyrosequencing	Applied Biosystems GeneAmp PCR System + Qiagen Pyromark	N/A	Not detected	N/A	Normal controls	0-100	Detected/Not detected
B Cell Gene Rearrangement	IGH gene rearrangement, B cell Clonality, IgH PCR	Polymerase Chain Reaction	Applied Biosystems GeneAmp PCR System + Genetic Analyzer	N/A	Negative	N/A	N/A	N/A	Positive/Negative
IGVH Mutation Analysis	IGH mut sequencing, KiVH, Ig mutation analysis, CLL IGVH	Clonal amplification, fluorescent fragment analysis, sequence analysis (non-NGS)	Applied Biosystems GeneAmp PCR System + Genetic Analyzer Applied Biosystems GeneAmp	N/A	N/A	N/A	N/A	N/A	mutated/unmutated
JAK2 V617 Mutation Detection KIT D816V Mutation Detection	JAK eKIT, CD117, PBT, SCFR	Pyrosequencing Allele-specific digital droplet polymerase chain reaction	PCR System + Genetic Analyzer Qiagen Pyromark BioRad	N/A %	<1%, Not detected <0.01%,	N/A N/A	N/A Validation	0-100	Detected/Not detected Detected/Not detected
		(AS-ddPCR)			Not Detected				
Lung Cancer Mutation Panel FISH, MALTI Rearrangement,	PULMOL	Next Generation Sequencing	Ion Torrent S5	N/A	Not detected	N/A	N/A	N/A	Detected/Not detected
Sign-out FISH, MDM2 Amplification,	MALTI - FISH MDM2 - FISH	Fluorescent In Situ Hybridization Fluorescent In Situ Hybridization	Bioview Bioview	N/A N/A	Negative Not detected	N/A N/A	N/A N/A	N/A N/A	Positive/Negative Detected/Not detected
Sign-out MTHFR (Methylene Tetrahydrofolate Red)	NADPH, 677C>T, MTHFR	PCR-based restriction fragment polymorphism	Applied Biosystems GeneAmp PCR System + Genetic Analyzer	N/A	Not detected	N/A	Gene Reviews	N/A	Not Detected, Heterozygous positive, Homozygous positive
MGMT Promoter Methylation, Tumor	MGMT1, O6-Metylguanine DNA methyltransferase	Pyrosequencing	PyroMark + Applied Biosystems GeneAmp PCR System	N/A	N/A	N/A	N/A	N/A	Hypermethylated / Not Hypermethylated
MLH1 Promoter Methylation	MLH1, Lynch syndrome, HNPCC	Bisulfite modification /	Applied Biosystems GeneAmp PCR System + Genetic Analyzer	N/A	N/A	N/A	N/A	N/A	Hypermethylated /
Microsatellite Instability (MSI) Analysis, Tumor	MSI, mismatch repair, HNPCC, non-polyposis colon cancer, MMR, Lynch syndrome	Pyrosequencing multiplex polymerase chain reaction, fluorescent fragment analysis	Qiagen Pyromark Applied Biosystems GeneAmp PCR System + Thermal Cycler, PCR System	N/A	N/A	N/A	N/A	N/A	Not Hypermethylated MSI-S, MSI-L, MSI-H
	man, Lyncu syndrome	·	. c.n. aysiem			i .	1		

MPL Mutation Analysis	TPOR, CD110, THPOR MYC - FISH	Pyrosequencing Fluorescent In Situ Hybridization	Qingen	% N/A	0 Negative	N/A N/A	Validation N/A	5% N/A	5% Positive/Negative
MYCF FISH		Allele-specific digital droplet	Bioview		<0.1%,		N/A		
MYD88 Mutation Analysis, Quant	N/A	polymerase chain reaction (AS-ddPCR)	BioRad	%	Not Detected	N/A	Validation	0-100	Detected/Not detected
Myotonic Dystrophy	DMPK Gene	Polymerase chain reaction, fluorescent capillary fragment	Applied Biosystems GeneAmp	Repeats	<34	N/A	Gene Reviews	5-1500	5-1500
,		analysis	PCR System + Genetic Analyzer		Negative	****			Negative; Premutation; Full Mutation
NPM1 Mutation Analysis, Quant	nucleophosmin, NPM exon 12 mutation	Allele-specific digital droplet polymerase chain reaction	BioRad	%	<0.1%, Not Detected	N/A	Validation	0-100	Detected/Not detected
		(AS-ddPCR)	Applied Biosystem GeneAmp						
NRAS Mutation	NRAS codon 12, 13, 61	Pyrosequencing	PCR system + Qiagen Pyromark	N/A	Not detected	N/A	N/A	0-100	Detected/Not detected
NTRK Fusion Panel	NTRK1, NTRK2, NTRK3	Next generation sequencing	N/A	N/A	Not Detected	N/A	Validation	N/A	Detected/Not detected
FISH, NUTM1 Rearrangement	NUT1, Midline Carcinoma	Fluorescent In Situ Hybridization	Bioview	N/A	Negative	N/A	N/A	N/A	Positive/Negative
Oral Rinse Sample (Molecular)	NGS normal, molecular normal,	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Pancreatic Fluid, Mutation	comprehensive genomic panel								
Analysis, Request	cyst fluid mutation analysis	Next Generation Sequencing	Ion GeneStudio	N/A	Not Detected	N/A	N/A	0-100	Detected, Not Detected
Prothrombin A20120G Mutation	G20210A, Prothrombin Mutation	Fluorescent capillary fragment analysis, restriction fragment length	Applied Biosystems GeneAmp PCR system + Genetic Analyzer	N/A	Not detected	N/A	Gene Reviews	N/A	Not Detected, Heterozygous positive,
		polymorphism	T CH System + Colone Family Al						Homozygous positive Not Detected, DETECTED, long form
PML-RARA, APL, Quant PCR	15:17, PML, APL, retinoic acid	Real-time PCR	ABI Fast 7500	NCN = % PML-RARA/ABL1	0.001 Diagnostic 0.0001 MRD	N/A	Blood samples with no history of AML-M3	NCN > 1	transcript, DETECTED, short form transcript
RET Rearrangement	RET FISH - FISH	Fluorescent In Situ Hybridization	Bioview	N/A	Negative	N/A	N/A	N/A	Positive/Negative
ROS1 Rearrangement	ROS1 - FISH Survival of Motor Neuron 1	Fluorescent In Situ Hybridization PCR, chain-termination sequencing,	Bioview Applied Biosystems GeneAmp	N/A	Negative	N/A	N/A	N/A	Positive/Negative
SMN1/SMN2 DNA Sequencing	(SMN1)	capillary electrophoresis	PCR System + Genetic Analyzer	N/A	Not Detected	N/A	Gene Reviews	N/A	Detected/Not detected
Spinal Musc Atrophy Dosage -	SMA Carrier test, SMA	Allele-specific digital droplet			SMN1: 2-5 copies			SMN1/SMN2:	SMN1/SMN2: 0-5 copies
Carrier Study	compound heterozygote testing, SMN1 gene	polymerase chain reaction (AS-ddPCR)	Biorad	N/A	SMN2: 0-5 copies SMN CIS: Not detected	N/A	Gene Reviews	0-5 copies	SMN CIS:
Spinal Muscular Atrophy -	Werdnig-Hoffman, Kugelberg-	Allele-specific digital droplet			SMN1: 2-5 copies			SMN1/SMN2:	Detected/Not Detected SMN1/SMN2:
Diagnostic	Welander, SMN1 gene	polymerase chain reaction (AS-ddPCR)	Biorad	N/A	SMN2: 0-5 copies	N/A	Gene Reviews	0-5 copies	0-5 copies
Tumor Hotspot Mutation Panel	Solid Tumor Mutation Panel (Cancer Hotspot)	Next Generation Sequencing	Ion Torrent S5	N/A	Not Detected	N/A	N/A	0-100	Detected/Not detected
FISH, SS18 (SYT1)	SYT-FISH,								
Rearrangement, Sign-out	SS18-FISH	Fluorescent In Situ Hybridization	Bioview	N/A	Negative	N/A	N/A	N/A	Positive/Negative
T Cell Receptor Gene	T-cell clonality, TCR beta, T-cell	Polymerase Chain Reaction	Applied Biosystems GeneAmp	N/A	Negative	N/A	N/A	N/A	negative / oligoclonal / clonal TCRB
Rearrangement	PCR	,	PCR System + Genetic Analyzer			****		****	rearrangements
									Polyclonal pattern, Predominantly
									polyclonal pattern with minimal skewing, Monoclonal, Monoclonal on
									polyclonal background, Oligoclonal with dominant peaks, Oligoclonal with
TCRG, PCR	T-cell clonality, TCR gamma, T- cell PCR	Polymerase Chain Reaction	Applied Biosystems GeneAmp PCR System + Genetic Analyzer	N/A	Polyclonal pattern	N/A	N/A	N/A	multiple peaks, Biallelic biclonal, Low clonal on polyclonal background, low
	CONFOR								levels of amplification seen with acquate
									controls, Low levels of amplification seen with suboptimal controls, No
									amplification. Poor quality or limited nucleic acid
	Inc. Inc.	Allele-specific digital droplet							
UBA1 M41T Mutation Detection	UBE1, UBE1X, POC20, CFAP124, A1S9T	polymerase chain reaction (AS-ddPCR)	BioRad	%	<0.1%, Not Detected	N/A	Validation	0-100	Detected/Not detected
FISH, XY, Sign-out	XY FISH - FISH	Fluorescent In Situ Hybridization	Bioview	N/A	Negative	N/A N/A	N/A	N/A N/A	Positive/Negative
CD1a 7AAD	Thymocyte Viability	Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	% %	N/A N/A	N/A N/A	N/A N/A	N/A N/A	0.0-100.0% 0.0-100.0%
Alpha/Beta cCD3	N/A T-CELL	Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	%	N/A N/A	N/A N/A	N/A N/A	N/A N/A	0.0-100.0% 0.0-100.0%
cCD79a CD10	N/A N/A	Flow Cytometry Flow Cytometry	Navios Flow Cytometer	%	N/A N/A	N/A N/A	N/A N/A	N/A N/A	0.0-100.0% 0.0-100.0%
CD103	N/A	Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	%	N/A	N/A	N/A	N/A	0.0-100.0%
CD107a CD107b	N/A N/A	Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	% %	N/A N/A	N/A N/A	N/A N/A	N/A N/A	0.0-100.0% 0.0-100.0%
CD117 CD11b	N/A N/A	Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	%	N/A N/A	N/A N/A	N/A N/A	N/A N/A	0.0-100.0%
CD11c CD123	N/A N/A	Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	%	N/A N/A	N/A N/A	N/A N/A	N/A N/A	0.0-100.0%
CD127	N/A	Flow Cytometry	Navios Flow Cytometer	%	N/A	N/A	N/A	N/A	0.0-100.0%
CD13 CD134	N/A N/A	Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	%	N/A N/A	N/A N/A	N/A N/A	N/A N/A	0.0-100.0% 0.0-100.0%
CD138 CD14	N/A N/A	Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	%	N/A N/A	N/A N/A	N/A N/A	N/A N/A	0.0-100.0% 0.0-100.0%
CD15 CD158b	N/A N/A	Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	%	N/A N/A	N/A N/A	N/A N/A	N/A N/A	0.0-100.0% 0.0-100.0%
CD159a	N/A	Flow Cytometry	Navios Flow Cytometer	%	N/A	N/A	N/A	N/A	0.0-100.0%
CD16 CD16-/CD56-/CD3-/CD117-	N/A N/A	Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	% %/ABS	N/A 5.2-23.0%	N/A N/A	N/A OSU Flow Lab established	N/A N/A	0.0-100.0%
CD16-/CD56-/CD3-/CD117-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	1-619 ABS/mm ³ 57.2-82.8%	N/A	OSC Flow Lab established	N/A	
CD16-/CD56-/CD3+/CD117-	N/A	Flow Cytometry	Navios Flow Cytometer	%/ABS	570-2430 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD16-/CD56-/CD3+/CD117+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0.0-0.0% 0-0 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD16-/CD56+/CD3-/CD117-	N/A				0.2-1.1%	N/A			
		Flow Cytometry	Navios Flow Cytometer		0.2-1.176			N/A	0.0-100.0%
CD16-/CD56+/CD3-/CD117+		, ,	Navios Flow Cytometer	% / ABS	3-24 ABS/mm ³ 0.0-0.2%		OSU Flow Lab established	N/A	0.0-100.0%
	N/A	Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	%/ABS	3-24 ABS/mm ³ 0.0-0.2% 0-3 ABS/mm ³	N/A	OSU Flow Lab established OSU Flow Lab established	N/A N/A	0.0-100.0%
CD16-/CD56+/CD3+/CD117-		, ,			3-24 ABS/mm ³ 0.0-0.2% 0-3 ABS/mm ³ 0.0-7.0% 0-157 ABS/mm ³				
CD16-/CD56+/CD3+/CD117- CD16-/CD56+/CD3+/CD117+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	3-24 ABS/mm ³ 0.0-0.2% 0-3 ABS/mm ³ 0.0-7.0% 0-157 ABS/mm ² 0.0-0.0%	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD16-/CD56+/CD3+/CD117+	N/A N/A N/A	Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / ABS % / ABS	3-24 ABS/mm ³ 0.0-0.2% 0-3 ABS/mm ³ 0.0-7.0% 0-157 ABS/mm ³ 0.0-0.0% 0-0 ABS/mm ³ 0.0-5.2%	N/A N/A N/A	OSU Flow Lab established OSU Flow Lab established OSU Flow Lab established	N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16-/CD56+/CD3+/CD117+ CD16+/CD56-/CD3-/CD117-	N/A N/A N/A	Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / ABS % / ABS % / ABS	3.24 ABS/mm ² 0.0-0.2% 0.3 ABS/mm ³ 0.0-7.0% 0.157 ABS/mm ³ 0.0-0.0% 0-0 ABS/mm ³ 0.0-5.2% 0-122 ABS/mm ³ 0.0-1.6%	N/A N/A N/A N/A	OSU Flow Lab established OSU Flow Lab established OSU Flow Lab established OSU Flow Lab established	N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16-/CD56+/CD3-/CD117+ CD16+/CD56-/CD3-/CD117- CD16+/CD56-/CD3+/CD117-	N/A N/A N/A N/A N/A	Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry	Navios Flow Cytometer	% / ABS % / ABS % / ABS % / ABS	3.24 ABS/mm ² 0.0-0.2% 0.3 ABS/mm ³ 0.0-7.0% 0.157 ABS/mm ³ 0.0-0.0% 0.0 ABS/mm ³ 0.0-3.2% 0.22 ABS/mm ³ 0.0-1.6%	N/A N/A N/A N/A N/A	OSU Flow Lab established	N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16-/CD56+/CD3+/CD117+ CD16+/CD56-/CD3-/CD117-	N/A N/A N/A	Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / ABS % / ABS % / ABS	3-24 ABS/mm ² 0.0-0.25 0.3 ABS/mm ² 0.0-7.05 0.157 ABS/mm ² 0.0-0.05 0-0.48S/mm ² 0.0-0.05 0-0.48S/mm ² 0.0-1.67 0.0-1.67 0.0-0.05 0.0-0.05 0.0-0.05	N/A N/A N/A N/A	OSU Flow Lab established OSU Flow Lab established OSU Flow Lab established OSU Flow Lab established	N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16-/CD56+/CD3-/CD117+ CD16+/CD56-/CD3-/CD117- CD16+/CD56-/CD3+/CD117-	N/A N/A N/A N/A N/A	Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry	Navios Flow Cytometer	% / ABS % / ABS % / ABS % / ABS	3-24 ABS/mm ² 0.0-0.25 0.3 ABS/mm ² 0.0-7.0% 0.157 ABS/mm ³ 0.0-0.0% 0.0 ABS/mm ³ 0.0-5.25 0.122 ABS/mm ³ 0.0-1.6% 0.36 ABS/mm ³ 0.0-0.0%	N/A N/A N/A N/A N/A	OSU Flow Lab established	N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16-/CD56-/CD3-/CD117+ CD16+/CD56-/CD3-/CD117- CD16+/CD56-/CD3-/CD117- CD16+/CD56-/CD3+/CD117+	N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS % / ABS % / ABS % / ABS % / ABS	3-24 ABS/mm² 0.0-2% 0.3 ABS/mm² 0.0-70% 0.157 ABS/mm² 0.0-0% 0.0-185 ABS/mm² 0.0-0.5% 0.0-185/mm² 0.0-5.5% 0.122 ABS/mm² 0.0-1.6% 0.36 ABS/mm² 0.0-0% 0.0 ABS/mm² 0.0-0%	N/A N/A N/A N/A N/A N/A N/A	OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16+CD56+(CD3+(CD17+ CD16+(CD56+(CD3+(CD17- CD16+(CD56+(CD3+(CD17- CD16+(CD56+(CD3+(CD17- CD16+(CD56+(CD3+(CD17- CD16+(CD56+(CD3+(CD17- CD16+(CD56+(CD3+(CD17- CD16+(CD56+(CD3+(CD17-	N/A	Flow Cytomotry	Navios Flow Cytometer	% / ABS	3-24 ABS/smr ² 0.9.0.2% 0.3 ABS/smr ² 0.17 OS/smr ² 0.17 OS/smr ² 0.17 ABS/smr ² 0.0 AOS/smr ² 0.0 ABS/smr ² 0.0 ABS/smr ² 0.0 ABS/smr ²	NIA	OSU Flow Lab enablished	NIA	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16+/CD56+/CD3+/CD17+ CD16+/CD56+/CD3-/CD17- CD16+/CD56+/CD3+/CD17- CD16+/CD56+/CD3-/CD17+ CD16+/CD56+/CD3-/CD17- CD16+/CD56+/CD3-/CD17+ CD16+/CD56+/CD3-/CD17- CD16+/CD56+/CD3-/CD17-	N/A	Flow Cytomorty	Navios Flow Cytometer	% / ABS	3-24 ABS/sum ² 0.0-27% 0.3 ABS/sum ² 0.3 ABS/sum ² 0.0-70% 0.157 ABS/sum ² 0.0-00% 0.0-00% 0.0-00% 0.0-27%	NIA	OSU Flow Lab enablished	N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16+CD56+CD3+CD17+ CD16+CD56+CD3+CD17- CD16+CD56+CD3+CD17- CD16+CD56+CD3+CD17- CD16+CD56+CD3-CD17- CD16+CD56+CD3-CD17- CD16+CD56+CD3-CD17- CD17- CD17- CD17- CD17- CD17- CD17- CD17-	NIA	Flow Cytometry	Navios Flow Cytometer	% / ABS	324 ABS/mm² 0.00.2% 0.1 ABS/mm² 0.1 ABS/mm² 0.00.6 D/s 0.00.6 D/s 0.00.5 T/s	NIA	OSU Few Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16+CD56+(CD3+CD117+ CD16+(CD56+(CD3+CD117- CD16+(CD56+(CD3+(CD117- CD16+(CD56+(CD3+(CD117- CD16+(CD56+(CD3+(CD117- CD16+(CD56+(CD3+(CD117- CD16+(CD56+(CD3+(CD17- CD16+(CD56+(CD3+(CD17-(CD17- CD16+(CD56+(CD3+(CD17-(CD17-(CD17- CD16+(CD56+(CD3+(CD17-(CD1	N/A	Flow Cytomorty	Navios Flow Cytometer	% / ABS	3-24 ABS/mm² 0-0-0-2% 0-3 ABS/mm² 0-0-0-2% 0-3 ABS/mm² 0-0-0-2% 0-	NIA	OSU Flow Lab enablished	N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD17- CD17- CD17- CD17- CD17- CD17- CD18-CD3-CD3-CD3-CD17- CD18-CD3-CD3-CD3-CD3-CD3-CD3-CD3-CD3-CD3-CD3	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	3-24 ABS/mm² 0-0-0-2% 0-3 ABS/mm² 0-3 ABS/mm² 0-3 ABS/mm² 0-3 ABS/mm² 0-4 ABS/mm² 0-4 ABS/mm² 0-4 ABS/mm² 0-10-12 ABS/mm² 0-10-12 ABS/mm² 0-10-12 ABS/mm² 0-10-12 ABS/mm² 0-10-12 ABS/mm² 0-10-17/9% 0-4 ABS/mm² 0-4 AB	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
C016-CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD17- CD17- CD17- CD18-CD56-CD3-CD17- CD18-CD56-CD3-CD17- CD19-CD56-CD3-CD17- CD19-CD56-CD3-CD17- CD19-CD56-CD3-CD17- CD19-CD56-CD3-CD17- CD19-CD56-CD3-CD17- CD19-CD56-CD3-CD17- CD19-CD56-CD3-CD17- CD19-CD56-CD3-CD17- CD19-CD56-CD3-CD17- CD18-CD56-CD3-CD17- CD19-CD56-CD3-CD17- CD18-CD56-CD3-CD17- CD18-CD5	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	3-24 ABS/mm² 0-0-0-2% 0-3 ABS/mm² 0-0-0-2% 0-3 ABS/mm² 0-0-0-2% 0-	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NCA	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16-(CD8-(CD3-(CD17- CD16-(CD8-(CD3-(CD17- CD16-(CD8-(CD3-(CD17- CD16-(CD8-(CD3-CD17- CD16-(CD8-(CD3-CD17- CD16-(CD8-(CD3-CD17- CD16-(CD8-(CD3-(CD17- CD16-(CD8-(CD3-(CD17- CD16-(CD8-(CD3-(CD17- CD18-(CD3-(CD3-(CD3-(CD3-(CD3-(CD3-(CD3-(CD3	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	3-24 ABS/mm² 0-0-0-2% 0-1 ABS/mm² 0-0-0-2% 0-1 ABS/mm² 0-0-0-0-2% 0-0-0-0-2% 0-0-0-0-2% 0-0-0-0-2% 0-0-0-0-2% 0-0-1-0-2% 0-0-1-0-2% 0-0-1-0-2% 0-0-1-0-2% 0-0-1-0-2% 0-0-1-0-2% 0-0-1-0-2% 0-0-1-0-2% 0-0-0-0-2% 0-0-0-0-2% 0-0-0-0-2% 0-0-0-0-0-2% 0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16-CD56+CD3+CD17+ CD16+CD56-CD3-CD17- CD16+CD56-CD3+CD17- CD16+CD56-CD3+CD17- CD16+CD56-CD3-CD17- CD16-CD56+CD3-CD17- CD16-CD56+CD3-CD17- CD16-CD56+CD3-CD17- CD19-CD15- CD19-CD15- CD19-CD15- CD19-CD15- CD19-CD15- CD19-CD16-CD17-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	3-24 ABS/mm² 0-0-0-2% 0-3 ABS/mm² 0-0-1/20% 0-1/3 ABS/mm²	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NA NA OSU Flow Lab enablished Known white, circulating CAR T can only be found in the control of the control	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD19-/CD85-/CD3-/CD18- CD19-/CD85-/CD8-/CD86- CD19-/CD86-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS % / AB	3-24 ABS/sum ² 0.0 a 2% 0.3 ABS/sum ² 0.3 ABS/sum ² 0.5 To 3 ABS/sum ² 0.5 To 3 ABS/sum ² 0.6 To 3 ABS/sum ² 0.6 To 3 ABS/sum ² 0.7 AB	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NA NA OSU Flow Lab enablished NA OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16-CD56+CD3+CD17+ CD16+CD56-CD3-CD17- CD16+CD56-CD3+CD17- CD16+CD56-CD3+CD17- CD16+CD56-CD3-CD17- CD16-CD56+CD3-CD17- CD16-CD56+CD3-CD17- CD16-CD56+CD3-CD17- CD19-CD15- CD19-CD15- CD19-CD15- CD19-CD15- CD19-CD15- CD19-CD16-CD17-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	324 ABS/mm² 0.0.0.2% 0.1 ABS/mm² 0.1 ABS/mm² 0.0.4 ABS/mm² 0.0.5.2% 0.0.4.0% 0.0.5.2% 0.0.4.0% 0.0.5.2% 0.0.1.7% 0.0.1.0% 0.0.5.2% 0.0.1.0% 0.0.1.0% 0.0.1.0% 0.0.1.0% 0.0.1.0% 0.0.1.0% 0.0.1.0% 0.0.1.0% 0.0.0% 0.	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NA NA OSU Flow Lab enablished Known white, circulating CAR T can only be found in the control of the control	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD19-/CD85-/CD3-/CD18- CD19-/CD85-/CD8-/CD86- CD19-/CD86-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	3-24 ABS/mm² 0-0-0-2% 0-3 ABS/mm² 0-0-20% 0-3 ABS/mm² 0-0-20%	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NA NA OSU Flow Lab enablished NA OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD19+/CD86-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	3-24 ABS/mm ² 0.0 a 2% 0.3 ABS/mm ² 0.157 ABS/mm ² 0.157 ABS/mm ² 0.0 a 257 ABS/mm ² 0.0 a 267 ABS/mm ² 0.0 a 267 ABS/mm ² 0.0 a 267 ABS/mm ² 0.0 a 275 ABS/mm	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NA NA OSU Flow Lab enablished NA OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16+CD86+CD3+CD17+ CD16+CD86+CD3+CD17- CD16+CD86+CD3+CD17- CD16+CD86+CD3+CD17- CD16+CD86+CD3+CD17- CD16+CD86+CD3+CD17- CD17- CD17- CD18-CD3+CD3+CD3+ CD19- CD19- CD19-CD3-CD86- CD19+CD30+CD86- CD19+CD30+CD86- CD19+CD80+CD86- CD19+CD86+CD86-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cynnetry	Navios Flow Cytometer	% / ABS	3-24 ABS/mm ² 0.0-25 0.3 ABS/mm ² 0.3 ABS/mm ² 0.15 ABS/mm ² 0.15 ABS/mm ² 0.15 ABS/mm ² 0.15 ABS/mm ² 0.0-25 0.0-25	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NCA NCA OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16-CD86-CD3+CD17- CD16+CD86-CD3-CD117- CD16+CD86-CD3+CD117- CD16+CD86-CD3-CD117- CD16+CD86-CD3-CD117- CD16-CD86-CD3-CD117- CD16-CD86-CD3-CD117- CD117- CD117- CD19-CD17- CD19-CD19-CD19-CD19-CD19-CD19-CD19-CD19-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	3-24 ABS/mm ² 0.0 a 2% 0.3 ABS/mm ² 0.3 ABS/mm ² 0.0 a 2% 0.3 ABS/mm ² 0.0 a 2% 0.0 a 3%	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab established NA NA OSU Flow Lab established	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD16-/CD86-/CD3-/CD17- CD17- CD19-/CD17- CD19-/CD18- CD19-/C	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS	3.24 ABS/smrl 0.00.27% 0.3 ABS/smrl 0.07/20% 0.3 ABS/smrl 0.07/20% 0.0 ABS/smrl	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD16-CD86-CD3-CD17- CD16+CD86-CD3-CD17- CD16+CD86-CD3-CD17- CD16+CD86-CD3-CD17- CD16+CD86-CD3-CD17- CD16-CD86-CD3-CD17- CD16-CD86-CD3-CD17- CD17- CD18-CD18- CD19-CD18- CD19-CD88- CD19-CD88- CD19-CD86-CD6- CD19-CD86-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS	3-24 ABS/mm² 0-0-0-2% 0-3 ABS/mm² 0-157 ABS/mm² 0-157 ABS/mm² 0-157 ABS/mm² 0-157 ABS/mm² 0-164 ABS/mm² 0-165 ABS/mm² 0-165 ABS/mm² 0-165 ABS/mm² 0-165 ABS/mm² 0-165 ABS/mm² 0-165 ABS/mm² 0-167 ABS/mm² 0-1759 ABS/mm² 1-1759 ABS/mm² 1-1759 ABS/mm² 1-1759 ABS/mm² 0-167	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NA NA OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD16-CD86-CD3+CD17- CD16+CD86-CD3-CD117- CD16+CD86-CD3-CD117- CD16+CD86-CD3-CD117- CD16+CD86-CD3-CD117- CD16+CD86-CD3-CD117- CD16-CD86-CD3-CD117- CD16-CD86-CD3-CD117- CD17- CD17- CD17- CD17- CD19-CD17- CD19-CD18-CD16- CD19-CD18-CD6- CD19-CD18-CD6- CD19-CD86-CD6- CD19-CD86-CD6- CD19-CD86-CD6- CD19-CD86-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cymnetry Fl	Navios Flow Cytometer	% / ABS	3-24 ABS/mm² 0-0-0-2% 0-1 ABS/mm² 0-0-0-2% 0-1 ABS/mm² 0-0-0-2% 0-0-0-2% 0-0-0-2% 0-0-0-2% 0-0-0-2% 0-0-0-2% 0-0-1-0-2% 0-0-1-0-2% 0-0-1-0-2% 0-0-1-0-2% 0-0-1-0-2% 0-0-0-2% 0	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD16+/CD86+/CD3+/CD17+ CD16+/CD86+/CD3+/CD17- CD16+/CD86+/CD3+/CD17- CD16+/CD86+/CD3+/CD17- CD16+/CD86+/CD3-CD17- CD16+/CD86+/CD3-CD17- CD16+/CD86+/CD3-CD17- CD16+/CD86+/CD3-CD17- CD19-(CD17- CD19-(CD18- CD18- CD19-(CD18- CD19-(CD18- CD18- CD19-(CD18- CD18- CD19-(CD18- CD18- CD18-(CD18- CD18- CD18-(CD18- CD18- CD18-(CD18- CD18- CD18-(CD18- CD18- CD18-(CD18- CD18-(CD18- CD18- CD18-(CD18- CD18-(CD18- CD18-(CD18- CD18-(CD18- CD18-(CD18- CD18-(CD18- CD18-(CD18-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cymnetry Fl	Navios Flow Cytometer	% / ABS % / AB	3-24 ABS/mm ² 0.0-0.2% 0.3 ABS/mm ² 0.0-1.2% 0.3 ABS/mm ² 0.0-1.2% 0.0-1	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab established NAA NAA OSU Flow Lab established NAA NAA NAA NAA NAA NAA NAA NAA NAA NA	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD16-CD86-CD3+CD17- CD16+CD86-CD3-CD117- CD16+CD86-CD3-CD117- CD16+CD86-CD3-CD117- CD16+CD86-CD3-CD117- CD16+CD86-CD3-CD117- CD16-CD86-CD3-CD117- CD16-CD86-CD3-CD117- CD17- CD17- CD17- CD17- CD19-CD17- CD19-CD18-CD16- CD19-CD18-CD6- CD19-CD18-CD6- CD19-CD86-CD6- CD19-CD86-CD6- CD19-CD86-CD6- CD19-CD86-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cymnetry Fl	Navios Flow Cytometer	% / ABS	3.24 ABS/mm² 0.0.0.2% 0.1 ABS/mm² 0.1.0.2% 0.1 ABS/mm² 0.0.4 ABS/mm² 0.0.5.2% 0.0.4 Sisson² 0.0.5.2% 0.0.4 Sisson² 0.0.5.2% 0.0.4 Sisson² 0.0.5.2% 0.0.1 Sisson² 0.0.0 Sis	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab established NA NA OSU Flow Lab established	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD16-CD86-CD3+CD17- CD16+CD86-CD3-CD17- CD16+CD86-CD3-CD17- CD16+CD86-CD3-CD17- CD16+CD86-CD3-CD17- CD16+CD86-CD3-CD17- CD16-CD86-CD3-CD17- CD17- CD17- CD17- CD19-CD17- CD19-CD19-CD19- CD19-CD19-CD19-CD19- CD19-CD19-CD19-CD19-CD19-CD19-CD19-CD19-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cymnetry Fl	Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / AB	3-24 ABS/mm² 0-0-0-2% 0-1 ABS/mm² 0-10-2% 0-1 ABS/mm² 0-10-2%	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NA NA OSU Flow Lab enablished NAA NAA OSU Flow Lab enablished NAA NAA NAA	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD16-CD56-(CD3-CD117- CD16+CD56-(CD3-CD117- CD16+CD56-(CD3-CD117- CD16+CD56-(CD3-CD117- CD16+CD56-(CD3-CD117- CD16+CD56-(CD3-CD117- CD16-CD56-(CD3-CD117- CD117- CD117- CD117- CD117- CD117- CD117- CD117- CD19- CD19- CD19- CD19- CD19-CD36- CD31-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS % / AB	3-24 ABS/mm ² 0.0-0.2% 0.3 ABS/mm ² 0.3 ABS/mm ² 0.0-1.0% 0.0-1	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NA NA NA OSU Flow Lab enablished NA OSU Flow Lab enablished NA NA NA OSU Flow Lab enablished NA NA NA OSU Flow Lab enablished NA	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD19-CD17- CD19-CD17- CD19-CD18- CD19-CD18- CD19-CD18-CD19- CD19-CD18-CD19-CD18- CD19-CD18-CD19-CD18- CD19-CD18-CD19-CD18- CD19-CD18-CD18- CD19-CD18-CD18- CD19-CD18-CD18- CD19-CD18- CD19-CD18- CD19-CD18- CD19-CD18- CD19-CD18- CD19-CD18- CD19-CD18- CD2- CD2- CD2- CD2- CD2- CD2- CD2- CD2	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / AB	3-24 ABS/mm² 0-0-0-2% 0-3 ABS/mm² 0-157 ABS/	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NA	NVA NVA NVA NVA NVA NVA NVA NVA	0.0-100.0% 0.0-100.0%
CD16-CD86-CD3-CD117- CD16-CD86-CD3-CD117- CD16-CD86-CD3-CD117- CD16-CD86-CD3-CD117- CD16-CD86-CD3-CD117- CD16-CD86-CD3-CD117- CD16-CD86-CD3-CD117- CD16-CD86-CD3-CD117- CD19-CD80-CD3-CD117- CD19-CD80-CD3-CD117- CD19-CD80-CD8-CD117- CD19-CD80-CD8-CD117- CD19-CD80-CD8-CD117- CD19-CD80-CD8-CD8-CD117- CD19-CD80-CD8-CD8-CD8-CD19-CD80-CD8-CD8-CD8-CD8-CD8-CD8-CD8-CD8-CD8-CD8	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cymnetry Fl	Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / AB	3-24 ABS/mm² 0-0-0-2% 0-1 ABS/mm² 0-0-0-2% 0-1 ABS/mm² 0-0-0-2% 0-0-1 ABS/mm² 0-0-0-2% 0-0-0-2% 0-0-0-2% 0-0-0-2% 0-0-1-0	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NA N	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD16-CD56-(CD3-CD117- CD16-CD56-(CD3-CD117- CD16-CD56-(CD3-CD117- CD16-CD56-(CD3-CD117- CD16-CD56-(CD3-CD117- CD16-CD56-(CD3-CD117- CD16-CD56-(CD3-CD117- CD16-CD56-(CD3-CD117- CD117- CD117- CD117- CD117- CD19-CD17- CD19- CD19-CD19- CD19-CD19-CD16- CD19-CD16-CD16- CD19-CD16-CD16- CD19-CD16-CD16- CD19-CD16-CD16- CD19-CD16- CD16- CD19-CD16- CD18- CD19-CD16- CD19-CD16- CD18- CD19-CD16- CD19-CD16- CD18- CD18- CD19-CD16- CD18- C	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS % / AB	3-24 ABS/mm ² 0.0-0.2% 0.3 ABS/mm ² 0.0-1.2% 0.3 ABS/mm ² 0.0-1.2% 0.0-1	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NA NA NA OSU Flow Lab enablished NA	NVA NVA NVA NVA NVA NVA NVA NVA	0.0-100.0% 0.0-100.0%
CD16+CD56+CD3+CD117+ CD16+CD56+CD3+CD117- CD16+CD56+CD3+CD117- CD16+CD56+CD3+CD117- CD16+CD56+CD3-CD117- CD16+CD56+CD3-CD117- CD16+CD56+CD3-CD117- CD16+CD56+CD3-CD117- CD16+CD56+CD3-CD117- CD19-CD17- CD19-CD17- CD19-CD18- CD19-CD19-CD18- CD19-CD19-CD18- CD19-CD19-CD18- CD19-CD18-CD18- CD19-CD18-CD18- CD19-CD18-CD18- CD19-CD18-CD18- CD19-CD18-CD18- CD19-CD18- CD2- CD2- CD2- CD2- CD2- CD2- CD2- CD2	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / AB	3-24 ABS/smm² 0-0-0-2% 0-3 ABS/smm² 0-10-70% 0-1	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NA	NVA NVA NVA NVA NVA NVA NVA NVA	0.0-100.0% 0.0-100.0%
CD16+CD56+CD3+CD117+ CD16+CD56-CD3+CD117- CD16+CD56+CD3+CD117- CD16+CD56+CD3+CD117- CD16+CD56+CD3-CD117- CD16+CD56+CD3-CD117- CD16+CD56+CD3-CD117- CD16+CD56+CD3-CD117- CD16+CD56+CD3-CD117- CD19-CD17- CD19-CD19-CD19-CD19-CD19-CD19-CD19-CD19-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cymnetry Fl	Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / AB	3-24 ABS/mm ² 0-0-0-2% 0-1 ABS/mm ² 0-1 AB	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD16-CD56-CD3+CD17- CD16+CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD17- CD17- CD17- CD17- CD19-CD17- CD19-CD19-CD17- CD19-CD19-CD18- CD19-CD19-CD18-CD16- CD19-CD18-CD16-CD16- CD19-CD16-CD16-CD16- CD19-CD16-CD16- CD19-CD16-CD16-CD16- CD19-CD16-CD16-CD16- CD19-CD16-CD16-CD16-CD16- CD19-CD16-CD16-CD16-CD16-CD16-CD16-CD16-CD16	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cymnetry Fl	Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / AB	3-24 ABS/mm² 0-0-0-2% 0-1 ABS/mm² 0-1 ABS	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab established NAA NAA NAA NAA NAA NAA NAA NAA NAA NA	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD16+CD56+CD3+CD117+ CD16+CD56-CD3+CD117- CD16+CD56+CD3+CD117- CD16+CD56+CD3+CD117- CD16+CD56+CD3-CD117- CD16+CD56+CD3-CD117- CD16+CD56+CD3-CD117- CD16+CD56+CD3-CD117- CD16+CD56+CD3-CD117- CD19-CD17- CD19-CD19-CD19-CD19-CD19-CD19-CD19-CD19-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cymnetry Fl	Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / AB	3-24 ABS/mm ² 0.04 25% 0.3 ABS/mm ² 0.3 ABS/mm ² 0.05 27% 0.0 ABS/mm ² 0.0 ABS/mm	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD16-CD56-CD3-CD117- CD16-CD56-CD3-CD117- CD16-CD56-CD3-CD117- CD16-CD56-CD3-CD117- CD16-CD56-CD3-CD117- CD16-CD56-CD3-CD117- CD16-CD56-CD3-CD117- CD16-CD56-CD3-CD117- CD117- CD16-CD56-CD3-CD117- CD19-CD17- CD19-CD17- CD19-CD17- CD19-CD18- CD19-CD18-CD18- CD19-CD18- CD19-CD18-CD18- CD19-CD18- CD19-CD18- CD19-CD18- CD19-CD18- CD19-CD18- CD2- CD2- CD2- CD2- CD2- CD2- CD2- CD2	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cymnetry Fl	Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / AB	3-24 ABS/mm² 0-0-0-2% 0-1 ABS/mm² 0-0-1 ABS/mm² 0-0-1 ABS/mm² 0-0-1 ABS/mm² 0-0-1 ABS/mm² 0-0-1 ABS/mm² 0-1-1 ABS/mm² 0-1 ABS/mm²	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab established NAA NAA NAA NAA NAA NAA NAA NAA NAA NA	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD16-CD56-CD3+CD17- CD16+CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD16+CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD16-CD56-CD3-CD17- CD17- CD17- CD19-CD17- CD19-CD19-CD19- CD19-CD3-CD17- CD19-CD3-CD17- CD19-CD3-CD17- CD19-CD3-CD17- CD19-CD3-CD17- CD19-CD3-CD18- CD19-CD3-CD6- CD19-CD6- CD6- CD7- CD7- CD7- CD7- CD7- CD7- CD7- CD7	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cymnery Flow	Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / AB	3-24 ABS/mm² 0-0-0-2% 0-1 ABS/mm² 0-10-2% 0-1 ABS/mm² 0-10-2% 0-1 ABS/mm² 0-10-2 ABS/mm² 0-10-2 ABS/mm² 0-10-2 ABS/mm² 0-1-2 ABS/mm² N/A 1-2 0-1 In% N/A 1-3 0-3 1/m² N/A 1-3 0-3 1/m² 0-3 ABS/mm² 0-3 ABS/mm² N/A 1-3 0-3 1/m² 0-3 ABS/mm² 0-3 A	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished NA	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%

March Marc	CD3-/CD5616+/CD107a107b+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS		N/A	OSU Flow Lab established	N/A	0.0-100.0%
Marchester Mar	CD3-/CD5616+/CD158b+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0.0-7.1%	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Company										
Company										
	CD107a107b+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Column	CD3-/CD5616+/CD314+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS		N/A	OSU Flow Lab established	N/A	0.0-100.0%
March Marc		N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS		N/A	OSU Flow Lab established	N/A	0.0-100.0%
		N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0.0-1.1%	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Marche 10										
	CD158b+		Flow Cytometry							
	CD3+/AlphaBeta+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	550-2158 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Company Company	CD3+/CD107a107b+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS		N/A	OSU Flow Lab established	N/A	0.0-100.0%
	CD3+/CD134+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0.0-4.3%	N/A	OSU Flow Lab established	N/A	0.0-100.0%
March Marc			Flow Cytometry							
Company Comp	CD3+/CD158b+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-89 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Marchander Mar	CD3+/CD159a+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS		N/A	OSU Flow Lab established	N/A	0.0-100.0%
Color Colo	CD3+/CD159a+/CD107a107b+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS		N/A	OSU Flow Lab established	N/A	0.0-100.0%
	CD2: (CD214)				ev / ADC			OSUEbar Lab and Bibliot	N/A	0.0.100.00/
March Marc	CD3+/CD63+/CD314+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-11 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
	CD3+/CD69+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-50 ABS/mm3	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Month Mont	CD3+/CD69+/CD134+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS		N/A	OSU Flow Lab established	N/A	0.0-100.0%
	CD3+/CD69+/CD134+/HLADR+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0.0-0.0%	N/A	OSU Flow Lab established	N/A	0.0-100.0%
						0.0-0.1%				
						0-3 ABS/mm ³				
March Marc	CD3+/CD69+/HLADR+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-4 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Control Cont	CD3+/CD80-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	59.8-86.5%	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Column	CD3+/CD80-/CD86-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	59.3-85.8%	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Section Sect	CD3±/CD9a+					0.0-0.2%				
						0-5 ABS/mm ³				
Colorado	CD3+/CD80+/CD86+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Coloran	CD3+/CD86-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS		N/A	OSU Flow Lab established	N/A	0.0-100.0%
March Marc	CD3+/CD86+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0.0-0.5%	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Company						0.0-7.3%				
Color						0-135 ABS/mm ³				
Column				,		0-139 ABS/mm ³				
Color	CD31 CD314		Flow Cytometry Flow Cytometry							
Color					%					
Company SA	CD34	N/A	Flow Cytometry	Navios Flow Cytometer	%	N/A	N/A	N/A	N/A	0.0-100.0%
Case	CD4				%	N/A				
Checkbook Chec		N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Checomorphism No. Des Common No.	CD4+/CD127+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	30.6-53.9% 318-1487 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Description No. Per Country No.	CD4+/CD183+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	6.7-30.5%	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Control Cont	CD 4 (CD 403)	2714			0/ 14700	84-696 ABS/mm ² 0.0-0.1%	N/A	ogur II - III I	N/4	0.0 100.00
Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control	CD4+/CD193+	N/A	Flow Cytometry	Navios Flow Cytometer	76 / ABS	0-3 ABS/mm ³	N/A	OSC Flow Lab established	N/A	0.0-100.0%
Concession Con	CD4+/CD193+/CD183+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Charles Char	CD4+/CD193+/CD194+	N/A	FI . C			0.0-0.0%			NIA	0.0.100.00
CRISTORIA CRIDER No. Proc Cymery No.			Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ABS/mm ³	N/A	OSU Flow Lab established	NA	0.0-100.0%
CHACUBH NA Pac Cymery Noar Pac Cymery	CD4+/CD193+/CD294+					0-0 ABS/mm ³ 0.0-0.0%				
CHAPTER N.A. Pro Cycordy Nove The Cycordy N. A. De Cycordy		N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ABS/mm ³ 0.0-0.0% 0-0 ABS/mm ³ 0.0-0.0%	N/A	OSU Flow Lab established	N/A	0.0-100.0%
Calc Calc Call Calc Calc Call Calc Calc Call Call Call Call Call Call	CD4+/CD193+/CD294+/CD183+	N/A N/A	Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / ABS	0.0 ABS/mm ³ 0.0-0.0% 0-0 ABS/mm ³ 0.0-0.0% 0-0 ABS/mm ³	N/A N/A	OSU Flow Lab established OSU Flow Lab established	N/A N/A	0.0-100.0%
Chancester Chance	CD4+/CD193+/CD294+/CD183+	N/A N/A	Flow Cytometry Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / ABS	0-0 ABS/mm ³ 0.0-0.0% 0-0 ABS/mm ² 0.0-0.0% 0-0 ABS/mm ³ 0.0-27.8% 0-560 ABS/mm ³	N/A N/A	OSU Flow Lab established OSU Flow Lab established	N/A N/A	0.0-100.0%
Charlest-Carlette	CD4+/CD193+/CD294+/CD183+ CD4+/CD194+	N/A N/A N/A	Flow Cytometry Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / ABS % / ABS	0.0 ABS/mm ³ 0.0-0.0% 0.0 ABS/mm ³ 0.0-0.0% 0.0 ABS/mm ³ 0.0-27.8% 0.550 ABS/mm ³ 0.0-27.8% 0.68 ABS/mm ³	N/A N/A N/A	OSU Flow Lab established OSU Flow Lab established OSU Flow Lab established	N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0%
CHASTON-CHRISTON NA De Cymery Nove Per Cymere NA 06279 NA 06279 La acadead NA 0431075	CD4+/CD193+/CD294+/CD183+ CD4+/CD194+ CD4+/CD25+	N/A N/A N/A	Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry	Navios Flow Cytometer Navios Flow Cytometer Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / ABS % / ABS % / ABS	0-0 ABS/mm ² 0-0-0.0% 0-0 ABS/mm ² 0-0 ABS/mm ² 0-0 ABS/mm ² 0-0-27.8% 0-560 ABS/mm ² 0-68 ABS/mm ² 0-0-2.1%	N/A N/A N/A N/A	OSU Flow Lab established OSU Flow Lab established OSU Flow Lab established OSU Flow Lab established	N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0%
CHAPTERSEALTERSON NA	CD4+/CD193+/CD294+/CD183+ CD4+/CD194+ CD4+/CD25+ CD4+/CD25+/CD127-	N/A N/A N/A N/A N/A	Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry	Navios Flow Cytometer	% / ABS % / ABS % / ABS % / ABS	0.0 ABS/mm ² 0.0.0 0% 0.0 ABS/mm ² 0.0.4 0% 0.0 ABS/mm ² 0.0.4 0% 0.0 ABS/mm ² 0.0.27 8% 0.550 ABS/mm ² 0.0.3 2% 0.648 ABS/mm ² 0.0.2 1% 0.43 ABS/mm ² 0.0.1 4%	N/A N/A N/A N/A N/A	OSU Flow Lab established	N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CHARLESTRUCK-LINEARD N.A. Pare Cymnery November Cymnery N. Ales Charlest N. A. Charlest N.	CD4+(CD193+)(CD294+)CD183+ CD4+(CD194+ CD4+)CD25+ CD4+(CD25+)CD127- CD4+(CD25+)CD127+	N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS % / ABS % / ABS % / ABS % / ABS	0.0 A RIS/mm ² 0.0.0 0% 0.0 A RIS/mm ² 0.0.0 0% 0.0 A RIS/mm ² 0.0.2 73% 0.0.2 73% 0.560 A RIS/mm ² 0.0.3 2% 0.68 A RIS/mm ² 0.0.2 1% 0.0.4 A RIS/mm ² 0.0.5 MIS/mm ² 0.0.5 MIS/mm ²	N/A N/A N/A N/A N/A N/A N/A	OSU Flow Lab entablished	N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CDH-CDB-CDB-CDB-CDB-NA Fine Cytomery Nature For Cytomery Natlant For Cytomery Nature For Cytomery Nature For Cytomery	CD4+/CD193+/CD294+/CD183+ CD4+/CD194+ CD4+/CD25+ CD4+/CD25+/CD127- CD4+/CD25+/CD127+ CD4+/CD25+/CD45RA-/CD45RO-	N/A N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ARS	0.0 A ISS/mm ² 0.0.0 0% 0.0 A ISS/mm ² 0.0.0 0% 0.0 A ISS/mm ² 0.0.0 0% 0.0 A ISS/mm ² 0.0.2 7.5% 0.0.3 7.5 mm ² 0.0.3 7.5 mm ² 0.0.3 7.5 mm ² 0.0.3 1.5 mm ² 0.0.3 1.5 mm ² 0.0.4 A ISS/mm ² 0.0.5 Mm ² 0.0.6 A ISS/mm ² 0.0.6 A ISS/mm ² 0.0.6 I A ISS/mm ²	N/A	OSU Flow Lab entablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
Checosts No. Pro-Cymery Note Pro-Cymery No. No.	CD4+/CD193+/CD294+/CD183+ CD4+/CD194+ CD4+/CD25+ CD4+/CD25+/CD127- CD4+/CD25+/CD127+ CD4+/CD25+/CD45RA-/CD45RO-	N/A N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ARS	0-0 ARS/mm ²	N/A	OSU Flow Lab entablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CHAPTED: Finder Pre Cissasty Non-Fre Cissas	CD4+/CD193+/CD183+ CD4+/CD194+ CD4+/CD25+ CD4+/CD25+ CD4+/CD25+ CD4+/CD25+/CD127+ CD4+/CD27+/CD45RA-/CD45RO- CD4+/CD29+/CD45RA-/CD45RO- CD4+/CD29+/CD45RA-/CD45RO-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ARS/mm ²	NIA	OSU Flow Lab established	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
Chi-Child Thight The Cymery Note The Cymers S. 20-21 Most The Cymers S. 20-	CD4+CD194+CD184+CD184+ CD4+CD25+ CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD25+CD127+ CD4+CD25+CD127+ CD4+CD25+CD127+ CD4+CD25+CD127+ CD4+CD25+CD127+ CD4+CD25+CD127+ CD4+CD25+CD127+ CD4+CD27+CD127+ CD4+CD27+CD127+ CD4+CD27+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ARS/mm ²	NIA	OSU Flow Lab enablished	N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
Chi-CDB-	CD4+CD39+CD194+ CD4+CD194+ CD4+CD25+ CD4+CD25+CD127- CD4+CD25+CD127+ CD4+CD25+CD127+ CD4+CD27+CD48RA-CD48RO- CD4+CD29+CD48RA-CD4+CD24+ CD4+CD294+CD394+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0. A ISS'um ² 0-0.0 A ISS'um ² 0-0.2 1 A ISS'um ² 0-0.2 1 A ISS'um ² 0-0.1 A ISS'um ² 0-0.1 A ISS'um ² 0-0.2 A ISS'um ² 0-1.2 A ISS'um ² 0-1.2 A ISS'um ² 0-1.4 A ISS'um ² 0-0.2 5 0-0.2 5 0-0.4 A ISS'um ² 0-0.0 2 5 0-0.2 5 0-0.4 A ISS'um ² 0-0.0 2 5 0-0.2 5 0-0.4 A ISS'um ² 0-0.0 2 5 0-0.4 A ISS'um ² 0-0.0 2 5 0-0.5 5 0-0	NIA	OSU Flow Lab established	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD4-CD86A-CD27- NA Per Cymnery Note The Cymner No. ABS	CD4+CD39+CD24+CD184 CD4+CD35+ CD4+CD25+ CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD27+CD48A-CD480- CD4+CD24+CD34+CD44- CD4+CD34+CD34+CD34-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0. ABS/mm² 0-0.0 O/S 0-0. ABS/mm² 0-0.0 O/S 0-0. ABS/mm² 0-0.0 O/S 0-0. ABS/mm² 0-0.2 T/S 0-0.0 ABS/mm² 0-0.2 T/S 0-0.0 ABS/mm² 0-0.2 T/S 0-0.4 ABS/mm² 0-0.4 ABS/mm² 0-0.4 ABS/mm² 0-0.2 T/S 0-0.4 ABS/mm² 0-0.2 T/S 0-0.4 ABS/mm² 0-0.2 T/S 0-0.4 ABS/mm²	NIA	OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD4-CD8RA-CD27-	CD4+CD39+CD294+CD183+ CD4+CD25+ CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD25+CD27- CD4+CD24+CD38- CD4+CD24+CD38- CD4+CD38+CD184- CD4+CD38+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ARS/sm ² 0-1 ARS/sm ²	NIA	OSU Flow Lab established	N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CH-CD8Ra+CD25-	CD4+CD39+CD89+CD184- CD4+CD25+ CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD27+CD88A-CD880- CD4+CD34+CD44- CD4+CD34+CD194- CD4+CD34+CD194- CD4+CD34-CD194- CD4+CD34-CD194- CD4+CD34-CD194- CD4+CD34-CD194-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 A RS/smm ² 0-0 A DS/smm ² 0-1 A DS/smm ²	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab established NA OSU Flow Lab established	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CH4-CD860+CD2+ NA For Cymory Neiso For Cymorer % / ABS 2-5-3-15 NA OSJ For Lie calibidad NA O-100/05	CD4+CD194+CD194+ CD4+CD25+ CD4+CD25+CD125- CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD27+CD48A-CD48A- CD4+CD294+ CD4+CD294+CD194+ CD4+CD294+CD194+ CD4+CD294+CD194+ CD4+CD394+CD194+ CD4+CD394+CD394+ CD4+CD394+ CD4+CD394+CD394+ CD4+CD394+ C	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ARS/smm² 0-1 ARS/smm²	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab outshished	N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CH-CD4800-CD27- NA Pire Cymerer No. Pire Cymerer No. All Society No. Society No.	CD4+CD194+CD194+ CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD27+CD48A-CD48A- CD4+CD24+CD34+ CD4+CD24+CD14+ CD4+CD3+CD4+ CD4+CD3+ CD4+CD4-CD4- CD4+CD4-CD4- CD4+CD4- CD4+CD4- CD4+CD4- CD4-CD4- CD4- CD4-CD4- CD4- CD4-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0.A RS/sum ² 0-0.0 A RS/sum ² 0-0.0 A RS/sum ² 0-0.0 A RS/sum ² 0-0.2 Tys 0-0.2 Tys 0-0.2 Tys 0-0.3 Eye 0-0.3 RS/sum ² 0-0.3 RS/sum ² 0-0.3 RS/sum ² 0-0.4 ARS/sum ² 0-0.4 ARS/sum ² 0-1.4 ARS/sum ² 0-1.4 ARS/sum ² 0-1.5 ARS/sum ²	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab cutshished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD4-CD48C0-CD29+ N.A Flow Cymonery No. No. Flow Cymonery N. ABS 143.4585 N.A OSI Flow Lab candibled N.A 0.0-10.00%	CD4+CD39+CD24+CD184 CD4+CD35+CD25+ CD4+CD35+CD127- CD4+CD35+CD127- CD4+CD35+CD127- CD4+CD35+CD487A-CD480A CD4+CD34+CD34+CD34+ CD4+CD34+CD34-CD44- CD4+CD34-CD34-CD34- CD4+CD34-CD38A+CD37- CD4+CD38A+CD27- CD4+CD38A+CD27-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ARS/sm ¹ 0-0 ARS/sm ² 0-1 ARS/sm ²	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CH-I/DESD-CD27	CD4+CD39+CD24+CD184 CD4+CD35+CD25+ CD4+CD35+CD127- CD4+CD35+CD127- CD4+CD35+CD127- CD4+CD35+CD487A-CD480A CD4+CD34+CD34+CD34+ CD4+CD34+CD34-CD44- CD4+CD34-CD34-CD34- CD4+CD34-CD38A+CD37- CD4+CD38A+CD27- CD4+CD38A+CD27-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ARS/smr ¹ 0-0 ARS/smr ² 0-1 ARS/smr ²	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CB4-CD4860-CD27- NA Five Cymnetry Nation Flow Cymnetry Natio	CD4+CD194+CD194+CD184+CD194+CD194+CD194+CD194+CD195+CD197-CD4+CD197-CD4+CD197-CD4+CD197-CD4+CD197-CD4+CD194+	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0.4 ABS/sum ² 0-0.2 T/S S 0-0.4 ABS/sum ² 0-0.2 ABS/sum ² 0-0.2 ABS/sum ² 0-0.2 ABS/sum ² 0-0.4 ABS/sum ² 0-1.4 ABS/s	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab enablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CH-CD880+CD2+ N/A Flow Cytometry New Flow Cytometry No. No. No. N/A N/A N/A O. 100.09.	CD4+CD194+CD194+CD184+CD184+CD194+CD194+CD25+CD127+CD4+CD25+CD127+CD4+CD25+CD194+CD34+CD34+CD34+CD34+CD34+CD34+CD34+CD3	N/A N/A N/A N/A N/A N/A N/A N/A N/A T Helper T Helper T Helper N/A N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0.A RS/sum ¹ 0-0.0 A RS/sum ¹ 0-0.0 O/S 0-	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab entablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CH-CD880-CD9+ NA	CD4+CD194+CD	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ARSem* 0-1 ARSem* 0-0 ARSem* 0-1 ARSEM*	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab entablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CH-CDSR0+CDS- NA Flow Cysmery New Flow Cysmerer S ₁ / AIS 2.00 AISC mm ² NA OSU Fow Lab candibided NA 0.0400 fb.	CD4+CD194+CD	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0. ARS/smm² 0-0.0 ARS/smm² 0-0.0 ARS/smm² 0-0.0 ARS/smm² 0-0.0 ARS/smm² 0-0.0 ARS/smm² 0-0.0 ARS/smm² 0-0.2 Ty 0-0.0 ARS/smm² 0-0.2 Ty 0	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab established	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD4+CD880+CD29+ NA	CD4+CD194+CD	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0.A RS/sum ² 0-0.0 A RS/sum ² 0-0.0 A RS/sum ² 0-0.A RS/sum ² 1-0.A RS/sum ² 1-0.A RS/sum ² 0-0.A RS/sum ² 0-0.A RS/sum ² 1-0.A RS/sum ² 1-0.A RS/sum ² 0-1.A RS/sum ² 0-1.A RS/sum ² 1-1.A RS/sum ² 0-1.A RS/sum ² 1-1.A RS/s	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab established	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CDH	CD4+CD194+CD	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0 ARS/smr ¹ 0-0 ARS/smr ² 0-1 AR	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catabilished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CD8	CD4+CD194+CD194+CD194+CD194+CD4+CD194+CD4+CD25+CD127+CD4+CD29+CD194+CD4+CD34+CD194+CD4+CD34+CD34+CD4+CD34+CD34+CD4+CD34+CD3	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0-0.A RESum* 0-0.0 A RESum* 0-0.0 A SES mm* 0-	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catabilished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CHSRA	CD4+CD1980+CD194+CD194+CD194	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS	0-0. ARS/smm² 0-0.0 ARS/smm² 0-0.0 ARS/smm² 0-0.0 ARS/smm² 0-0.0 ARS/smm² 0-0.0 ARS/smm² 0-0.0 ARS/smm² 0-0.2 Ty 0-0.0 ARS/smm² 0-0.2 Ty 0-0.2 ARS/smm² 0-0.2 Ty 0-0.2 ARS/smm² 0-0.2 Ty 0-0.2 ARS/smm² 0-0.2 Ty 0-0.3 ARS/smm² 0-1.7 ARS/smm² 0-1.7 ARS/smm² 0-1.7 ARS/smm² 0-1.7 ARS/smm² 0-1.7 ARS/smm² 0-1.8 ARS/smm² 1-1.3 ARS/smm² 0-1.8 ARS/smm²	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab established	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
CP96	CD4+CD39+CD29+CD18+ CD4+CD39+CD29+CD18+ CD4+CD29+CD12+ CD4+CD29+CD12+ CD4+CD29+CD19+ CD4+CD29+CD39+CD39+ CD4+CD39+CD39+ CD4+CD39+CD39+ CD4+CD39+CD39+ CD4+CD39+CD39+ CD4+CD39+CD39+ CD4+CD38-CD29+ CD4+CD3-CD29+ CD4+CD3-CD3-CD29+ CD4+CD3-CD3-CD3-CD29+ CD4+CD3-CD3-CD3-CD3-CD3-CD3-CD3-CD3-CD3-CD3-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS	0-0.A RS/sum ¹ 0-0.0 A RS/sum ¹ 0-0.0 O/S 0-	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catabilised	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD56	CD4+CD194+CD194+CD184+CD194+CD	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS % / AB	0-0.A RS/smm² 0-0.0 A RS/smm² 0-0.0 A RS/smm² 0-0.0 A RS/smm² 0-0.0 A RS/smm² 0-0.0 RS/smm² 0-0.0 RS/smm² 0-0.2 TS/smm² 0-0.2 TS/smm² 0-0.2 RS/smm² 0-0.2 RS/smm² 0-0.2 RS/smm² 0-0.3 RS/smm² 0-0.3 RS/smm² 0-0.4 RS/smm² 0-0.5 RS/smm²	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CBS(16+CD)	CD4+CD194+CD	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS	0-0.A RSSum ¹ 0-0.0 A RSSum ¹ 0-0.0 A RSSum ¹ 0-0.0 A RSSum ¹ 0-0.4 A RSSum ¹ 0-0.4 A RSSum ¹ 0-0.4 A RSSum ¹ 0-0.2 TS RSSum ¹ 0-0.3 TS RSSum ¹ 0-0.3 TS RSSum ¹ 0-0.3 TS RSSum ¹ 0-0.3 TS RSSum ¹ 0-0.4 RSSum ¹ 0-0.4 RSSum ¹ 0-0.4 RSSum ¹ 0-0.4 RSSum ¹ 0-1.4 A RSSum ¹ 0-1.5 A RSSum ¹ 0-1.5 A RSSum ¹ 0-1.5 A RSSum ¹ 0-1.5 A RSSum ¹ 0-1.6 A RSS	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catalished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CBF	CD4+CD39+CD29+CD18+ CD4+CD39+CD29+CD18+ CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD29+CD38A+CD380- CD4+CD39+CD394- CD4+CD39+CD394- CD4+CD39+CD394- CD4+CD39- CD4+CD38A+CD27- CD4+CD3A+CD27- CD4+CD3A+CD27- CD4+CD3A+CD27- CD4+CD3A+CD27- CD4+CD3A+CD27- CD4+CD3A+CD27- CD4+CD3A+CD27- CD4+CD3A+CD27	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer Navios Flow Cytometer	% / ABS % / AB	0-0.A RS/sum ¹ 0-0.0 A RS/sum ¹ 0-0.0 O/S 0-	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CDS	CD4+CD194+CD194+CD184+CD	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS % / AB	0-0 ARScum* 0-1 AR	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catabilished	N/A N/A N/A N/A N/A N/A N/A N/A	0100.0% 0100.0%
CD4	CD4+CD194+CD	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS % / AB	0-0.A RESum! 0-0.0 A RESum! 0-0.0 A SES mm! 0-0.1 A SES mm! 0-0.2 TS, 0-0.4 A SES mm!	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catalished	N/A N/A N/A N/A N/A N/A N/A N/A	0.100.0% 0.100.0%
CD7	CD4+CD39+CD29+CD189+ CD4+CD39+CD29+CD189+ CD4+CD29+CD127- CD4+CD29+CD127- CD4+CD29+CD49+ CD4+CD29+CD49+ CD4+CD39+CD49+ CD4+CD39+CD49+ CD4+CD39+CD49+ CD4+CD39+CD49+ CD4+CD39+CD39+ CD4+CD38-CD27- CD4+CD48RA+CD27- CD4-CD48RA+CD27- CD4-CD4-CD4-CD4-CD4-CD4-CD4-CD4-CD4-CD4-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS % / AB	0-0.A RS/smm ¹ 0-0.0 A RS/smm ¹ 0-0.0 O/S 0-	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.100.0% 0.100.0%
CDF N.A Flox Cytometry Naive Flox Cytometer S. N.A N.A N.A N.A N.A 0.61600 ft.	CD4+CD39+CD29+CD18+ CD4+CD39+CD29+CD18+ CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD25+CD127- CD4+CD29+CD38A-CD480- CD4+CD29+CD38A-CD480- CD4+CD38A-CD48-CD38- CD4+CD38A-CD27- CD4-CD38A-CD27- CD4-C	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS % / AB	0-0 A RSS mm ¹ 0-0 A A RSS mm ¹ 0-1	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD8	CD4+CD194+CD194+CD184+CD	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS % / AB	0-0 A RSS mm ¹ 0-0 A ABS mm ² 0-1 A ABS mm ²	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catabilished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CDH-CD127+CD25	CD4+CD39+CD29+CD189+ CD4+CD39+CD29+CD189+ CD4+CD29+CD127- CD4+CD29+CD127- CD4+CD29+CD49+ CD4+CD29+CD49+ CD4+CD39+CD49+ CD4+CD39+CD49+ CD4+CD39+CD49+ CD4+CD39+CD49+ CD4+CD39+CD39+ CD4+CD39+CD39+ CD4+CD38A+CD27- CD4+CD38A+CD27- CD4+CD48A+CD27- CD4+CD48A+CD29- CD4+CD48A+CD3- CD4-CD48A+CD3- CD4-CD4-CD4-CD4-CD4-CD4-CD4-CD4-CD4-CD4-	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS % / AB	0-0 A RS/smm² 0-0 A ABS/smm² 0-0 A D ABS/smm² 0-0 A BS/smm² 0-0 A BS/smm² 0-0 A BS/smm² 0-0 A ABS/smm² 0-0 A ABS/s	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catalhided	N/A N/A N/A N/A N/A N/A N/A N/A	0.100.0% 0.100.0%
CIBH-CID25+CID25- NA Flow Cytometry News Flow Cytometry % / AIS \$50.46 AISS.mm² NA OSU Flow Lab candabladed NA 0.0-100.07%	CD4+CD39+CD29+CD18+ CD4+CD39+CD29+CD18+ CD4+CD25+CD12+ CD4+CD25+CD12+ CD4+CD25+CD12+ CD4+CD25+CD12+ CD4+CD29+CD38+CD380- CD4+CD39+CD39+ CD4+CD39+CD39+ CD4+CD39+CD39+ CD4+CD3+ CD4+CD38+CD2+ CD5+CD38+CD2+ CD5+CD38+	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS % / AB	0-0 A RSS mm ¹ 0-0 A A RSS mm ¹ 0-1 A RSS mm ¹ 1-1 A RSS mm ¹ 1-1 A RSS mm ¹ 0-1 A RSS mm ¹ 0-1 A RSS mm ¹ 1-1 A RSS mm ¹ 0-1 A RSS mm ¹ 1-1 A RSS mm ¹ 1-1 A RSS mm ¹ 0-1 A RSS mm ¹ 0-1 A RSS mm ¹ 1-1 A RSS mm ¹ 0-1	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catablished	N/A N/A N/A N/A N/A N/A N/A N/A	0.100.0% 0.100.0%
CD8+CD25+ N/A Flow Cytunery Novie Flow Cytunerer % / ABS 0.0.0.1% N/A OSU Flow Lab enablished N/A 0.0.100.0%	CD4+CD39+CD29+CD18+ CD4+CD39+CD29+CD18+ CD4+CD25+CD12+ CD4+CD25+CD12+ CD4+CD25+CD12+ CD4+CD25+CD12+ CD4+CD29+CD38+CD380- CD4+CD39+CD39+ CD4+CD39+CD39+ CD4+CD39+CD39+ CD4+CD3+ CD4+CD38+CD2+ CD5+CD38+CD2+ CD5+CD38+	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS % / AB	0-0 A RSS mm ¹ 0-0 A RSS mm ¹ 0-0 A A RS	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catablished	N/A N/A N/A N/A N/A N/A N/A N/A	0100.0% 0100.0%
O. J. AliSome* O. J	CD4+CD194+CD194+CD184+CD184+CD194+CD194+CD194+CD195+CD194+CD	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS % / AB	0-0.A RSS mm ¹ 0-0.0 A RSS mm ¹ 0-0.0 A RSS mm ¹ 0-0.0 A RSS mm ¹ 0-0.0 RSS mm ¹ 0-0.2 Tys	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catabilished	N/A N/A N/A N/A N/A N/A N/A N/A	0.100.0% 0.100.0%
CBM-CDS-CDU27- NA Faw (ymercy News Faw (ymercy 7s) AlS 0.0 ABS-mir NA GSU Fow Lac enhabled NA 0.0 (0.07s) NA Faw (ymercy News Faw (ymercy 7s) AlS 0.0 ABS-mir NA GSU Fow Lac enhabled NA 0.0 (0.07s) NA GSU Fow Lac enhabled NA 0.0 (0.07s)	CD4+CD194+CD194+CD189+CD194+CD194+CD194+CD195+CD194+CD195+CD	N/A N/A N/A N/A N/A N/A N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS	0-0.A RSS mm ¹ 0-0.0 A RSS mm ¹ 0-0.2 Tys 0-0.2 Ty	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catabilished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%
CD8+/CD25+/CD45RA-CD45RO- N/A Flow Cytometry Navior Flow Cytometer 5-/ ABS 0-10.00% O/ABS 0-10.0	CD4+CD194+CD194+CD184+CD	N/A N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS	0-0 A RSS mm ¹ 0-0 A A RSS mm ¹ 1-0 A RSS mm ¹ 1-	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catabilished	N/A N/A N/A N/A N/A N/A N/A N/A	0100.0% 0100.0%
	CD4+CD194+CD194+CD184+CD184+CD194+CD	N/A	Flow Cytometry Flow C	Navios Flow Cytometer	% / ABS	0-0.A RSS mm ¹ 0-0.0 A RSS mm ¹ 0-0.2 TS m ² 0-0.2 TS m ² 0-0.3 TS m ² 0-0.4 A RSS mm ¹ 0-0.2 TS m ² 0-0.4 A RSS mm ¹ 0-0.2 TS m ² 0-1.4 A RSS mm ¹ 0-1.4 A RSS mm ¹ 0-1.4 A RSS mm ² 0-1.5 A RSS mm	NIA NIA NIA NIA NIA NIA NIA NIA	OSU Flow Lab catabilished	N/A N/A N/A N/A N/A N/A N/A N/A	0.0-100.0% 0.0-100.0%

CD8+/CD29+/CD45RA-/CD45RO-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0.0-0.1% 0-2 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD8+/CD3+	T Suppressor	Flow Cytometry	Navios Flow Cytometer	%	11.0-40.0% 91-1428 ABS/mm ³	N/A	N/A	N/A	0.0-100.0%
CD8+/CD3+	T Suppressor	Flow Cytometry	Navios Flow Cytometer	%	N/A	N/A	N/A	N/A	0.0-100.0%
CD8+/CD3+	T Suppressor	Flow Cytometry	Navios Flow Cytometer	%/absolutes	11.0-40.0% 91-1428 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD8+/CD45RA+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	8.9-32.5% 64-836 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD8+/CD45RA+/CD27-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0.0-15.0% 0-341 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD8+/CD45RA+/CD27+	N/A	Flow Cytometry	Navios Flow Cytometer	%/ABS	0.8-18.3% 0-426 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD8+/CD45RA+/CD29-	N/A	Flow Cytometry	Navios Flow Cytometer	%/ABS	0.0-14.2% 0-331 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD8+/CD45RA+/CD29+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	2.6-18.1% 30-408 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD8+/CD45RO+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	2.0-22.8% 0-545 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD8+/CD45RO+/CD27-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0.0-4.7% 0-122 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD8+/CD45RO+/CD27+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0.0-12.9% 0-291 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD8+/CD45RO+/CD29-	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0.0-2.6% 0-56 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD8+/CD45RO+/CD29+	N/A	Flow Cytometry	Navios Flow Cytometer	% / ABS	0.0-14.4% 0-343 ABS/mm ³	N/A	OSU Flow Lab established	N/A	0.0-100.0%
CD80	N/A	Flow Cytometry	Navios Flow Cytometer	%	N/A	N/A	N/A N/A	N/A N/A	0.0-100.0%
CD86 CD9	N/A N/A	Flow Cytometry Flow Cytometry	Navios Flow Cytometer	%	N/A N/A	N/A N/A	N/A N/A	N/A N/A	0.0-100.0%
			Navios Flow Cytometer						
cMPO SARS-COV-2 Nucleocapsid (N) Protein Antibody	N/A SARS-CoV-2, COVID-19 IgG (N)	Flow Cytometry ELISA	Navios Flow Cytometer Epitope Diagnostic (KIT) DSX (Plate Reader)	% Detected / Not Detected	N/A Not Detected	N/A N/A	N/A N/A	N/A N/A	0.0-100.0% Detected / Not Detected
SARS-COV-2 Nucleocapsid (N)	SARS-CoV-2, COVID-19 IgG (N) N/A		Epitope Diagnostic (KIT) DSX	Detected / Not Detected %	Not Detected N/A	N/A N/A	N/A N/A	N/A N/A	Detected / Not Detected 0.0-100.0%
SARS-COV-2 Nucleocapsid (N) Protein Antibody FMC7 Gamma/Delta	SARS-CoV-2, COVID-19 IgG (N) N/A N/A	FLISA Flow Cytometry Flow Cytometry	Epitope Diagnostic (KIT) DSX (Plate Reader) Navios Flow Cytometer Navios Flow Cytometer	Detected / Not Detected %	Not Detected N/A N/A	N/A N/A N/A	N/A N/A N/A	N/A N/A N/A	Detected / Not Detected 0.0-100.0% 0.0-100.0%
SARS-COV-2 Nucleocapsid (N) Protein Antibody FMC7 Gamma/Delta HLA-DR	SARS-CoV-2, COVID-19 IgG (N) N/A N/A N/A	ELISA Flow Cytometry Flow Cytometry Flow Cytometry	Epitope Diagnostic (KIT) DSX (Plate Reader) Navios Flow Cytometer Navios Flow Cytometer Navios Flow Cytometer	Detected / Not Detected % %	Not Detected N/A N/A N/A N/A	N/A N/A N/A N/A	N/A N/A N/A N/A	N/A N/A N/A N/A	Detected / Not Detected 0.0-100.0% 0.0-100.0%
SARS-COV-2 Nucleocapsid (N) Protein Antibody FMC7 Gamma/Delta HLA-DR Kanna	SARS-CoV-2, COVID-19 IgG (N) N/A N/A N/A N/A	Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry	Epitope Diagnostic (KIT) DSX (Plate Reader) Navios Flow Cytometer Navios Flow Cytometer Navios Flow Cytometer Navios Flow Cytometer	Detected / Not Detected % % % %	Not Detected N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A	Detected / Not Detected 0.0-100.0% 0.0-100.0% 0.0-100.0%
SARS-COV-2 Nucleocapsid (N) Protein Antibody FMC7 Gamma/Delta HLA-DR Kanna Ki-67	SARS-CoV-2, COVID-19 IgG (N) N/A N/A N/A N/A N/A	Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry Flow Cytometry	Epitope Diagnostic (KIT) DSX (Plate Reader) Navios Flow Cytometer	Detected / Not Detected %6 % % % % % % /% % % / ratio %	Not Detected N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A	Detected / Not Detected 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
SARS-COV-2 Nucleocapsid (N) Protein Antibody FMC7 Gamma/Delta HIL-DR Kanna Ki-67 Lambda	SARS-CoV-2, COVID-19 IgG (N) N/A N/A N/A N/A N/A N/A N/A N	Flow Cytometry	Epitope Dignostic (KIT) DSX (Plate Reader) Navios Flow Cytometer	Desected / Not Detected % % % % % % % % / ratio % % / ratio	Not Detected N/A N/A N/A N/A N/A N/A N/A N/	N/A N/A N/A N/A N/A N/A N/A N/A	N/A	N/A	Detected / Not Detected 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
SARS-COV-2 Nucleocapsid (N) Protein Antibody FMC7 Gamma/Delta HLA-DR Kanon Ki-67 Lambda nTdT	SARS-CoV-2, COVID-19 IgG (N) N/A N/A N/A N/A N/A N/A N/A N	ELISA Flow Cytometry	Epitope Diagnostic (KIT) DSX (Plate Reader) Navios Flow Cytometer	Detected / Not Detected % % % % % % % % /* /* /*/ /*/ /*/ /* /*/ /*/	Not Detected N/A N/A N/A N/A N/A N/A N/A N/	N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A	Detected / Not Detected 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0% 0.0-100.0%
SARS-COV-2 Nucleocapsid (N) Protein Antibody FMC7 Gamma/Delta HLA-DR Kanna Ki-67 Lambda ####################################	SARS-CoV-2, COVID-19 IgG (N) N/A N/A N/A N/A N/A N/A N/A N	Flow Cytometry	Epitope Diagnostic (KIT) DSX (Plate Render) Navios Flow Cytometer	Detected / Not Detected % % % % % % %/ratio % %/ratio % % % % % % % % % % % % % % % % % % %	Not Detected N/A N/A N/A N/A N/A N/A N/A N/	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A	Detected / Not Detected 0.0.100.0% 0.0.100.0% 0.0.100.0% 0.0.100.0% 0.0.100.0% 0.0.100.0% 0.0.100.0%
SARS-COV-2 Nucleocapsid (N) Protein Antibody FMC7 Gamma/Delta HL-DR Kanna Ki-67 Lambda #TdT Vb1 Vb1	SARS-CoV-2, COVID-19 IgG (N) N/A N/A N/A N/A N/A N/A N/A N	Flow Cytometry	Epitope Diagnostic (KIT) DSX (Plate Reader) Navios Flow Cytometer	Detected / Not Detected % % % % % % % % % % % % / / / / / / /	Not Detected N/A N/A N/A N/A N/A N/A N/A N/	N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A	Detected / Net Detected 0.0 100.0% 0.0 100.0% 0.0 100.0% 0.0 100.0% 0.0 100.0% 0.0 100.0% 0.0 100.0% 0.0 100.0%
SARS-COV-2 Nucleocapsid (N) Protein Antibody Protein Antibody FMC7 Gamma Delta HLA-DR Kanna Ki-67 Lambda aTdT VbH VbH VbH Vb12	SARS-CoV-2, COVID-19 IgG (N) N/A N/A N/A N/A N/A N/A N/A N	Flow Cytometry	Epitope Diagnostic (KIT) DSX (Plate Render) Navios Flow Cytometer	Detected / Not Detected % % % % % % %/ratio % %/ratio % % % % % % % % % % % % % % % % % % %	Not Detected N/A N/A N/A N/A N/A N/A N/A N/	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A	Detected / Not Detected 0.0.100.0% 0.0.100.0% 0.0.100.0% 0.0.100.0% 0.0.100.0% 0.0.100.0% 0.0.100.0%
SARS-COV-2 Nucleocapsid (N) Protein Antibody FMC7 Gamma/Delta HL-DR Kanna Ki-67 Lambda #TdT Vb1 Vb1	SARS-CoV-2, COVID-19 IgG (N) N/A N/A N/A N/A N/A N/A N/A N	Flow Cytometry	Epitope Diagnostic (KIT) DSV (Plate Reader) Navios Flow Cytometer	Detected / Not Detected Not Detected % % % % % % / ratio % % / ratio % % % / ratio % % % % % % % % %	Not Detected N/A N/A N/A N/A N/A N/A N/A N/	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A	Detected / Not Detected / Not Detected / Not Detected 0.0.100.0% 0
SARS-COV-2 Nucleocapsid (N) Protein Autilbady FMC7 Gamma Delta HLADR Ki-67 Lambda a fdf Vbl Vbl Vbl Vbl.2 Vbl.3.2 Vbl.3.6	SARS-CoV-2. COVID-19 IgG (N) N/A	FLISA Flow Cytementy	Epitope Diagnostic (KIT) DSX (Plate Reader) Navios Flow Cytometer	Detected / Not Detected / Not Detected / Not Detected / Si	Not Detected N/A N/A N/A N/A N/A N/A N/A N/	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	N/A	Detected / Not Detected / Not Detected / 0.0-100/Dr; 0.0-1100/Dr; 0.0-
SARS-COV-2 Nucleocapsid (N) Protein Antibody FMC7 Gamma Delta HLA-DR Kanna Ki-67 Lambda 1617 VMI	SARS-COV-2 COVID-19 IgG (N) N/A	FLISA Flow Cytomeny	Episope Diagnostic (KIT) (Plate Reader) (Plate Reader) (Plate Reader) (Nesis Flave Cytometer Nesis Flave Cytometer	Detected / Not Detected Not Detected %	Not Detected N/A N/A N/A N/A N/A N/A N/A N/	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Descrid No Descrid 0.0-100 pts
SMESCOV-2 Nucleocapid (N) Protein Antibudy PMCT Genema Delta HIL-DR ksens ksens Lambda ### ### ### ### ### ### ### ### ### #	SARS-CAV-2. COMD-19 (gG (N) N/A	FLISA Flow Cytometry	Epidope Diagnostic (KIT) (Plate Reader) (Plate Reader) (Plate Reader) (Notice Processory	Descrid / Not Descrid Not Descrid Not Descrid Not Descrid Not Descrid Not Descrid Not Described	Not Detected N/A N/A N/A N/A N/A N/A N/A N/	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Detected / Not Detected / Not Detected / Not Detected 0.0 (0.05%) 0.0 (10.05%
SSRS-COV-2 Nucleocopid (N) Protein stabledy FMCC General Data Heat Heat Heat Heat Heat Heat Heat H	SARS COV.2 COVID-19 IgG (N) NA TOR WHITA	ELISA Bus CAMMENT Flow COMMENT	Epispe Diagnosis (KIT) DSS Plate Reader) [Plate Reader) Maron File Connector Nesion Fi	Detected / Not Detected Not Detected %	Not Detected NO. NO. NO. NO. NO. NO. NO. NO. NO. NO	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Descend / Not Descend / Not Descend / Not Descend 0.0.100105, 0.0.100105, 0.0.100105, 0.0.100075, 0.
SRESCOVE Nucleospoid IN Protein Authority of the Protein Authority of the INFO INFO INFO INFO INFO INFO INFO INFO	SARS CAV-2. COVID-19 (gG (N) N/A	ELISA But Cramery Flue Comercy	Epispe Diagnosis (KIT) (Patte Reader) (Patte Reader) (Patte Reader) (Patte Reader) (Navier Bare Optionater Navier Bare Optionater	Descrid / Not Descrid Not Descrid Not Descrid Not Descrid Not Descrid Not Descrid Not Described	Not Detected NO. NO. NO. NO. NO. NO. NO. NO. NO. NO	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Descrid No Descrid 0.0.100 Pr.
SRIS-COV-2 Nucleocopid (N) Protein Authbody FMCT Gameso Derlin Research Research Research Ris-67 Lambda a Taff VMI VMI VMI VMI VMI VMI VMI V	SMS-CW-2 CSMD-19 kg (N) NIA	ELISA Plea Cytometry	Epitope Diagnosis (KIT) (Plate Reader) (Plate Reader) (Plate Reader) Notice Plate Cytometer	Descend / New Detected New Description New Detected New D	Not Detected NGA NGA NGA NGA NGA NGA NGA NG	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Decent / Not Decent / Not Decent / Not Decent / Not Decent / On July / Not Decent / On July / On
SRESCOVE Nucleospoid (N) Protein Article Policy Committee BMC To Gramme Chair Gramme Chair HA-DR Kaman Ki-G Lambide Abi	SARS COV.2. COVID-19 (gr. N) NA NA NA NA NA NA NA NA NA	ELISA Plac Cytanery Flor Cyta	Epispe Diagnosis (KIT) DSS (Plate Reader) (Plate Reader) Menta Plan Connector Nerios Flor Connector Nerios F	Detected / Not Detected / Not Detected %	Not Detected No.1 No.4 No.4 No.4 No.4 No.4 No.6 No.6	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Descrid 0.0-10075.
SRESCOVE Yeak-neeped (V) Protiss Anthology Brotis Antholo	SARS CW-2. COVID-19 (gG N) NA NA NA NA NA NA NA NA NA	FEISA Flow Cytometry Prox Cytometry Prox Cytometry Prox Cytometry Flow Cytometry	Epidope Diagnosite (KIT) (Plate Reader) (Plate Reader) (Plate Reader) Notice Face Connector Notice Face Connec	Detected / Not Detected Not Detected Not Detected Not Section No	Not Detected NO. NO. NO. NO. NO. NO. NO. NO	NÍA NÍA NÍA NÍA NÍA NÍA NÍA NÍA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Debend J No Debend J Debend J Debend
SRSCO'\ 3 Vaches april (N) Protein Author) GMCC GMCC IMAGE III.A.DR Kenne Ki.67 Lambia a Elff Vali	SARS COV.2 COVID-19 (gG N) NA NA NA NA NA NA NA NA NA	ELISA Flue Colmency Flue Colm	Epispe Diagnosis (KIT) Dist. Dist. Public Reader) (Public Reader) Neston Fine Contenting Neston	Detected / Not Detected 8	Not Detected NA	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Decent / No Decent
SRESCOVE Nucleospoid IV Protis Attached IV Protis Attached IV Gamma Debta HLA-DR Kanna Kan	SARS CAV.2. COVID-19 (gr N) NA NA NA NA NA NA NA NA NA	ELISA Flue Cytametry	Epispe Diagnosis (KIT) (Pate Reader) (Pate Reader) (Pate Reader) Note a Pare Connector Notice The Connect	Detected / Not Detected / Not Detected Signature S	Not Detected No.	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Descrid No Descrid 0.0.10075.
SRS-COV-2 Nucleocopid (N) Protein delibedy FMCP General Deliber Henric Street	SARS COV-2 COVID-19 (4G IN) NIA NIA NIA NIA NIA NIA NIA NIA NIA NI	ELISA Place Coloniery Place C	Epispe Diagnosis (KIT) DSS Plate Reader) Mario Fibr. Connector Nation Fibr	Descried / Not Detected / Not Not	Not Detected NO. A NO	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Decent / Nor Decent / Nor Decent / Nor Decent / On Julius / On Jul
SRESCO'S Nucleospoid (N) Protein Methods (N) Protein Methods (N) Games Order Kenne Ki-67 K	SARS COV.2. COVID-19 (gr (N) NA NA NA NA NA NA NA NA NA	ELISA But Crimery Flor Cytenery Flor Cytene	Epispe Diagnosis (KIT) Dist Reader) (Plate Reader) (Plate Reader) (Plate Reader) Nerios Flav Cytometer	Detected / Not Detected / Not Detected / % % % % % % % % % / % / ratio % % % / ratio % % % % % % % % % % % % % % % % % % %	Not Detected No.1 No.1 No.4 No.4 No.4 No.4 No.4 No.5 No.5	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Descrid No Descrid 0.0.10075.
SRS-COV-2 Nucleocopid (N) Protein delibedy FMCP General Deliber Henric Street	SARS CW-2. COVID-19 (gG N) NA NA NA NA NA NA NA NA NA	ELISA But Connecty Flux Conne	Epispe Diagnosis (RTI) (Plane Roader) (Plane Roader	Descried / Not Detected / Not N	Not Detected NO. A NO	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Descrid No Descrid 0.0.100 Pr.
SSES COV. 3 Nucleospoid (N) Protein Marches FMC 700 FMC	SARS COV.2 COVID-19 (gG N) NA NA NA NA NA NA NA NA NA	ELISA Flue Colonery Flue Colo	Epispe Dagmonis (KIT) (Patte Reader) (Patte Reader) (Patte Reader) (Patte Reader) Nerion Fare Connector Neri	Detected / Not Detected / Not Detected Sc	Not Detected No. 1 No	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Descend / No Desce
SMSCOV2 Varlescopid (1) Protis Attlibely (1) Protis	SARS CW-2. COVID-19 (gG N) NA NA NA NA NA NA NA NA NA	ELISA But Connecty Flux Conne	Epispe Diagnosis (RTI) (Plane Roader) (Plane Roader	Detected / Not Detected % 5 % 5 % 5 % 7 % 7 % 7 % 7 % 7 % 7 % 7 % 7 % 7 % 8 % 5 % 5 % 5 % 5 % 5 % 5 % 5 % 5 % 5 % 5	Not Detected No. 1 No	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Detected / Not Detected / Not Detected / Not Detected 0.0.100.0% 0
SMESCOVI Nucleospid Di Protis Attlebed Di Protis Attlebed Di HA-DR Kenna Ki-Di	SARS CAV.2. COVID-19 (gr (N) NA NA NA NA NA NA NA NA NA	ELISA Flue Connector	Epispe Diagnosis (KIT) (Pate Reader) (Pate Reader) (Pate Reader) (Pate Reader) (Pate Reader) (Note The Contenter Notion Flor Cytometer	Detected / Not Detected / Not Detected / Signature / S	Not Detected No.	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Descrid / Not Descrid / Not Descrid / Not Descrid / 0.0-100.0%
SMSCOV2 Varlexcopid (V) Protis Attended (V) HILADR HILA	SARS CW-2 COVID-19 (gr N) NA NA NA NA NA NA NA NA NA	ELISA But Connecty Flux Conne	Epispe Diagnosis (RTI) (Patte Roader) (Patte Roader	Descend / Not Detected / Not Detecte	Not Detected NO. NO. NO. NO. NO. NO. NO. NO	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Desired J No Desired J No Desired J No Desired J 0.0 ± 100.0%
SRESCO'S Nucleospoid (N) Protein Methods (N) Protein Methods (N) Games Order (HA-DR Kennes Ki-67 Kennes Ki-67 Vol. V	SARS COV.2. COVID-19 (gr N) NA NA NA NA NA NA NA NA NA	ELISA Plus Connervy Floor Cymerry Floor Cymerry Floor Cymerry Floor Cymerry Floor Cymerry Floor Connervy Floor Connervy Floor Cymerry Floor C	Epispe Diagnosis (KIT) (Path Reader) (Notice Path Contented Notice Path Con	Detected / Not Detected / Not Detected / S	Not Detected No.1 No.4 No.4 No.4 No.4 No.4 No.4 No.5 No.5 No.5 No.5 No.6 No.6	NIA NIA NIA NIA NIA NIA NIA NIA	N/A N/A N/A N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A N/A N/A N/A	Descript J No Descript J No Descript J 0.0-100.0%